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Thesis Summary 
Vaccines have already made a significant impact on global healthcare with the eradication or reduction 
in disease states; however, further work is required to develop ‘safer’ vaccines by the use of sub-unit 
antigens. When considering immunisation, whilst the oral route is the most convenient route for drug 
and vaccine administration, most vaccines are still delivered via an injection. To be able to be given 
orally, vaccine antigens need to be associated with carrier systems to both protect the antigen from 
degradation within the harsh gut environment and to improve uptake by appropriate target sites, 
namely M cells located in the Peyer’s patches, which are responsible for secretory IgA and other 
mucosal responses. Therefore, niosomes have been considered within this thesis to enhance the 
protection and delivery of sub-unit vaccines via the oral route and intramuscularly.  
Initial work included using Design of Experiments to optimise niosome/ bilosome vesicles prepared 
from of Monopalmitoyl glycerol (MPG), Synthecol (Chol), Dicetyl Phosphate (DCP) and bile salt in 
terms of their vesicle size, surface charge, suspension pH and antigen loading. Optimisation studies, 
demonstrated that the ideal composition was a 5:4:1 ratio of MPG:Chol:DCP respectively. Langmuir 
balance and differential scanning calorimetry studies also demonstrated that, cholesterol inserts 
between the lipids within the bilayer hence, preventing crystallisation of the hydrophobic tails of the 
other surfactants.  
Using the optimised niosome formulation, oral biodistribution of these niosomes (3H) and the H3N2 
(125I) antigen showed that of the dose administered (t=1h), significantly (p< 0.05) higher antigen 
(59.8%) was recovered within all organs of the gastrointestinal tract (GIT) when formulated with 
niosome vesicles compared to the free antigen (38 %). Uptake at the target site of the Peyer’s patches 
revealed that on average 1.4 % antigen was present within the Peyer’s patches when associated with 
the niosome vesicles compared to the free antigen dose which demonstrated only 0.4 % antigen was 
acquired within the Peyer’s patches. Furthermore, uptake within the mesenteric lymph tissues 
demonstrated 0.7 % antigen recovery when associated with niosomes compared to 0.2 % recovery of 
the free antigen dose. Hence, uptake studies demonstrated that niosome associated antigen show a 2-
fold improved uptake and retention at the target sites compared to administering the free antigen alone. 
Reduction in vesicle size of the niosomal systems to 2 µm made no significant difference in recovery 
of either the vesicles or associated antigen in the mesenteric lymph tissue. However, when comparing 
the Peyer’s patches, whilst there was no significant difference in localisation of antigen, there was a 
greater recovery of vesicles within the Peyer's patches of the larger 6 µm vesicles (p< 0.05) in 
comparison to the 2 µm vesicle formulation, which is an indicator of achieving increased mucosal 
immunity. Within ferrets, the optimised niosomes containing bile salts were shown to lower median 
temperature differential change and show inflammatory cell counts in nasal washes to be comparable 
to the commercial vaccine administered intramuscularly after challenge with a clinical H1N1 isolate.  
 
In terms of intramuscular administration, niosomes incorporating H1N1 and H3N2 antigen provided 
thermostability when stored at elevated temperatures for 3 months at 40 °C confirmed by HAI and 
ELISA studies when compared to the commercial vaccine. In addition, the association of antigen 
confirmed the dose sparing ability of niosome preparations to elicit immune responses comparable to 
the control vaccine doses.  
In conclusion, this thesis demonstrates that niosomes can be used as delivery systems for peptides and 
protein sub-unit antigens by providing antigen protection thereby, enhancing vaccine efficacy when 
administered orally and intramuscularly. 
Keywords: oral vaccine delivery, immunisation, vaccine delivery, niosomes, liposome, lyophilisation.
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1. Introduction 
1.1   Why vaccines? 
Vaccines are essential in healthcare as they can promote protection against infection by 
a pathogen (Orenstein et al., 2013). For example, vaccines that are available currently 
include those which offer protection against measles, mumps, tetanus, polio, hepatitis, 
and Human papillomavirus (HPV) (Ritvo et al., 2005). However, despite continued 
advances in healthcare where immunisation prevents ~ 2.5 million deaths/year globally, 
high levels of morbidity and mortality are still caused by infectious diseases (Orenstein 
et al., 2013, Liu et al., 2012). This is due to the underlying problem that for many 
infectious diseases, there are low efficacy or no vaccines available (e.g. Human 
immunodeficiency virus (HIV), Tuberculosis and malaria). However a second 
consideration in the development of vaccines is accessibility; whilst well developed 
public health strategies are in place in many developed countries, many areas of the 
world still lack the required infrastructure to support wide-scale public health vaccine 
programmes (Di Fabio and de Quadros, 2001, Graham et al., 2012). To support this, 
accessibility to vaccines is a key requirement; cost, the ability to transport vaccines 
without the need for cold-chain transport, and the ability to administer the vaccine 
without the needs of needles would make a major impact on improving accessibility 
(Mitragotri, 2005, Giudice and Campbell, 2006, Levine, 2003). Therefore, it is essential 
to maintain research in vaccines to develop new and improved vaccines including novel 
methods of vaccine delivery which could address the above outlined challenges.  
1.2 Vaccine classification and their limitations 
An effective vaccine can be described as one which prevents infection and disease with 
the capability of eliciting specific immune responses with the aim of providing 
Chapter 1 : General Introduction 
 
25 
 
protective immunity (Bramwell and Perrie, 2005). In general, vaccines should satisfy 
certain criteria in order for it to be classed as a good vaccine and these criteria include: 
1. the capability of inducing the correct immune response, 
2. the safety of administration (stable),  
3. increased patient compliance by offering alternative routes of delivery and/or 
the potential of needle-free administration. 
To achieve the above outcomes, a range of vaccines have been developed and these 
may be divided into three categories; live attenuated, inactivated and sub-unit vaccines 
depending upon their properties. 
1.2.1  Live vaccines 
Live vaccines (also referred to as attenuated vaccines) promote strong immune 
protection; they are very effective in initiating mucosal and humoural immune 
responses as they are able to mimic a natural infection (Webster et al., 2003). The 
ability of live attenuated vaccines to replicate intracellularly allows sufficient quantities 
of the antigenic peptides to be produced which are represented by MHC-1 molecules, in 
turn activating cytotoxic T lymphocyte (CTL) responses (Webster et al., 2003, Burgdorf 
et al., 2007). However, in general live vaccines tend to have higher associated risks 
compared to other types of vaccines; there is an associated risk for live attenuated 
vaccines to revert back to the wild form, posing as a risk for inducing a disease state 
especially to immunocompromised individuals (Chadwick et al., 2010). However, 
whilst in general live vaccines have proven to be very effective this has not to be the 
case for all. For example, Mycobacterium tuberculosis (TB) is an infection that affects 
the population across the world with about 1.7 million people dying each year from the 
infection (Ryan et al., 2011). Currently, there is a vaccine available for tuberculosis 
based on the attenuated strain of the Mycobacterium bovis (BCG) however, only offers 
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protection against some forms of the strain (Holten-Andersen et al., 2004). Using 
attenuated strains have the advantages of producing a full immune response and is 
generally cost effective as there is a long duration of immunity. The problem above is 
that by using the live attenuated strains of viruses is that mutations can lead to a 
reversion to virulence.  
1.2.2  Inactivated vaccines 
As an alternative to attenuated vaccines, inactivated vaccines have been developed 
where microorganisms have been inactivated by the use of heat or chemicals such as 
formaldehydes (Perrie, 2006, Baxter, 2007). The use of inactivated vaccines offer 
advantages in terms of reduced side effect profiles compared to live vaccines; however, 
inactivated vaccines tend to have reduced efficacy as they are unable to multiply in the 
host to give a strong signal to the adaptive immune system hence, further doses are 
required when using inactivated vaccines (Baxter, 2007). 
1.2.3  Sub-unit vaccines  
A third group of vaccines are sub-unit vaccines. These are based on synthetic protein or 
peptide-based antigens and therefore offer major advantages in terms of improved 
safety profiles compared to other types of vaccines. However, subunit vaccines are 
limited by their poor immunogenicity and are unable to elicit strong CTL responses 
when administered without adjuvants or compared to live vaccines (Vangala et al., 
2006, Perrie et al., 2008).  
As mentioned, subunit antigens are weak immunogens and therefore generally require 
the use of adjuvants. Adjuvants augment the effects of vaccines due to the increased 
stimulation of the immune system in its response to the vaccine, allowing increased 
immunity to a specific disease (Schijns, 2000). The inclusion of an adjuvant within the 
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vaccine formulation can enhance immunological memory and coverage, and allows for 
antigen sparing and reduced number of doses (Tritto et al., 2009).  Currently there are 
only a handful of adjuvants licensed for human clinical use. One of the oldest adjuvants 
is Alum which, since the 1920s, has been incorporated into various human vaccines as 
an aluminium salt such as aluminium hydroxide (Al(OH)3) and aluminium phosphate 
(AlPO4). For human use, USA only approved the aluminium salt adjuvants for over 80 
years, however, more recently ASO4 (oil-in-water emulsion combining Alum and 
Monophosphoryl Lipid A) has been approved by European regulators and by the FDA 
as an adjuvant for vaccines (Baldwin et al., 2012, Mbow et al., 2010). In addition, 
European regulators have approved and licensed MF59 (squalene oil in water emulsion) 
as an adjuvant in e.g. a flu vaccine known as Fluad. Despite these systems, further 
adjuvants are needed. Pre-clinical studies and clinical studies have shown that alum is 
often less potent than adjuvants such as the oil in water emulsion ones and has shown to 
be a poor inducer of protective Th-1 immune responses which are crucial for protection 
against intracellular pathogens (Mbow et al., 2010).  Adjuvants will be discussed in 
further detail within section 1.8. 
1.3 Oral vaccines 
Currently, most of the vaccines available are injectables which have several 
disadvantages including irritation at site of injection which causes a lack of patient 
compliance. Moreover, needle phobia is a concern in adults and children as 
immunisation can then become a stressful procedure (Breau et al., 2001). When 
introducing herd immunity, patient compliance is essential as a large percentage 
(generally >95 %) of the population needs to be immunised. Vaccines delivered via 
parenteral injection need to be stored in a fridge during transport, therefore needle-
based vaccines cause issues in relation to cost, efficiency and logistics. Furthermore, 
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trained personnel are required when administering the vaccines which may not be 
possible in certain countries. In addition, the injuries associated with needles and the 
reuse of needles and syringes in developing countries is leading to unsafe injection 
practices. For example, the number of HIV infections resulting from the reuse of 
needles by health care providers was reported by Kane et al, (1999) of being 80,000-
160,000 (Kane et al., 1999). Therefore it is essential to find a new delivery route for 
vaccines with needle free immunisations being an important goal.  
The oral route is the preferred route of delivery due to its non-invasive structure and 
low infection risk and, most importantly, the mucosal immunity can be promoted by 
oral vaccines by offering strong resistance against many pathogens that infect via the 
mucosal lining (Clark et al., 2001). Furthermore, the safety profile of oral vaccines is 
more acceptable as side effects such as flu like symptoms, fever and diarrhoea 
associated with parenteral formulations are reduced or absent (Santiago, 1995).  The 
efficacy in the elderly could also be improved as the mucosal associated lymphoid 
tissue (MALT) does not diminish through the ageing process (Santiago, 1995). 
However, there is conflicting data where researchers suggest that the mucosal immune 
response in the GIT is compromised by ageing (Schmucker et al., 1996). A review by 
Ogra (2010) suggests that ageing reduces the number of Peyer’s patches which are 
required for the uptake of antigens and carrier systems (Ogra, 2010).
 
The M cells 
located in the Peyer’s patches are responsible for secretory IgA and other mucosal 
responses, hence if there is a decrease in numbers of Peyer’s patches due to ageing, the 
production of secretory IgA will also decrease (Schmucker et al., 1996). There are 
animal models to understand the ageing immunity, however, due to the lack of elderly 
human data on ageing mucosal immunity the implications of ageing remain to be 
defined.  
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In general, even though the oral route is the most accessible and has good patient 
compliance, only a small number of vaccines can be administered via the oral route due 
to problems with vaccine stability within the gastro-intestinal tract (GIT). This results 
from metabolism and degradation of the vaccine occurring pre-systemically in the GIT, 
where low pH and protease enzymes promote degradation (Russell-Jones, 2000). In 
addition, the residence time of the vaccines at the immune induction sites within the 
GIT have short exposure times due to normal GI transit. Due to this short exposure 
time, higher doses or an increased in frequency of dosing would be required to supply 
sufficient antigen to elicit an immune response (Webster et al., 2003). However, it is 
also essential to avoid promoting systemic tolerance and low secretion of antigen 
specific IgA through excessive dosing with the vaccine (Mowat, 2003, Russell-Jones, 
2000). 
In relation to the above points, an oral polio vaccine was developed in 1958 by Dr. 
Albert Sabin where he attenuated the wild polio virus. The most common form of oral 
polio vaccine (OPV) is the trivalent vaccine, which means that it contains live 
attenuated strains of the three serotypes of poliovirus (Fine and Carneiro, 1999). As 
attenuated vaccines show transient growth an advantage of OPV is that it allows 
prolonged exposure of the immune system to the attenuated organism. This results in 
increased immunogenicity and allows the cells to enhance their memory, hence making 
the OPV superior to the traditional inactivated injectable polio vaccine (IPV). Both 
vaccines produce antibodies in the blood, with the OPV also producing a local immune 
response with the release of SIgA within the mucosa. The extra mucosal immunity 
achieved by the body indirectly protects other individuals in the community who have 
not been vaccinated, which is advantageous as it inhibits the spread of the polio virus. 
As a result, the OPV confers long lasting immunity which is one of the important 
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criteria in making a vaccine successful. However, the main limitation of OPV is the risk 
of the attenuated form of the polio virus reverting back to the virulent form; its 
replication in the GIT can cause it to mutate into various neurovirulent forms, hence 
back to its wild-type sequence which can induce polio in humans (Troy et al., 2011). 
This is a major problem in developing countries, as other GIT viruses can interfere with 
the replication of the attenuated polio vaccine virus in the intestine of the vaccines (Fine 
and Carneiro, 1999).   
Indeed, the use of OPV can cause vaccine-associated paralytic poliomyelitis (VAPP), 
either in the vaccinees or people who are in close proximity to them (Troy et al., 2011). 
The OPV mutations are associated with VAPP and more recently, prolonged replication 
of the OPV can cause up to 15 % mutation to a vaccine-derived poliovirus (VDPV). 
This in turn, can cause outbreaks of poliomyelitis (Minor, 2009). VDPV revertant 
strains are reported to be transmissible and hence pose significant population risks (Hull 
and Minor, 2005). Thus in industrialised countries, IPV is now more widely used to 
prevent risk of outbreaks from regular use of OPV and its mutant forms (Troy et al., 
2011, Heinsbroek and Ruitenberg, 2010). 
Therefore, due to specific problems associated with the oral route and the use of live 
vaccines such as OPV, researchers have used various strategies to overcome these 
barriers which will result in potential effective oral vaccines. These strategies include 
developing particulate carrier systems which use sub-unit vaccines instead of live or 
attenuated vaccines and developing carriers which protect the macromolecule from the 
enzymes in the GIT from degradation and metabolism and other epithelial barriers 
which are discussed in Section 1.5. 
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1.4  Mucosal vaccination 
The mucosal surface area is 400 m
2 
 (Baudner and O'Hagan, 2010) and the main 
functions of the mucosal immune system are to: 
1. Protect the mucous membrane from invasion and colonisation of potentially 
harmful microbes,  
2. Prevent the uptake of foreign proteins derived from food sources or airborne 
matter, 
3. to prevent the development of a harmful immune response to (2) if they reach 
the site (Holmgren and Czerkinsky, 2005).  
The MALT acts as a physical barrier between the external environment and the internal 
cavity of the body, protecting and preventing invasion by bacteria, foreign pathogens 
and micro-organisms. However, due to the large surface area of the overall mucosal 
surface, it is highly susceptible to many pathogenic microorganisms, and therefore has a 
highly specialised immune system in order confer immune protection. The immune 
system is adapted to establish a difference between antigens, pathogens and vaccines 
that enter via mucosal surfaces to those entering via the blood supply or through tissues 
(Neutra and Kozlowski, 2006). It is essential to develop vaccines which target the 
effective cells required to achieve immunity. For example, injected vaccines are poor 
inducers of mucosal immunity hence, are less effective against infection at mucosal 
surfaces (Levine, 2000). Mucosal immune responses are initiated via the MALT which 
is comprised of several sites which include Peyer’s patches, Mesenteric Lymph Nodes 
(MLN), appendix, tonsils and adenoids in the respiratory tract (Kiyono and Fukuyama, 
2004). Within this thesis, one of the aspects will concentrate on vaccine delivery 
systems to the Peyer's patches which contain specialised epithelial cells known as the 
Microfold ‘M’ cells which capture the antigens and subsequently process the antigen to 
local APC’s such as dendritic cells, macrophages and B lymphocytes (Figure 1.1) 
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(Bilsborough and Viney, 2004). M cells are specialised epithelial cells that deliver 
antigens from the lumen of the gut to the epithelial lymphocytes and subsequently to the 
subepithelial lymphoid tissues (Mitragotri, 2005).   
Orally delivered vaccines are recognised by the M cells within the Peyer’s patches 
which uptake the antigen and deliver it to the dendritic cells which reside at this 
location (Holmgren and Czerkinsky, 2005). The immunological response of the 
dendritic cells has been reviewed in detail by Coombes and Powrie (2008), where 
findings indicate that dendritic cells within the Peyer's patches produces higher levels of 
Interleukin-10 (IL-10) than those dendritic cells present within the spleen (Coombes 
and Powrie, 2008). In addition, the CD4
+
 T cells which are activated by the Peyer's 
patches produce higher levels of IL-4 as well as IL-10 (which are represented by a T 
helper 2 phenotype) than those of the spleen dendritic cells (Iwasaki and Kelsall, 1999).  
Figure 1.1 shows that particulates and subunit antigens are taken up by the M cells or 
epithelial cells which predominantly consists of enterocytes and mucus secreting goblet 
cells. M cells have a sparse, irregular microvilli on their apical surface in addition to the 
presence of a basolateral cytoplasmic invagination which creates a pocket containing 
lymphocytes and macrophages (Clark et al., 2001). These features of the M cells are 
believed to establish mucosal immunity by allowing a route for antigens to be delivered. 
This route delivers the antigens to underlying lymphoid tissues where a secretory 
immune response is initiated.  The epithelial cells play a major role in mucosal defence 
as they are able to detect foreign bodies through pattern recognition receptors such as 
Toll-like receptors (TLRs). The release of cytokine and chemokine signals to the 
dendritic cells and macrophages which underline the mucosal cells as shown in Figure 
1.1, allow an innate and adaptive immune response to be triggered (Kagnoff and 
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Eckmann, 1997, Izadpanah et al., 2001, Kraehenbuhl and Neutra, 2000, Neutra and 
Kozlowski, 2006).   
Although the mechanism of action upon absorption by the Peyer’s patches remains 
unknown, the M cells remain good targets for subunit particulate and other oral vaccine 
delivery systems. However, tolerance and mechanisms of uptake still need to be 
resolved and determined. This leads on to the next topic of barriers and strategies of 
delivering vaccine delivery systems to the Peyer's patches and M cells.  
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Induction of a mucosal response 
Figure 1.1: Sequence of events which take place after the antigen is ingested and reaches the mucosal surfaces within the small intestine. (Kiyono and Fukuyama, 
2004, Mitragotri, 2005) 
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1.4.1 Barriers and strategies for effective delivery to M cells 
The small intestine is the site of absorption for electrolytes, nutrients and fluids. 
However, it also acts as a barrier which prevents the absorption of potentially toxic or 
harmful substances. In order for vaccine particulates to be absorbed in the small 
intestine, they must penetrate through two barriers which include the mucus gel layer 
and the mucosa. The intestinal mucosa comprises epithelial cells and their associated 
glands and mucus layer which is a secretion of the high molecular weight glycoprotein 
and other non-specific defences including mucins and antimicrobial proteins 
(Kraehenbuhl and Neutra, 2000). These structures of the mucosal lining trap enzymes 
and create an environment which is highly degradative to substances it comes in contact 
with (Clark et al., 2001). This layer has a major role in protecting the mucosa from 
harmful bacteria, pathogens or chemicals. In addition to protecting the mucosa the 
mucus layer maintains the pH difference that is observed between the GI lumen and the 
mucosa. Therefore, the mucus layer will hinder the diffusion of certain compounds and 
as a result size, pH and electric charge will be major parameters when targeting delivery 
of oral vaccines to these areas. As well as the mucus layer acting as a diffusion barrier, 
it also acts as a physical barrier by preventing the absorption of particles. The mucus 
entraps the particles, causing agglomeration in the mucus layer which then causes an 
increase in net size and a decrease in the diffusion coefficient through the mucus layer. 
The surface charge has a significant impact upon the uptake of particulate delivery 
systems e.g. studies by Tabata and Ikada (1988) have shown that the peak uptake of 
particles occurs with a zeta potential of -70 mV (Tabata and Ikada, 1988). This zeta 
potential also shows excellent stability and results in no coagulation of the particles due 
to the high surface charge (Freitas and Müller, 1998, González-Rodríguez and Rabasco, 
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2011). As a result zeta potential studies should be aimed to achieving such values to 
enable them to be taken up by the membranous cells. 
1.5 Approaches for delivery systems (particulate delivery systems) 
Fundamentally for the delivery of soluble antigens, carrier systems should be designed 
with the target site in mind, therefore for oral vaccines these carriers must be 
sufficiently acid/enzyme resistant, and formulated to promote uptake by the GALT. To 
allow efficiency to be achieved, in terms of eliciting an immune response and providing 
mucosal immunity by mucosal vaccines, particulate delivery systems can be employed 
as presented in figure 1.2. Ideal properties of particulate delivery systems should be 
able to successfully target the mucosal sites (in this case, Peyer's patches) and to allow 
specific interactions to take place at these sites to initiate an immune response. When 
considering particulate uptake, there are a range of factors which have been identified 
as key parameters including: size, charge and hydrophobicity of the particulate, 
designing the systems to be muco/bioadhesive, and the addition of targeting moieties 
and adjuvants to the system. 
Although there are several mucosal routes of administration, such as oral, intranasal, 
inhalation and intravaginal of antigens (Holmgren and Czerkinsky, 2005, Mitragotri, 
2005) this thesis will be focussing on oral delivery of vaccines to the specialised 
epithelial cells of the small intestine and intramuscular delivery of influenza vaccines. 
Mucosal tract epithelial cells vary from site to site within the body with the composition 
of the APCs and lymphocytes also vary at these sites hence Peyer's patch epithelial cells 
will be the main focus of targeting (Baudner and O'Hagan, 2010).  
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Figure 1.2: The current particulate approaches to mucosal delivery systems  
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1.5.1 Microspheres  
Microspheres are small particles with large surface area to volume ratios, which have a 
good potential to deliver drugs. Generally, microspheres are solid, approximately 
spherical particles ranging in size from 1-1000 µm (Lu et al., 2007). Microspheres for 
vaccine delivery have been useful in the delivery of antigens which are ingested by the 
immuno-competent cells, in turn providing controlled antigen release and lasting 
immunity. Microspheres have been reported to protect the antigen from intestinal bile 
salts, the variation in pH along the GIT and from the degradative enzymes (Hanes et al., 
1995, O'Hagan and Illum, 1990).  
Several studies with microspheres have shown that antigens encapsulated in 
microspheres can elicit secretory IgA and circulating antibody IgG in comparison to 
unencapsulated antigen (Langer et al., 1997).  Studies by Eldridge et al, (1989); 
Shakweh et al, (2005) and a review by O’Hagan (1990) have suggested that the Peyer's 
patches readily uptake particles less than 10 µm in size and prefer hydrophobic 
surfaces. Particles within the size range 3 - 10 µm reside within the lymphoid tissue of 
the Peyer's patches (Florence, 2005). In addition to vesicle size, surface charge and 
hydrophobicity are also crucial factors in the uptake of microparticles via the Peyer's 
patches, with both being essential as particles have to translocate between a 
hydrophobic mucus layer and then across a hydrophilic interior of the cell (Hussain et 
al., 2001). In terms of hydrophobicity, Norris and Sinko in 1998 established its role 
through the intestinal mucin and Caco-2 cell monolayers; different poloxamers were 
coated onto microspheres to promote different hydrophobicities and reduce the contact 
angles between the particle/water phase (Norris et al., 1998). Using this range of 
microspheres the authors were able to demonstrate that as the hydrophobicity of the 
microspheres increased better diffusion is observed through the mucus layer. However, 
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this enhanced diffusion effect then decreases through the hydrophilic environment of 
the cellular cytoplasm (Hussain et al., 2001). However, despite the range of advantages 
microspheres offers, one of the major problems hindering the progression of 
microspheres as carriers for vaccine formulations for human use is stability of the 
antigen during microencapsulation, storage and release (Cleland, 1998).  
1.5.2 Nanoparticles  
Nanoparticles are colloidal carriers which range in size between ~10-1000 nm and is a 
fast developing field offering several advantages for potential oral vaccine delivery. 
Whilst generally this could include liposomes, micelles, etc most specifically it can 
refer to polymeric solid particulates within the nano range. With such nanoparticles the 
antigen or vaccine components can be adsorbed onto the surface of the nanoparticles or 
dispersed within the matrix (Vauthier and Bouchemal, 2009). In addition to 
nanoparticles, nanocapsules can be used where the antigen is fully encapsulated within 
the nanocapsule within the core. The core can either be aqueous or oil based depending 
upon the antigen to be used, hence allowing lipophilic or hydrophilic antigens to be 
incorporated (Vauthier and Bouchemal, 2009). Oral administration of antigen-loaded 
nanoparticles can promote antigen stability within the particulate as it transits through 
the GIT due to protection. Alongside stability and protection, the polymers used to 
formulate nanoparticles can be modulated to control physicochemical characteristics 
such as zeta potential and hydrophobicity. In a review by des Rieux et al, (2006) it is 
suggested that in addition to the above advantages, the drug/antigen release properties 
and biological behaviour of the nanoparticles can also be modified (des Rieux et al., 
2006). The resulting nanoparticles are subsequently taken up by the epithelial cells 
within the mucosa, M cells and Peyer's patches (represented in figure 1.1) (Gelperina et 
al., 2005).  
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The materials used to form the particles must be non-reactive and compatible with a 
broad range of excipients as well as their availability in pharmaceutical grade purity 
(Bhavsar and Amiji, 2007, Bhavsar and Amiji, 2007b) and various materials can be 
applied in the formulation of nanoparticles including polymers, lipids, proteins and 
metals (Chadwick et al., 2010). When considering the construction of such 
nanoparticles, the main consideration for oral delivery involves finding equilibrium 
between the desired surface properties and the matrix used in the formulation. These 
factors control nanoparticle uptake and stability; hence it is vital to establish a 
relationship between these two factors. Nanoparticles work on a mechanism of 
releasing their loaded antigen either by particle degradation, erosion, diffusion out of 
the matrix or swelling (Gelperina et al., 2005). Due to these release mechanisms, the 
particulates must be sensitive to the local milieu of the environment such as pH, 
temperature and enzymes including the presence of other particulates such as food.  
The size of the nanoparticles also plays an important role as colloidal instability leads to 
aggregation and flocculation. Similarly the chemical stability of a nanoparticle matrix is 
crucial for its biodegradability and release of the encapsulated antigen (Florence, 2005). 
A recent review by Chadwick et al (2010) studies, in depth, the different polymers 
available for producing nanoparticles, and how the size of the particulates vary 
depending on the polymer used and its properties. The review also suggests how 
polymers can be used to create micelles and complexes of micelles to potentially 
delivery antigens orally with a possibility of improved bioavailability. Micelles in 
general, due to the lack of covalent bonding, have the potential to dissociate especially 
under acidic conditions. This is good when delivering a drug to an acidic compartment, 
such as the stomach, but in terms of oral vaccine delivery to the mucosa, this will not be 
useful as there will be premature release of the antigen. However in general, due to the 
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lack of comparative studies available, there is no conclusion regarding which polymers 
or other formulation factors are the most efficient for nanoparticles in oral delivery. 
Therefore, due to the multitude of parameters which influence the uptake and 
facilitation of nanoparticles in oral delivery there is no general establishment for the 
non-specific uptake into M cells or enterocytes.    
1.5.3 Bioadhesive delivery systems 
As previously mentioned, the primary function of mucosal vaccination relies on the 
movement and transport of the antigen along the mucosa, through the barriers and 
finally to be taken up by the APCs. Bioadhesion is a technique employed to prolong 
residence time of particulate delivery systems by targeting the specialised mucosal M 
cells and adhering to the surfaces. This mechanism of action can allow better uptake of 
the antigen by the APCs, therefore providing an effective means of mucosal vaccine 
delivery (Brayden et al., 2005, Kuolee and Chen, 2008). Bioadhesive delivery systems 
would still require the use of immunological adjuvants to provide an increased immune 
response. Mucoadhesion is another term used to refer to bioadhesion. However, 
generally this describes the interaction of delivery systems and the mucosal surfaces. In 
terms of vaccine delivery, studies carried out by O’Hagan et al, (1993) suggest that 
mucoadhesives contribute to an immune response by several means which include 
increased duration of retention at mucosal site, greater interactions with the mucosal 
epithelium sites, enhanced absorption and the possibility of achieving sustained release 
from the particulate systems (O'Hagan et al., 1993, Baudner and O'Hagan, 2010).   
Currently there are several bioadhesives used within the vaccine field which include 
starch (Rydell et al., 2005), chitosan (Arca et al., 2009, Amidi et al., 2010), hyaluronic 
acid (Singh et al., 2001), carbopol (Kockisch et al., 2003), alginates and lectins (Lavelle 
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et al., 2002, Lavelle et al., 2004, Jepson et al., 2004). Factors which influence these 
bioadhesives and the polymers include the molecular weight, cross-linking and packing, 
concentration, flexibility and the degree of swelling the polymer undergoes upon 
hydration. In addition to these factors, the antigens used within these bioadhesive 
particulates must be compatible in terms of charge interactions and the solubility of the 
antigen in relation to the solubility of the polymer. As a result, bioadhesive systems 
become a very complex system with various parameters that need to be addressed in 
addition to the particulate size, charge and hydrophobicity.  
In various research studies into these bioadhesive systems, bioadhesive particulate 
delivery systems have shown to be successful in animals such as mice; however, when 
up-scaled to human trials these systems become ineffective. For example a study by 
Rydell and Sjoholm (2005), where microparticles made from starch, show promising 
results as an adjuvant carrier in mice (Rydell and Sjoholm, 2005). The results of the 
experiment show that mucosal immunity and systemic immunity was achieved when 
oral dosing starch microspheres in mice. Further to this, Stertman et al (2004) 
challenged the mice with live bacteria and successful protection was achieved 
(Stertman et al., 2004). However at a later stage when Rydell et al (2006) prepared the 
vaccines for human trials, the vaccine was not effective (Rydell et al., 2006). There 
could be a number of possible reasons for the ineffectiveness such as differences in the 
GIT between humans and mice, the longer transit time in humans in relation to mice 
and the differences in the barriers such as thickness of mucous, interference of food 
particulates and other enzymes present. Furthermore, alginate microparticles have 
shown to induce protective immunity against specific bacteria where intestinal IgA 
antibody responses are achieved by alginates delivered orally (Kim et al., 2002, Sun et 
al., 2007). 
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Several recent reviews have been carried out on bioadhesives with an overall review 
carried out by Baudner and O’Hagan (2010) and further in depth reviews on specific 
bioadhesives such as the chitosans by Arca et al (2009) and Amidi et al (2010). In terms 
of bioadhesive particulates as a carrier for antigens, there are promising 
microparticulate formulations available in a broad range of animals using different 
antigens for the oral route. However, there is such a diverse range of properties 
effecting the transit and mechanisms of antigen release from these systems that no 
conclusion can be formed in terms of what is the best design of a bioadhesive 
particulate delivery system. In terms of having a complete delivery system based upon 
bioadhesive particulates, the increased residence time should not be deemed the most 
important parameter to focus on as vesicle size and charge also play a major role in 
protective immunity via the oral mucosal route. 
1.6 Lipid based systems 
As previously mentioned, there are a range of particulate constructs that are being 
considered for drug and vaccine delivery including solid particulate systems (which can 
be built from polymers, lipids, proteins, etc) and bilayer type vesicles (which are built 
from molecules with surfactant type properties). Of these, liposomes are the most well 
known and investigated after their early recognition as vesicles by Bangham (Bangham 
and Horne, 1964) and their first use as delivery systems by Gregoriadis et al (1971). 
However, a wide number of variations, based on these initial liposome systems, have 
been developed including stealth liposomes to improve circulation profiles (Lasic et al., 
1991), vesicles built from non-ionic surfactants also known as non-ionic surfactant 
vesicles (NISVs) or niosomes (e.g. for cosmetics (Handjani-Vila et al., 1979) or as 
drug/antigen carriers (Azmin et al., 1985, Baillie et al., 1985), surfactant polymers (e.g. 
polymersomes (Okada et al., 1995), cationic systems which can electrostatically bind 
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DNA (e.g. lipoplexes (Felgner et al., 1987), vesicles incorporating bile salts to improve 
stability (e.g. bilosomes (Conacher et al., 2001), or virus components (e.g. virosomes 
(Almeida et al., 1975) to name but a few. Many of these systems use alternatives to 
phospholipids to circumvent potential issues related to storage instabilities and cost 
(e.g. synthetic based systems), to improve stability within harsh biological 
environments (e.g. bilosomes and polymersomes), or alternatively to modulate the 
properties of the vesicles in terms of immunological efficacy (e.g. virosomes). 
1.6.1 Liposomes as vaccine adjuvants    
Similar to polymers, lipids are already used in a wide range of commercial product and 
there are a variety of carrier systems that can be formulated from lipids, with liposomes 
probably being the most commonly thought of, given the substantial body of research 
investigating them. However, there are various types of lipid employed in formulations 
including non-polar lipids and polar lipids, with the later being sub-divided into 3 
classes and of these class II being used to formulate liposomes and class III lipids for 
micelles. Liposomes (bilayer vesicles generally composed of phospholipids ranging 
from around 50 nm to several microns in size) were identified as being effective 
immunological adjuvants by Allison and Gregoriadis (1974) where the ability of 
negatively charged liposomes (prepared with the inclusion of dicetyl phosphate) to 
deliver and potentiate immune responses against diphtheria toxoid (DT) was 
demonstrated; from this work a plethora of investigations have subsequently steamed. 
The main cited advantage of bilayer vesicles over microspheres is the ability to easily 
formulate liposomes in a range of sizes with the choice of lipids dictating the liposomes 
surface properties. Like polymer systems, there is a wide range of options for 
manufacturing liposomes with lipid hydration (based on the original work of (Bangham, 
1968)) remaining the simplest and most commonly employed method. After production 
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of multilamellar vesicles (MLV), the vesicles can easily be manipulated to control their 
size and also their antigen loading depending on methods adopted. 
Liposomes have been used in vaccine technology as carriers of antigens, which are 
either encapsulated into the aqueous space, incorporated into the bilayer of the 
liposomes or associated with the surface of the vesicles. Liposomes as carriers of 
antigens allow a reduction in biodistribution but enhance targeting which are vital for 
immunotherapy (Gregoriadis et al., 1999). There are many advantages through the use 
of liposomes for vaccine delivery which include: 
 Protection of drug or antigen from the external milieu of the body such as the 
GIT, due to the encapsulation process. Also, encapsulation of an antigen into 
liposomes can reduce the toxic effects that the antigen exerts in the body upon 
administration. 
 Liposomes themselves are generally non-immunogenic therefore allowing 
suitable systemic and non systemic administrations (Perrie et al, 2008). 
 Variation in liposome size, allows for a broader range of administration routes, 
e.g. nasal, oral, intramuscular, subcutaneous or intravenous. 
 Formulation of liposomes can take place in many forms such as suspensions, 
aerosols, gels, creams and lotions. This is crucial as immunisation via the 
parenteral injection is less economical for a mass immunisation; trained 
personnel and sterile needles are required which poses cost issues. Needle-free 
vaccinations in turn, will also have better patient compliance. 
Cationic liposomes have been studied by Perrie et al (2002) where DNA is either 
entrapped within the bilayers or by a complexation process onto the surface of the 
liposomes. These cationic liposomes result in a positively charged carrier hence 
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allowing electrostatic interactions between the vesicle and the negatively charged cell 
membrane, resulting in intracellular delivery of the DNA (Kirby et al., 2008, Rosada et 
al., 2008). Studies carried out by Szentkuti et al (1997) showed that nanosized cationic 
dyes become entrapped within the negatively charged mucus, hence this could aid 
retention at the cell surface (Szentkuti, 1997).  
 
Lipids have also been the foundation for use as polymerised liposomes or ISCOMS 
where the use of polymerised liposomes has been developed and tested which stabilise 
the vesicles to be used orally (Chen et al., 1996, Gaucher et al., 2010). The generation 
of polymerised liposomes involves creating cross linked networks between the 
liposome membranes which provides stability through the GIT. Studies carried out by 
Chen et al (1996) have shown promising data in protecting the antigen from GIT 
enzymes and degradation. These systems then behave similarly to micro and 
nanoparticulates where polymers are used to protect antigens; however, the release 
mechanisms then vary depending upon the type of polymer used, and its degree of 
crosslinking and other physiochemical properties. Lipid based delivery systems can also 
form immune stimulating complexes (ISCOMs) where they form 3 dimensional cage-
like structures. ISCOMs are generally in the size range similar to viruses of 30 – 70 nm 
in diameter and are composed of phospholipids, cholesterol, antigen and the saponin 
adjuvant Quil A (Copland et al., 2005, Maloy et al., 1994). Saponins comprise powerful 
immunostimulatory activity and then by combining the advantages of particulate 
delivery systems alongside incorporating the antigen forms the basis of ISCOMs and as 
a result can be used to delivery antigens orally. Studies by Mowat and Maloy (1994) 
have shown that hydrophobic antigens readily incorporate into ISCOMs, whereas 
hydrophilic antigens require modification before they can insert into the system. Using 
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ISCOMs to deliver antigens promotes higher induction of Th1 and specific CTL 
responses in comparison to micelle formulations (Sjolander et al., 2001). Clinical trials 
for use in human vaccines are currently ongoing to test the safety, efficacy and toxicity 
profile (Copland et al., 2005). 
For oral vaccine delivery, lipid based vesicles such as liposomes can be used as 
effective carriers of macromolecules, however, when in the GIT they are exposed to 
intestinal bile salts. The intestinal bile salts cause the membrane of the lipid vesicles to 
deform and lyse resulting in the release of macromolecules from the vesicle prior to it 
reaching its intended site of action, thereby resulting in poor vaccine efficacy (Chen et 
al., 1996). Lipid vesicles formed from phospholipids including liposomes can be 
modulated to increase their stability and acceptability to a wide range of antigens by 
manipulating the main lipid used within the formulation. Lipids with different chain 
lengths can be used to alter the phase transition temperatures which can alter the release 
mechanisms of the entrapped antigen. In addition to altering the phase transition of the 
vesicles, the change in the hydrophobic tail lengths also influences the molecular 
packaging configuration of the vesicles. A recent review by Moghaddam et al (2011) on 
the monolayer studies of liposomes shows that increasing the hydrophobic tail regions 
of the lipids results in increased pressure being required to distort the lipid monolayer 
(Moghaddam et al., 2011a). This is ideal when a highly hydrophobic antigen is present 
as it will have a higher chance of encapsulating more antigen within the bilayer 
(Uchegbu and Vyas, 1998). 
In general lipid based vesicles provide several advantages of antigen delivery where 
they can be tailored to have desired effects in vivo. The application needs to be further 
enhanced to see the effects in humans, lipid based vesicles provide a significant 
technological platform however due to the low number of marketed drugs available for 
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oral delivery the field is not moving at the rate it should be. The current focus is on 
making vaccines safer by replacing the attenuated pathogens with subunit vaccines such 
as recombinant proteins or synthetic peptide antigens. These synthetic peptide antigens 
are referred to as new generation vaccines which are usually non-immunogenic. Lipids 
themselves are non-immunogenic; however, lipids themselves may undergo physical or 
chemical transformations over a period of time which may alter stability or formulation 
performance. Long term and continued exploration of these lipid based formulations 
will enable an ideal formulation to be doctored at some stage in the future.  
1.6.2 Niosomes as vaccine delivery systems 
Given the ability of many surfactants to form bilayer vesicles, it is no surprise that such 
a wide range of components have been used to construct these systems. In the case of 
non-ionic surfactants, the ability of these molecules to act as an alternative to lipids as 
building blocks for bilayer vesicles (known as non-ionic surfactant vesicles (NISVs) or 
niosomes) was first reported by Baillie et al, (1985). These niosomes offer all of the 
structural attributes of liposomes in terms of their ability to entrap drugs and antigens 
within the bilayer and/or the aqueous phase, they can be formed in a range of sizes from 
small unilamellar to large multilamellar structures, and they can be surface modified in 
a range of ways similar to liposomes (Uchegbu and Florence, 1995). In addition to these 
standard attributes, niosomes have also been shown to offer additional abilities such as 
forming polyhedral vesicles in aqueous media (Arunothayanun et al., 1999) and have 
been suggested to offer greater chemical stability compared with liposomal systems and 
reduced special handling upon storage (Baillie et al., 1985, Conacher et al., 2001). 
Furthermore in harsh biological environments (such as within the gastro-intestinal tract) 
they have been shown to offer greater stability to acidic and enzymatic degradation 
compared to liposomes (Yoshida et al., 1992, Rentel et al., 1999). However like 
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liposomes, the formation of niosomes requires the input of energy in forms such as 
physical agitation or heat where the structure consists of an enclosed aqueous core 
(Uchegbu and Vyas, 1998).   
Niosomes have been widely used in cosmetics and were first patented by L’Oreal in the 
1970s with their first use being in 1979 as cosmetic products (Handjani-Vila et al., 
1979). Since then, they have been investigated for the delivery of a wide range of drugs 
e.g. anticancer agents (e.g.(Hong et al., 2009, Uchegbu and Duncan, 1997), low 
solubility drugs (e.g.(Mokhtar et al., 2008), antigens (e.g.(Murdan et al., 1999, Gupta et 
al., 2005) and gene therapy (e.g.(Huang et al., 2006). An early review by Gregoriadis 
(1990) has shown that the association of antigen with liposomes improves antigen 
delivery to the antigen presenting cells (APCs) and this attribute is not restricted to 
liposomes;  niosomes, have also been shown to enhance cell mediated immunity in 
addition to humoural immunity (Brewer and Alexander, 1992, Brewer and Alexander, 
1994).  
Whilst niosomes are analogues of liposomes,  the surfactants used to formulate 
niosomes can offer increased chemical stability compared with their phospholipid 
counterparts and therefore, as mentioned above, maybe more resistant to degradation 
within the GIT (Conacher et al., 2001). Unfortunately, there are limited studies on the 
interactions between dendritic cells and niosomes; however, several studies have 
investigated their adjuvant properties which have been confirmed by in vivo studies. As 
discussed by Uchegbu and Vyas (1998), there are various factors which influence 
niosomes and their chemical stability. These factors are generally similar to the factors 
which also influence other particulate delivery systems which include nature of drug, 
hydration temperature, nature of surfactants, characteristics of additives, size reduction 
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techniques and the energy added to the niosome vesicles. Niosomes can be modified in 
terms of drug/antigen loading by altering the nature of the hydrophilic head groups this 
in turn can increase drug efficiency. 
1.6.2.1  Building non-ionic surfactant vesicles (Niosomes, NISV) 
There are a wide range of non-ionic surfactants that can be used to prepare niosomes 
and examples of the types of surfactants which can be used are given in table 1.1. These 
surfactants are most commonly tested and formulated into niosomes with the presence 
of cholesterol due to their chemical stability, resultant sustained release of drugs, low 
toxicity profile and enhanced permeation when delivering via the skin (Manosroi et al., 
2003). 
In general, the formation of non-ionic surfactants into bilayer vesicles is dependent on 
many factors including: temperature, surfactant concentration, electrostatic and 
electrodynamic interactions of the surfactants within the aqueous phase. Furthermore 
the molecular attributes of the surfactant is also an important parameter as the type of 
colloidal or vesicular structure a specific surfactant forms is to a large extent dictated by 
its molecular shape and the mixture of surfactant combinations used, as this will 
influence its geometrical packing properties in a given solution environment. The shape 
of a surfactant may be expressed as its critical packing parameter (CPP) which is 
defined as: 
CPP is the critical packing parameter, 
v  is the molecular volume of the hydrophobic part 
of the lipid, 
ao  is the surface area of the hydrophilic head group, 
lc  is the length of the hydrocarbon chain. 
 
 
CPP =   v 
            aolc 
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Table 1.1: Properties of some commonly used surfactants in the preparation of niosomes.  
Surfactant  Structure Molecular 
Weight 
Melting point 
(°C) 
Tc (°C) 
1-monopalmitoyl-rac-
glycerol (MPG) 
 
330.5 71-72 23 
Dicetyl Phosphate (DCP) 
 
546 74-75 - 
Sorbitan monostearate 
(span 60) 
 
430.62 54-57 55 
Polyethylene glycol sorbitan 
monostearate (Tween 60) 
 
1309 55-60 40.6 
Glyceryl monostearate 
(GMS) 
 
358.57 58-59 >65 
Polyoxyethylene (4) lauryl 
ether (Brij 30) 
 362.5 1.67 <10 
Cholesterol 
 
296.65 147-149 - 
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The CPP value can be used as an indicator to predict geometry of surfactants and the 
resultant structures they can form as represented in figure 1.3: a CPP value < 0.5 
(indicating a large contribution from the hydrophilic head group area) suggests the 
surfactant forms spherical micelles, a value between 0.5 < CPP < 1 forms bilayer 
vesicles and a CPP > 1 (indicating a large contribution from the hydrophobic group 
volume) results in inverted micelles (Uchegbu and Vyas, 1998, Biswal et al., 2008, 
Perrie and Rades, 2009, Israelachvili and Mitchell, 1975, Israelachvili et al., 1977). 
Therefore, depending upon the type of vesicle required, the CPP gives a good indication 
on the surfactants that can be used.  
 
Figure 1.3: The critical packing parameters of lipids and the structures they form. 
It is interesting to note that many single chain surfactants have CPP < 0.5 and form 
micelles, yet these are often used to formulate niosomes; however, not without the 
addition of additional components. For example, soluble surfactants (such as solulan C-
24 and polysorbate 20) with high hydrophilic-lipophilic balance values (HLB) readily 
form micelles. Yet with the inclusion of cholesterol into the mixture, niosome vesicle 
structures are formed, thus increasing the physical stability of the vesicles (Uchegbu 
and Florence, 1995, Manosroi et al., 2003, Carafa et al., 1998). The ability of 
cholesterol to promote the formation of two-phase bilayer systems, rather than single 
phase micellar solutions, is related to the overall CPP of the lipid mixture. It is 
understood that in cases where a mixture of surfactants and additives such as 
Chapter 1 : General Introduction 
 
53 
 
cholesterol are used to prepare vesicles, the operational CPP values will consider the 
average of the overall components (Kumar, 1991) and Manosroi et al, (2003) have 
confirmed that as cholesterol is incorporated within a Tween 61 surfactant mixture, an 
average CPP value between 0.5 - 1 was obtained hence the formation of bilayer vesicles 
rather than micelles (Manosroi et al., 2003). Similarly, Tween 20 has a CPP below 0.5; 
however, when mixed with cholesterol unilamellar vesicles were formed (Carafa et al., 
1998) as does with Span 60, which is widely used in the formulation of niosomes (Ning 
et al., 2005, Uchegbu et al., 1995). This is due to the average CPP of the mixture 
moving into the range of 0.5-1, hence showing capabilities of forming bilayer vesicles. 
Due to high phase transition temperatures of Span 60, leakage of drug molecules from 
the bilayer has been reported (Srinivas et al, 2010);  the incorporation of cholesterol has 
also been shown to stabilise the vesicles by abolishing the phase transition temperature 
of the vesicles hence avoiding leakage of drug molecules from the bilayer (Srinivas et 
al., 2010, Uchegbu and Vyas, 1998). It is clear from the thermodynamic consideration 
that bilayer structures do not exist as such in the absence of water because it is water 
that provides the driving force for surfactant molecules to assume a bilayer 
configuration and unlike micelles, the assembly into closed bilayers is rarely 
spontaneous and usually involves input of energy such as physical agitation or heat 
(Lasic, 1990). The excess free energy change between water and a hydrophobic 
environment explains the preference of appropriate surfactants to assemble into bilayer 
structures, excluding water as much as possible from their hydrophobic regions, in 
order to achieve the lowest free energy level and consequently the highest stability for 
the aggregate structure.  
Another commonly used non-ionic surfactant, monopalmitoyl-glycerol (MPG) used to 
formulate niosomes for a range of studies (e.g. (Brewer and Alexander, 1992), requires 
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the inclusion of additional surfactants to support vesicle construction. The addition of 
cholesterol and dicetyl phosphate to MPG forms stable niosomes and the ratio of these 
combinations can dictate the physical attributes of these systems. This interplay 
between vesicle size and cholesterol content has also been noted by Van Hal et al, 1996 
who reported a decrease in vesicle size upon increased cholesterol content. 
Furthermore, cholesterol has the ability to influence the packing density within the 
bilayer and in turn increase the planarity of the bilayer resulting in uniform bilayers 
(van Hal et al., 1996, Moghaddam et al., 2011a). In addition, DCP incorporation in 
niosomes has been proven in several studies, including vaccine delivery to alcohol free 
niosome gel formulations, to stabilise vesicles against fusion and aggregation where the 
vesicles obtain their net negative charge (Uchegbu and Florence, 1995, Barakat et al., 
2009, Jadon et al., 2009). 
1.6.2.3  The addition of cholesterol to niosome formulations 
Given the above outlined advantages the addition of cholesterol can offer to a 
formulation, it is understandable why nearly all current studies investigating niosomes 
have incorporated cholesterol into the vesicle composition. Indeed when dispersed 
without the presence of cholesterol, high solubility non-ionic surfactants form micelles 
and low solubility non-ionic surfactants often form a gel (Yoshioka et al., 1994). 
However the use of cholesterol not only promotes vesicles formation from a wide range 
of non-ionic surfactants, its inclusion in both liposome or niosome formulations is 
known to remove the gel-liquid transition of the surfactant bilayer and hence influences 
bilayer fluidity (Taylor and Morris, 1995).  
The preparation method is a key parameter in the formation of structured bilayers when 
considering the transition temperature. For example, the hydration temperature 
determines the overall size and shape of the vesicles formed. In both liposome and 
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niosome systems the bilayer membrane is an ordered structure and may exist in the gel 
state, indicating a situation where the alkyl chains are tilted at a slight angle with 
respect to the plane of the bilayer, or the liquid crystalline state. The difference between 
these two phases is the degree of order, with the gel state being the most ordered 
structure than the liquid crystalline state. In the liquid crystalline state there is lateral 
diffusion of bilayer material whereas in the gel state the alkyl chains are crystallised or 
otherwise less mobile. For any system, the liquid crystalline state exists at a higher 
temperature than the gel state. The increase in the temperature (Tc), although yielding 
an increase in the enthalpy term (ΔH), also results in an increase in entropy (ΔS) and 
thus a lowering of the free energy (ΔG) of the system occurs and it is the application of 
heat that is the driving force for this transition (New, 1990). Hence the formation of 
niosome vesicles should occur above the Tc of the gel to liquid phase transition 
allowing mobility of the bilayer and hence reordering of surfactants to produce 
spherical uniform vesicles. 
Interestingly, controlling the phase in which the bilayer is in can influence the structure 
of niosomes: for example not all niosomes are spherical in nature, as is the case with 
polyhedral niosomes (Arunothayanun et al., 1999). The niosomes in this study were 
prepared by hydrating thin films of surfactant/lipid blends where they were analysed for 
morphology and rheological properties. The studies showed that niosomes formed from 
hexadecyl diglycerol and other polyoxyethylene alkyl esters form a variety of shapes 
due to the differences in membrane composition. The incorporation of cholesterol 
results in large spherical vesicles; however, the exclusion of cholesterol resulted in the 
formation of polyhedral niosomes (Arunothayanun et al., 1999). These polyhedral 
niosomes were heated above their transition temperature, at which a reversible shape 
transformation into spherical niosomes occurred indicating that the niosomes go from a 
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gel state at room temperature to a liquid-crystalline state at their Tc. As a result, the 
rheological properties of the polyhedral niosomes are more rigid and viscous in 
comparison to their spherical counterpart structures at the elevated temperatures. 
Therefore, when formulating niosomes for different routes of administration, 
characterisation should be carried out to ensure the niosomes are able to effectively 
perform at their intended site of action.  
1.6.3 Bilosomes 
Vesicle lysis of lipid based vesicles when administered orally has been the foundation 
for the development of modified lipid based vesicles which have increased stability to 
allow the vesicle to reach the site of action and to have increased absorption through the 
GIT. These modified vesicles are known as bilosomes, which are a relatively new drug 
delivery system for oral vaccine delivery. Bilosomes intend to protect antigens from the 
enzymes present in the GIT and they can act as potent immunological adjuvants. 
Bilosomes incorporate bile salts, such as sodium deoxycholate, into the niosome 
formulation (Bennett et al., 2009) protecting them from the effects of bile acids within 
the GIT (Schubert et al., 1983). The aim is to aid vaccine technology by increasing the 
stability of the carrier thus, preventing premature release of the protein/ antigen via the 
oral route.  
Research suggests (Schubert et al., 1983) that by incorporating bile salts into the 
vesicles they resist degradation and disruption from the digestive enzymes (Figure 1.4) 
therefore making the formulation more stable and giving the potential rise for an oral 
route of delivery for vaccines (Conacher et al., 2001). By preventing premature release, 
bilosomes deliver the vaccines to the site of action which means the antigen is directly 
delivered to the mucosal tissue. As a result of the bilosomes delivering the antigen to 
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the mucosal tissue, smaller concentrations of the antigen can be used to provide an 
effective response. An advantage of this is that a wide range of antigens can be used, 
including weaker ones as the delivery is site specific.  
Alexander and Brewer (Brewer et al,. 2001) first developed and formulated bilosomes 
by exploiting non-ionic surfactant vesicle (NISV) technology. NISVs resemble 
liposomes in their structure but possess very low toxicity thus, can function as 
successful adjuvants which elicit immune responses after parenteral administration. 
Bilosomes use NISVs as their structure but with the incorporation of bile salts as part of 
the vesicle structure. Recent studies using bilosomes incorporating several antigens 
have proven to be successful in animals such as the A/panama (Mann et al., 2004), 
tetanus toxoid (Mann et al., 2006) and hepatitis B (Shukla et al., 2008). These studies 
on the various antigens have shown significant antibody titres and have also shown 
increased antibody production, lower temperatures and reduced symptoms in relation to 
IM injections when dosing with influenza haemgglutinin entrapped bilosomes (Bennett 
et al., 2009). Bile salt incorporation within the vesicles, stabilise and protect the vesicles 
from the GIT (Figure 1.4) and other enzymes present in the body allowing bilosomes to 
be used orally as vaccine drug delivery system. In the bilosome studies by Mann et al, 
(2006), Bennet et al, (2009), Mann et al, (2004) and Mann et al, (2009) the anionic lipid 
dicetyl phosphate (DCP), is used in the formulation of bilosomes. These studies all 
show that, by orally administering the bilosome vesicles with the antigen entrapped, a 
mucosal immune response is elicited with specific IgA production increased from the 
mucosal cells in the small intestines is initiated.   
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Figure 1.4: Representation of vesicles with and without bile salts. Present are two pathways where A) is a normal lipid vesicle which is disrupted by the intestinal bile 
salts, causing degradation and vesicle lysis and pathway B) where the lipid vesicles have bile salt incorporated into the structure prior to gastrointestinal exposure 
shows membrane stability when in the presence of intestinal bile salts.   
A 
B 
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The production of IgA levels suggests that the oral immune response has been 
successfully initiated (Figure 1.1).  The incorporation of the DCP lipid within the 
formulation results in the vesicles having a highly negative surface charge which could 
potentially be the reason for such increased levels of immunity achieved from orally 
dosing the bilosome vesicles. These studies confirm previous work by Tabata and Ikada 
(1988) where they showed that the peak uptake of particles occurs with a zeta potential 
of -70 mV in the epithelial cells (Tabata and Ikada, 1988). This is also in line with 
studies by Norris et al, (1998) and Eldridge et al, (1990) where they also found that the 
uptake of negatively charged particulates is favoured (Norris et al., 1998, Eldridge et 
al., 1990). In addition, the work carried out by Shakweh and co-workers (2005) 
suggests that negatively charged or neutral particles in mice have a greater affinity for 
the Peyer’s patches than positively charged particles (Shakweh et al., 2005). As a result, 
various studies carried out on mucosal particulate uptake all stem down to the presence 
of a negative surface charge. This allows uptake by the M cells within the Peyer's 
patches and trigger the dendritic cells and initiate the immune response.      
1.7 Virosomes 
Virosome vesicles are reconstituted viral envelopes which are made of unilamellar 
phospholipid bilayers which incorporate virus derived cell binding and fusion 
properties. The key to virosomes are that they are absent in the genetic material of the 
virus which is the ‘danger’ part of the virus (Copland et al., 2005). Virosomes, as they 
are formed by the extraction of glycoproteins and phospholipids from virus particles 
they can be engineered and tailored to incorporate antigenic material. This antigenic 
material can be incorporated into the lipophilic or hydrophilic regions of the virosome 
depending upon the antigen solubility. Virosomes are similar to liposomes; however, 
the presence of haemagglutinin allows the virosome mechanism of action to vary where 
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it can deliver the contents directly to the cytoplasmic compartment.  Currently the only 
licensed virosome formulations are parenteral formulations taken intramuscularly the 
products are Epaxal (Hepatitis A) and Inflexal V (Influenza seasonal) which is patented 
and developed by Berna Biotech Switzerland (Copland et al., 2005).  
Virosomes although they are delivered IM provide a platform which can be adapted to 
many vaccines where lipids, adjuvants, combination of antigens and other materials 
such as bioadhesives can be added to the viral membrane and possibly administered 
orally to animals to test the efficacy. Potentially, studies may modify the virosome 
surface to be exposed to mucosal surfaces; however, this will need to be monitored 
carefully as the delivery system will be highly immunogenic and as a result no immune 
response should be created to the delivery system. 
1.8 Mucosal adjuvants 
A range of immunostimulatory agents are available such as monophosphoryl lipid A, 
Quillaja saponaria (Quil-A), CpG oligodeoxynucleotides, trehalose 6,6-dibhenate 
(TDB).   Currently, the most potent mucosal adjuvants which are studied for 
immunisation are the cholera toxin (CT) and the heat labile enterotoxin E.coli (LT) 
(Tamura and Kurata, 2000, Holmgren et al., 2003, Plant and Williams, 2004). These 
mucosal adjuvants provide long lasting immune responses either systemic or mucosal in 
turn, allowing the body to induce immunity at low antigen concentrations and doses 
(Holmgren and Czerkinsky, 1992, Rappuoli et al., 1999). The major drawback of these 
two mucosal adjuvants are that they are extremely toxic hence are not in human clinical 
trials. As a result, there is research being carried out on acceptable derivatives of these 
toxins with reduced toxicity but retaining the adjuvant activity for use in humans. One 
of these products includes a non-toxic recombinantly produced Cholera toxin B subunit 
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(CTB) which promotes mucosal immunity sIgA which is important in the elucidation of 
an oral immune response. In addition to mucosal immunity, the CTB also provides anti-
inflammatory tolerance to self antigens (Holmgren and Czerkinsky, 2005, Stanford et 
al., 2004). Other examples of current mucosal adjuvant derivatives include detoxified 
mutants of the LT where the active toxic subunit has been modified to remove the toxic 
components. This has resulted in the loss of adjuvanticity however, studies show that 
there are a few proteins with significant adjuvanticity even without the presence of the 
detectable toxic component when administered intranasally (Pizza et al., 2001). A 
recent review by Baudner and O’Hagan (2010) and studies by Holmgren and 
Czerkinsky (2005) show different mucosal adjuvants and their effectiveness; however, 
the majority of studies focus on nasal administration (Holmgren and Czerkinsky, 2005). 
A promising approach has been identified where hybrid molecules of the cholera toxin 
subunit has been linked to specific APC (CTA1-DD) from a bacteria Staphylococcus 
aureus (Lycke, 2004).  The incorporation of this CTA1-DD and antigen into ISCOM 
vesicles may provide oral usage possibilities by maintaining adjuvant effectiveness 
(Holmgren and Czerkinsky, 2005).  
Novasome
™
 adjuvants, also referred to as non-phospholipid liposomes (Chambers et 
al., 2004) are multicomponent adjuvant systems made up of dioxyethylene cetyl ether, 
cholesterol, and oleic acid have been licensed for veterinary application (for the 
immunisation of fowl against Newcastle virus disease and avian rheovirus). The 
Novasome
™
 technology, made with glycerol monostearate and butyl alcohol and 
included the potent adjuvant monophosphoryl lipid A (Chambers et al., 2004), was 
shown to offer protection of guinea pigs against aerosol challenge with virulent M. 
bovis. 
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Mucosal adjuvants show promising data in terms of eliciting an immune response by 
increasing the immunity to low concentration antigens however, due to the toxicity of 
the adjuvants they have been rendered unsafe to use for human clinical trials. Mucosal 
adjuvants essentially if formulated to show minimal toxicity can be administered and 
used in combination with other particulate delivery systems to enhance mucosal 
immune responses therefore, reducing the requirement for multiple dosing or high 
concentrations of antigen use. 
1.9 Characterisation of niosomes – commonly measured parameters  
To achieve effective sub-unit vaccine delivery or drug delivery via the use of niosomes, 
it is essential to study the physico-chemical characteristics which will determine the 
stability and efficacy of the delivery system. In general, there are various methods 
employed to characterise delivery systems which include vesicle size, suspension pH, 
vesicle zeta potential, entrapment loading studies and microscopy studies such as freeze 
fracture, transmission electron microscopy or basic light microscopy. It is important to 
ensure that the niosomes produced and tested whether in vitro or in vivo have the same 
characteristics in terms of charge, vesicle size, and amount of antigen or drug entrapped 
as differences could lead to differences in efficacy and results obtained.  
1.9.1 Antigen entrapment within vesicles  
Entrapment efficiency is obviously an important parameter as it influences 
surfactant/antigen ratio and total amounts of antigens needed. It can be measured using 
a range of techniques including: separating the unentrapped drug or antigen e.g. by 
centrifugation (Brewer and Alexander, 1992), dialysis (Baillie et al., 1985) or gel 
filtration (Uchegbu and Florence, 1995). For protein and peptide-based antigen assays 
such as the ninhydrin assay can be used to measure entrapment of peptides and proteins 
within niosomes as this assay eliminates any interference of lipids or surfactants when 
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compared to other assays such as the BCA assay (Brewer et al., 1995). In some cases 
the Lowry method for protein concentrations are used, which works on the general 
principle under alkaline conditions where the divalent copper ion reacts with peptide 
bonds hence forming a complex in which it is reduced to a monovalent ion. This 
monovalent copper ion, along with the other radical groups of the reagents, react with a 
Folin reagent resulting in an unstable product which is reduced to tungsten blue. The 
limitations of this method are that for the reaction to occur a pH of 9-11 needs to be 
maintained and that certain buffers, lipids and drugs may interfere with the assay hence 
appropriate filtration and dilutions are needed before running the assay (Lowry et al., 
1951). Due to the limitations of the Lowry method, a simpler and less sensitive to 
interference assay is the Bradford assay. The Bradford assay is analysed at a 
wavelength of 595 nm as this becomes the lambda max for the reagent Coomassie 
brilliant blue G-250 when protein binding occurs. The colour change is observed due to 
the stabilising effect of the anionic dye by hydrophobic and ionic interactions of the 
reaction (Kruger, 2002).  
1.9.2 Vesicle diameter and morphology  
The vesicle size and polydispersity of a niosome suspension can be determined using 
various techniques including: e.g. light microscopy, freeze fracture electron microscopy 
and laser diffraction. Laser diffraction is commonly used in the analysis of particle size 
for suspensions, aerosols, emulsions and other pharmaceutical products. Of the physical 
attributes, particle size and polydispersity are often seen as key factors that may affect 
product stability and in vivo efficacy.  The basic principle of laser diffraction is that a 
laser which supplies the light is passed through the suspension and the interactions of 
the light with the particles (diffraction) is measured.  Generally, the laser beam runs 
parallel to the laser diffraction sensors and the intensity of the diffracted laser from each 
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particle which passes through a Fourier lens is measured by a detector. The intensity of 
the diffraction is recorded on the photo-detector which establishes the particle size. 
Within the studies a wet dispersion system will be used with a Quartz cuvette which 
creates a dynamic event rather than a static measurement and any simultaneous 
diffraction on more than one particle will result in a superposition of the diffraction 
patterns of the individual particles where an average will be taken. 
As already noted, particle size is a critical factor in determining the fate of orally 
delivered particulates both, in terms of their uptake and potentially the type of response 
the systems potentiate.  Whilst three possible routes of GI uptake of small particles 
(intracellular uptake by enterocytes, intercellular/paracellular transfer and uptake via the 
M cells of the Peyer’s patch) have previously been considered, it is now mainly agreed 
that particulate uptake in mammals is chiefly via the M cells of Peyer’s patches (Lavelle 
et al., 1995).   
When orally administering vaccines the size of the carrier systems are crucial for 
determining uptake and retention at the immuno-competent cells within the gut which 
are known as Peyer’s patches. Studies by Eldridge et al. (1990) on vesicle size uptake in 
the Peyer's patches show that uptake is dependent on both the vesicle size and 
hydrophobicity (Eldridge et al., 1990). The results from their experiments indicate that 
a vesicle size of 10 µm or less are taken up by the Peyer’s patches; however, particles 
with a size less than 5 µm can traffic to other tissue cells by a process of lymphoid 
drainage. Therefore, the vesicle size plays a crucial role when designing vaccine carrier 
systems to successfully allow the vaccine and the carrier to reach and retain at the target 
site to allow them to exert their therapeutic effect. In addition to laser diffraction, it is 
important to confirm the shape and structure of the niosomes and microscopy 
techniques can be used to consider this.  
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A review by Bibi et al, discusses the advantages and limitations of specific microscopy 
techniques to analyse vesicles (Bibi et al., 2011). Although there are several microscopy 
techniques available for the image analysis of vesicles, techniques such as light 
microscopy offers basic conformation of morphology and size of the vesicles. However, 
when examining vesicles in greater detail, advanced microscopy techniques are 
available such as the various transmission electron microscopy (TEM) techniques 
which include, negative stain TEM, Cryo-TEM and freeze fracture TEM. In particular 
the use of freeze-fracture can give greater detail on both the size and number of bilayers 
the niosomes have; however general light microscopy can offer a good overview of 
heterogenicity.  
1.9.3 Surface charge 
In terms of characterising niosomes, the zeta potential is the simplest way to measure 
surface charge of vesicles and gives a representation of the stability of a formulation. A 
highly positive or negative zeta potential can imply that the vesicle suspension is more 
likely to resist aggregation (Freitas and Müller, 1998, González-Rodríguez and 
Rabasco, 2011). Zeta potential is a function of the vesicle surface charge which is 
calculated at the surface interface and the nature of the surrounding medium. The Zeta 
potential is the nearest experimental approximation of surface potential in milivolts 
(mV), as both the surface potential and stern potential are difficult to measure. When an 
electric current is passed through each particle, the rate and extent of ion movement 
within the double layer and the surrounding medium can be used to determine the zeta 
potential. Hence, the zeta potential is the potential at the surface of shear which is 
measured by electrophoresis and reflects the effective charge on the vesicles and the 
repulsion between them, in turn giving an insight into the stability and flocculation of 
the suspension (Florence and Attwood, 2006).  
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In terms of surface charge, anionic, cationic and neutral systems have been used as oral 
vaccine delivery systems. In most cases PLGA microspheres, unless modified, will 
have an anionic charge due to the presence of the carboxylic groups, and as already 
noted these particulates are taken up after oral administration (Shakweh et al., 2005). 
The bilosome formulations investigated are all highly negatively charged as they are 
formulated from bile salts, non-ionic surfactant, cholesterol and the anionic surfactant 
dicetyl phosphate (DCP), generally at around a 10 % molar content. Based in 
fluorescent microscopy studies, anionic liposomes formulated using phosphatidyl serine 
(PS) were also shown to have improved uptake by Peyer’s Patches compared to 
liposomes formulated without the inclusion of PS (Tomizawa et al., 1993, Aramaki et 
al., 1993). Norris et al, (1998) and Eldridge et al, (1990) also found that the uptake of 
negatively charged particulates was favoured (Norris et al., 1998, Eldridge et al., 1990). 
The work carried out by Shakweh and co-workers (2005) also compared the binding 
and uptake of differently charged PLGA microsphere formulations and noted that 
whilst the binding to Peyer’s Patch free tissue was similar for all microspheres over 48 
h, the uptake by Peyer’s patches was notably higher for negatively charged or neutral 
particles in mice positively charged particles (Shakweh et al., 2005).  
However cationic formulations (e.g. employing cationic lipids or chitosan), often 
employed for DNA delivery, have also been shown to be effective oral vaccine 
adjuvants. For example, a cationic liposomal oral mycobacterium DNA vaccine 
formulated using Lipofectamine
TM 
2000 (Invitrogen Corporation, USA) was shown to 
be effective in protecting and delivering plasmid DNA via the oral route to the 
epithelium, M cells, DCs and Peyer’s patches of the small intestine of mice, and 
subsequently they were able to promote expression of the encoded Ag85A antigen at 
these sites. By doing so the cationic liposome formulation was able to induce higher 
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specific mucosal cellular and humoural immune responses compared to DNA alone 
(Wang et al., 2010). The use of oral DNA vaccines using cationic particulates is also 
being extensively investigated for vaccination of fish (Rajesh Kumar et al., 2008, Ning 
et al., 2009, de las Heras et al., 2010). 
Whilst considering these surface characteristics, it should be kept in context that the 
surface charge (commonly considered by measuring the zeta potential) is measured 
generally in a buffer or water, and not in the various environments of the GIT. Given 
the changes in pH, the presence of salts, enzymes and other moieties it would not be 
unsurprising to consider the surface characteristics of these particulates will change.  
Indeed studying the zeta potential of cationic liposomes was shown to be dramatically 
different (~ 40 mV vs ~15 mV) depending if the liposomes were in simulated gastric or 
intestinal media respectively (Perrie et al., 2002). Whilst changes in zeta potential of 
vesicles, due to changes in pH, are often reversible, such changes may impact on 
antigen loading which relies on electrostatic interactions.  
1.9.4 Hydrophobicity 
Further to surface charge of vesicles, the hydrophobicity/hydrophilicity of particles can 
play an important role in vesicle delivery and uptake. For example, liposome uptake 
within the body can be influenced by the presence of a polyethylene glycol coating on 
the vesicle surface which modifies the surface hydrophilicity and in return reduces 
opsonisation and macrophage recognition (Allen et al., 1995). By reducing 
opsonisation, the liposomes increase their circulation time within the body however for 
a vaccine delivery system this may be counter-productive. As a result the 
hydrophobicity of the vesicles should be taken into consideration when optimising 
bilayer vesicles for adjuvant activity. 
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Figure 1.5: Summary of barriers and particulate delivery systems to overcome these barriers. 
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1.10 Aims and Objectives 
Over the decade it has become apparent that more research is needed to develop 
mucosal vaccines as an alternative to the current needle based vaccines due to the 
increased pressure of regulations and immunisation strategies. With greater 
understanding of the mucosal immune response, and the advantages of the immunity 
achieved via the mucosal route, interesting research is being carried out on the various 
oral delivery systems to achieving an ideal formulation. Although there are a few oral 
vaccines on market such as the OPV for human use, it is essential to develop a broader 
range of mucosal vaccines by using particulate delivery systems which protect the 
antigens and supply them to the site of action where an immune response can be 
initiated. The use of effective adjuvants, either in combination, or formulated within the 
particulate delivery system will promote the mucosal immune response towards the 
desired effect.  
Several particulate delivery systems and mucosal adjuvants have been developed and 
are showing promising data, their effectiveness and usefulness is yet to be established in 
humans. The push towards particulate delivery systems stem from the safety issues 
which arise when administering live or attenuated vaccines as reversion to the virulence 
form can take place. The use of inactivated vaccines often fail to initiate an immune 
response where subunit vaccines are generally weak immunogens and are subject to 
degradation before reaching the site of action. As a result delivery systems which 
protect the subunit antigen from the external milieu of the body need to be formulated 
which can incorporate adjuvants exerting its desired effect on the mucosal immune 
system. Delivery systems include the use of lipid based vesicles (liposomes, niosomes, 
bilosomes, virosomes etc), micelles, ISCOMs, nanoparticles and microspheres where 
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they can be manufactured using lipids, polymers, proteins and in some cases metals. 
The carrier system must not be affected by the type of antigen or be influenced by the 
payload of the antigen. The major advantage of particulate delivery systems is the 
diverse range of materials which can be used to produce the particulates and how they 
can be tailored and modified to give specific release profiles and protection of antigen 
or drugs. 
As a result, the aim of this research was to design and produce a delivery system with 
desirable characteristics of size, charge, hydrophobicity and antigen retention to enable 
successful delivery of subunit vaccines when administered intramuscularly or 
administered to the oral mucosa safely and efficiently. In order to accomplish this, the 
objectives were to: 
 design a suitable carrier system with optimal characteristics for size, charge and 
antigen entrapment by the use of Design of Experiments and various 
microscopy techniques. 
 understand surfactant structure interactions and molecular packaging by the use 
of Langmuir monolayer studies and the thermodynamics of the surfactants and 
vesicles with the use of Thermogravimetric (TGA) and Differential Scanning 
Calorimetry (DSC) analysis. 
 evaluate the oral biodistribution of the niosome vesicles and the associated 
antigen to determine the physicochemical characteristics with the uptake by the 
Peyer's patches to determine immunological function. 
 compare the immunogenicity and thermostability of the niosome vesicles 
against a previously published method of manufacture of niosome vesicles. 
 develop an alternative solid dosage format in the form of tablets and capsules 
for the vaccine carrier systems. 
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2.1 Introduction 
2.1.1 Overview 
An effective vaccine is one which prevents infection and disease through its capability 
to elicit specific immune responses and hence provide protective immunity (Bramwell 
and Perrie, 2005). However, ease of use is also a key consideration for global 
vaccination campaigns. In this respect, oral vaccines offer significant benefits over 
traditional vaccines due to their ease of administration, improved patient compliance 
(due to their needle-free format), potentially enhanced mucosal immunity, and strong 
resistance against many pathogens. Furthermore due to its non-invasive nature and ease 
of access, the oral route can circumvent the need for trained personnel to administer the 
vaccine. Unfortunately, the ability of many vaccines to withstand the harsh journey 
through the gastrointestinal tract and to be effectively taken up in the appropriate target 
site is limited (Wilkhu et al., 2011).  
To address this barrier, delivery systems can be employed. For example, lipid based 
vesicles such as liposomes or niosomes can be used as effective carriers of 
macromolecules (Bramwell and Perrie, 2006). Yet, many of these constructs can be 
destabilised after exposure to intestinal bile salts which have the potential to cause the 
membrane deformation and vesicle lysis, resulting in the release of macromolecules 
from the vesicle prior to its intended site of action. In response to this, a range of 
modified lipid based vesicles, which have increased stability and increased absorption 
through the GIT, have been developed. Such vesicles include bilosomes, which have 
been shown to protect antigens from the enzymes present in the GIT and act as potent 
immunological adjuvants (Mann et al., 2004). This has been attributed to the 
incorporation of bile salts into the vesicles which increases resistance to degradation 
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and disruption by digestive enzymes (Schubert et al., 1983) allowing the vaccine to 
reach the target site, the M cells located in the Peyer’s patches (Schmucker et al., 1996).   
The ability of bilosomes to act as potential carriers for oral vaccines has been 
established by e.g. Conacher et al, (2001) who demonstrated that by including bile salts 
in the vesicle constructs, the vesicles could prevent antigen degradation within the 
highly acidic conditions of the stomach and improve oral vaccine efficacy (Norris et al., 
1998, Conacher et al., 2001). 
 
Similar studies have also confirmed this with a range of 
antigens e.g. tetanus toxoid (Mann et al., 2006), the A/panama (Mann et al., 2004), and 
hepatitis B (Shukla et al., 2010).  These studies all show that, by orally administering 
the bilosome vesicles with entrapped antigen, a mucosal immune response is elicited 
with specific IgA production increased. Therefore, bilosomes can aid vaccine 
technology by increasing the stability of the vaccine during transit through the GIT, 
preventing premature release of the antigen during oral transit (Wilkhu et al., 2011). 
However, from these studies several potential controlling parameters for the design of 
bilosome constructs become apparent: vesicle size is vital as this determines the end 
location of the vaccine when administered, and the surface charge of the vesicles 
(which is measured via the zeta potential, and influenced by the suspension pH) is also 
important when determining the stability and absorption of the vaccine (Norris et al., 
1998).  
2.1.2 Design of experiments (DoE) 
DoE can be used to plan and conduct experiments in a random order and be used to 
extract the utmost information from the data obtained. The aim of designing an 
experiment through MODDE was to gather data in the fewest number of experimental 
runs, therefore, saving time and resources. In general, MODDE (Umetrics, Sweden) 
varies the factors in the experiment simultaneously over the planned experiments with 
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the aim to analyse the data using a mathematical model which the software generates. 
Using the model, the data can then be interpreted and predictions can be made which 
will result in the optimisation of the experiment parameters. 
Within this study all of the formulations to be tested were calculated using MODDE 
and each was prepared and was analysed for suspension pH, vesicle size and vesicle 
zeta potential. The study undertaken in this chapter involves the use of DoE, where 
bilosomes were produced with and without peptides to see if there are any changes to 
the responses upon the addition of peptides to the bilosomes. To do this an experimental 
design was planned out and two copies of the design were used where one was for an 
empty bilosome study and the other for a study with peptides. The bilosomes were 
produced as stated in the method in section 2.2.3.  
2.1.3 Aims and objectives 
In the formulation of bilosomes, a range of formulations have been considered 
including compositions comprise of monopalmitoyl glycerol: cholesterol : dicetyl 
phosphate (5:4:1 molar ratio) and bile salt or sorbitan tristearate : cholesterol : dicetyl 
phosphate (7:4:1) with bile salts (Mann et al., 2004, Shukla et al., 2008). As a result, 
this study will use MPG as the main surfactant and will be kept constant at a molar ratio 
of 5 as this is an important component for the formulation of the bilosomes. The major 
components that were varied in this experiment were cholesterol, DCP and bile salt as 
represented within the design space in figure 2.1. This experiment has used the 
capabilities of MODDE to design an experiment for the formulation of bilosomes with 
the outcome of potentially selecting an optimised formulation. Therefore within this 
study the aim was to undertake a systematic investigation into the effect of bilosome 
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composition on their physico-chemical characteristics and then to test the optimum 
formulation for efficacy. This will be carried out by:  
 Using Design of Experiments, a d-optimal factorial design, was used to plan and 
conduct experiments in a random order and used to extract the utmost 
information from the data obtained. The relationship between the factors 
influencing the bilosome composition and physiological and biological 
outcomes was investigated by optimising for vesicle size, zeta potential, pH and 
antigen loading for their ability to deliver antigen for Influenza. Using the model 
the data can then be interpreted and predictions can be made which will result in 
the optimisation of the experiment parameters.  
 Validating the results from the DoE study by an extra series of experiments and 
then use the optimised formulation, and test for efficacy in a ferret animal 
model.   
 
Figure 2.1: Design space for experimental study showing variation in DCP, cholesterol and bile salt. 
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2.2 Materials and Methods 
2.2.1 Materials 
A range of non-ionic surfactant based bilayer vesicles were prepared by high shear 
homogenisation and analysed using several materials and methods. The surfactants used 
in the study were Monopalmitoyl glycerol (MPG) (Larodan Labs, Sweden), Synthecol 
(Chol) (Sigma Aldrich, UK) and Dicetyl phosphate (DCP) (Sigma Aldrich, UK). The 
aqueous buffer sodium bicarbonate (Sigma Aldrich, UK) was buffered to pH 7.6 using 
a 1 M sodium hydroxide solution (Sigma Aldrich, UK). The peptide antigens used were 
purchased from Cs Bio (California, USA); Glacial acetic acid was purchased from 
BDH, Isopropanol (propan-2-ol) from EMD and the 2 % Ninhydrin Reagent was 
purchased from Sigma. 
2.2.2 Preparation of peptide mixture 
The peptides used throughout the experiments were dissolved in a mixture of ratios of 
the 5 peptides which were  the combination of epitopes from Influenza A 
Hemagglutinin H3 and H1, Influenza B Hemagglutinin and Influenza A nucleoprotein 
subtypes; (i) INF-H1-88-S1, (ii) INF-HA-1-V1(C3S), (iii) INF-NP-1-V1, (iv) 02-HB-
01-S1-01 and (v) 02-HB-01-S2- 01. The ratios used were (i) 2 mg, (ii) 2 mg, (iii) 2 mg, 
(iv) 1 mg and (v) 1 mg in 0.8 mL of double distilled water with a final concentration of 
10 mg/mL in a siliconised tube. The peptide solution was then vortexed for 4 minutes 
and then spun down for 2 minutes at 6,000 x g. 
2.2.3 Bilosome preparation  
A paraffin oil bath was set up at 120 °C and alongside a water bath (Grant, VWR) at 50 
°C. Two 25 mM sodium bicarbonate buffers were made up with one at a pH of 7.6 and 
the other with a pH of 9.7. After the buffers were prepared, the bile salt solution was 
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prepared by making a 100 mM solution using the freshly made 25mM sodium 
bicarbonate buffer of pH 9.7.  
The 5:4:1 molar ratio of the lipids 135 mg of MPG, 127.5 mg of Chol and 45 mg of 
DCP were weighed and placed in a 25 mL flat bottom glass beaker (Pyrex, UK) 
ensuring no powder sticks to the sides of the glass beaker. The lipids were melted by 
heating at 120 °C for 10 minutes. Once the lipids were set to melt the peptide solution 
prepared in section 2.2.2 was pre-incubated for 5 minutes at 30 °C. 
 
While maintaining the melted lipid solution at 120 °C, an emulsion was created by the 
addition of 5.2 mL of the 25 mM sodium bicarbonate pH 7.6 buffer (preheated to 50 
°C) and immediately homogenised (Silverson L4RT, UK) for 2 minutes at 8000 rpm. 
While still homogenising 0.55 mL of 100 mM bile salt in 25 mM sodium bicarbonate 
buffer pH 9.7 was added and homogenised further for 3 minutes. After the 3 minutes 
homogenising 0.28 mL of the pre-incubated peptide solution was added to the beaker 
containing the suspension and was homogenised for a further 5 minutes. Once 
homogenisation had finished the bilosome suspension was allowed to cool to room 
temperature and was then left for 2 hours in an incubator/shaker at 220 rpm.  
2.2.4 Characterisation of size, charge and pH 
The vesicle size distribution was determined using laser diffraction on a sympatec 2005 
(Helos/BF) cuvette analyser. 20 μL of the bilosome suspension was diluted into the 
cuvette with 40 mL double distilled water. The zeta potential which is an indirect 
measurement of the vesicle surface charge, was measured in 1.5 mL double distilled 
water at 25 °C on a Zeta Plus Brookhaven Instrument. 15 μL of the niosome suspension 
was mixed in 1.5 mL double distilled water and then analysed. The pH studies were 
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determined using a pH meter (Mettler Toledo), the size of the bilosomes were 
determined using a sympatec 2005 (Helos/BF) analyser.  
2.2.5 Centrifugation optimisation 
For quantification of peptide entrapment, ultra-centrifugation of the bilosome 
formulations was required to isolate peptide-entrapped bilosomes, from non-
incorporated antigen. To achieve this 300 µL aliquots of sample (Optimised in Figure 
2.2) was diluted in a Beckman 3.9 mL Polo-allomer tube and filled up to the neck with 
double distilled water.  The tubes were carefully heat sealed ensuring that there were no 
air bubbles present within the tube. The tubes were then placed accordingly in the TLN-
100 rotor and centrifuged at 354,000 X g for 45 minutes at 4 °C with the acceleration 
set at 8 (Slowest) and the deceleration at coast. When centrifugation was complete, the 
tubes were opened and the supernatant removed. The sample was resuspended and the 
centrifugated state repeated. After the second ‘wash’ the peptide-loaded bilosomes were 
then re-suspended with 100-200 µL of appropriate buffer and transferred to a 
clean/labelled 1.5 mL micro-centrifuge tube. 
2.2.6 Determination of peptide loading in vesicles 
The peptide loading was determined on the pellets produced after centrifugation as 
section 2.2.4 the using the modified Ninhydrin assay (Figure 2.3) at a wavelength of 
560 nM (Brewer et al., 1995). Following centrifugation, supernatant was removed with 
a pipette and vesicles re-suspended. Then 100 μL of the sample into a 1.5 mL 
polypropylene micro-centrifuge tube and the samples were then dried at 110 °C on a 
digital heat block (VWR). When dry, the samples were hydrolysed by adding 150 μL of 
13.5 M NaOH to each tube. 
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The tubes were then heated at 110 °C for 20 minutes and then cooled to room 
temperature. 250 μL glacial acetic acid (Fisher Scientific, UK) was added to the 
samples to neutralise the NaOH and 500 μL ninhydrin (Sigma Aldrich, UK) solution 
was added to each tube, vigorously vortexed and then placed on the digital heat block 
for 20 minutes at 110 °C. 250 μL aliquots of the samples from these tubes were 
transferred to fresh micro-centrifuge tubes containing 750 μL of propan-2-ol: water 
(Fisher Scientific, UK) (1:1 in v/v) and vigorously vortexed. The 1 mL sample was 
transferred into a semi-micro cuvette and the absorbance was read and recorded at a 
wavelength of 560 nM on a Jenway 6405 UV/Vis spectrophotometer. The amount of 
peptide present (μg/mL) is determined from a standard curve which is also made at the 
same time as carrying out the ninhydrin assay of the samples. 
.  
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Figure 2.2: Optimisation of centrifugation cycle by optimising sample volume.
   Sample 
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 Figure 2.3: Ninhydrin Protocol for determination of antigen concentration within vesicles.  
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2.3 Results and Discussion 
2.3.1 Design of Experiments (DoE) analysis   
An experimental design consisting of 3 surfactants and bile salt as the factors was 
generated with the responses to test being pH, vesicle size, zeta potential and peptide 
entrapment where the MPG lipid was always kept constant at a ratio of 5 and the 
cholesterol, DCP and bile salt was varied (Table 2.1). The experimental design 
consisted of three centre points to form the control for the experiment, by appearing in a 
random order, with the same molar ratios for each of the factors. The centre points were 
calculated by taking the average of each factor for all the experimental runs and in turn 
will determine the accuracy and reproducibility of the experimental model that is 
calculated. 
Table 2.1 shows that the MPG ratio was always kept constant at 0.5 and the varying 
factors were the bile, cholesterol and the DCP also ratios (Ratios are in fractions due to 
MODDE set up). Runs 5, 14 and 16 have the same formulation ratios and are the centre 
points for this experiment and the run order shows the order in which to conduct the 
experiment to introduce randomness and reproducibility. The results were inputted into 
the table generated from MODDE showing pH, vesicle size and zeta potential. All 
responses were taken in triplicate and a standard deviation where n=3 (A= Empty 
vesicles, B= Peptide loaded vesicles). 
The overall data (Figure 2.4) show three significant variables which are highlighted 
from the results of the design of experiments study which involved cholesterol, DCP 
and bile salt. In particular the DCP and cholesterol lipids together have shown to have a 
significant impact on the pH and zeta potential with the p-value being less than 0.05 
(Table 2.2). 
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Table 2.1: Experimental plan for the composition of bilosomes using MODDE. The table is generated 
from MODDE and shows the ratios of each factor to be used into the formulation. A) Empty vesicles, B) 
Peptide loaded vesicles. 
A 
 
B 
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Figure 2.4: The partial least squares (PLS) orthogonal coefficients of the bilosome composition 
containing peptide which involved varying the different lipid ratios on A) pH, B) zeta potential, C) 
vesicle size and D) Peptide entrapment. The PLS plot takes into consideration several responses and fits a 
model showing the variation of the responses to the factors.  
Table 2.2: ANOVA results for pH, zeta potential, vesicle size and peptide entrapment as a response (Y1) 
Response F-value P-value 
pH 14.8585 0.001 
Zeta  10.7774 0.002 
Size 1.53747 0.292 
Peptide 0.327196 0.939 
   
Furthermore, in terms of vesicle size and peptide entrapment, statistically there is no 
significance of the lipids as shown in table 2.2. However, by taking the vesicle size 
coefficients from Figure 2.4C the bile salt has a negative impact that is to say that an 
increase in bile salt content in the formulation reduces the vesicle size of the bilosomes. 
Due to constraints placed on the DCP and cholesterol when designing the experiment, 
the total combined ratio of the two components does not exceed 5. In which case, when 
DCP content is used in its highest ratio the cholesterol is used in its lowest ratio with 
MPG kept constant at a ratio of 5. The individual effects of the formulation parameters 
will be looked into throughout the rest of this section. 
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2.3.1.1  The effect of formulation parameters on pH 
Whilst it is recognised the pH can be modified after formulation, the effect on the 
formulation and hence the need for any pH modification was initially investigated, as 
the stability of formulations can be linked to their pH and formulations with and 
without the addition of the peptide antigen were considered.  
Results from the ‘empty’ vesicles when directly compared to vesicles loaded with 
peptide antigen show very similar pHs (Table 2.1) suggesting that the addition of 
peptides made no notable effect on pH of the vesicle suspensions, as would be expected 
given the low volumes added to the formulations. However, the key factor shown to 
influence pH in both ‘empty’ and peptide loaded bilosomes was the concentration of 
DCP within the vesicles. Figure 2.5 shows that increasing the concentration of DCP 
within the bilosome formulation resulted in a decrease in pH, with formulations 
containing 1 molar DCP having pH values of over 8, whilst those containing high DCP 
values of 3 molar ratio having pH values of around 4 to 5 (Figure 2.5). The buffers used 
in the experiment were of pH 7.6 and pH 9.7, so the pH in theory should lie between 7.6 
and 9.7. However this was not the case and figure 2.5 suggests that this was due to the 
DCP content of the bilosomes. These preliminary results suggest that increasing 
concentration of DCP may have resulted in the increased dissociation of the anionic 
surfactant which increased H
+
 concentrations and therefore lead to a reduction in pH, 
However as both cholesterol and DCP concentrations were varied, this result was the 
starting platform for a series of further experiments where cholesterol content was kept 
constant and the DCP was varied (Section 2.3.2). 
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Figure 2.5: Main effects response for DCP upon the pH of the bilosomes. As DCP content is increased 
the cholesterol content decreases as the two lipid together must have an overall ratio totalling 5 (i.e. 0.5) 
Cirlces represent actual experimental values and triangles represent predicted values from the model. 
2.3.1.2  The effect of formulation parameters on vesicle size 
Given the importance of vesicle size in relation to both physico-chemical and biological 
attributes, it is important to elucidate the link between formulation and particle size 
such that it can be optimised. Vesicle size plays a crucial role in the final destination 
site of the vesicles, thus it was important to optimise vesicle size for the route of 
delivery. Vesicle size as a function of bile salt is presented in figure 2.6 and an initial 
observation suggests increasing bile salt reduces vesicle size. What this figure fails to 
indicate is that at each ratio of bile salt used, the lipid content varied. For example, by 
selecting 3 data points from Table 2.1 B, runs 11, 10 and 1 all have the same ratio of 
lipids (5:4:1 MPG:Chol:DCP respectively), however, the only thing which changed was 
the addition of bile salts. Run 11 contained no bile salt and resulted in a vesicle size of 
5.45 µm and by increasing the bile salt concentration to 100 mM the vesicle size 
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reduced to 4.66 µm. A further increase in bile salt to 200 mM (run 10) resulted in a 
vesicle size of 4.23 µm. 
Figure 2.6: Main effect of the Bile salt upon vesicle size of formulations with different lipid ratios of 
MPG:Chol:DCP. 
 
This same trend of bile salt influence for the large variation in vesicle size also applies 
when DCP is used in a ratio of 3 (Runs 2 and 9 from Table 2.1A). Runs 2 and 9 both 
have a lipid ratio content of 5:2.3 of MPG:Chol:DCP respectively with the only 
difference being that run 2 had 0 mM bile salt with a vesicle size of 18.03 µm and run 9 
contained 200 mM bile salt which resulted in a vesicle size of 4.83 µm. These results 
from the DoE study once again gave another platform into the insight of how bile salt 
could be affecting the size of the vesicles and this study is also extended in the next 
section (Section 2.3.2). 
Overall, from the formulations investigated it can be seen that the two components 
studied that make a notable impact on vesicle size is the concentration of DCP and bile 
salt, with the presence of peptide to the formulation having no impact at the 
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concentrations used. Previous studies by Chupin et al. (2002) on peptide interactions 
with bilayer vesicles showed that peptides bind to DCP increases the volume of the 
head group, thus lowering the charge (Chupin et al., 2002). To examine this further the 
effect of formulation on zeta potential was also investigated.  
2.3.1.3  The effect of formulation parameters on peptide entrapment 
Peptide loading within the vesicles is crucial as the higher the entrapment, the more 
peptide can be present at the target site, which in turn, can result in using lower doses 
overall. As a result, to investigate the effect of formulation on peptide loading, the 
formulations outlined in Table 2.1B were also tested for peptide association using a 
modified ninhydrin assay. The bilosomes were centrifuged using a protocol developed 
in section 2.2.4 and assayed using the ninhydrin assay (Section 2.2.6) to determine 
peptide entrapment. The ninhydrin assay was used to measure entrapment of peptides 
and proteins within bilosomes; this assay eliminated any interference of lipids or 
surfactants when compared to other assays, such as the BCA assay and Lowry method 
(Brewer et al., 1995, Lowry et al., 1951). Results from the study showed that no 
individual component was significant in influencing peptide entrapment within the 
vesicles (Figure 2.4D). The peptide entrapment was not dependent upon any of the 
excipients used to form vesicles and was proven to occur independent of lipids used. As 
a result, the vesicle size and peptide entrapment was investigated to determine if the 
larger vesicles result in increased peptide association as presented in figure 2.7.  
The results in figure 2.7 showed no correlation between peptide entrapment and vesicle 
size, suggesting that antigen loading may be determined by other factors. The lipid ratio 
and bile salt concentration changes for each formulation in table 2.1B and the resultant 
peptide entrapment differs. An example of this is the triplicate control experiment from 
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Table 2.1B which showed peptide entrapment at 60 %, 61 % and 86 % for the same 
ratio of lipids used.    
 
Figure 2.7: The effects of vesicle size upon the peptide entrapment within the vesicles. 
Studies by Brgles et al, (2008) also confirm findings that anionic liposomes did not 
change in vesicle size upon increasing the amount of entrapped protein; however, they 
found that for cationic liposomes entrapment efficiency is highly dependent on ionic 
strengths of buffers used (Brgles et al., 2008). Furthermore, Brgles et al, (2008) report 
that negatively charged OVA in anionic liposomes is not affected by ionic strength of 
buffers used and that the entrapment is presumably due to hydrophobic interactions 
between the OVA and phospholipid bilayers as the vesicle size of the liposomes 
remains unchanged. One of the underlying reasons for variation in entrapment 
efficiency could be due to the change in lipid ratios used. For example, studies have 
shown that the increase in cholesterol content within MLVs can result in increased 
content of citocoline (Puglisi et al., 1992). Furthermore the effect of varying lipid 
content within this design of experiment study can result in variation in number of 
bilayers within the vesicles which in turn affects the volume of the aqueous core and the 
bilayer volume hence affecting loading efficiency. 
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2.3.1.4  The effect of formulation parameters on zeta potential 
Zeta potential is the nearest experimental approximation of surface potential, as both 
the surface potential and stern potential are difficult to measure. Thus the zeta potential 
is the potential at the surface of shear which is measured by electrophoresis and is a 
good indicator of stability of dispersed systems. This charge at the vesicle surface 
affects the distribution of ions within the region which causes an electric double layer to 
be formed. When an electric current is passed through each particle and its ions in the 
region move throughout the solution. The rate and extent of movement within the stern 
layers and the surrounding medium determine the zeta potential. Therefore, zeta 
potential is a function of the vesicle surface charge which is calculated by the adsorbed 
layers at the interface and the nature of the surrounding medium. Figure 2.8 shows that 
a highly negative zeta potential in the vesicle formulations tested, can be achieved with 
lower ratios of DCP to cholesterol (e.g. as in the case of run 2 in Table 2.1A),  which 
appears counter intuitive, as it would be predicted that increasing DCP and reducing 
cholesterol content would increase the anionic nature of the vesicles. This trend in zeta 
potential values was apparent for both the peptide loaded and ‘empty’ vesicles with no 
significant difference in zeta potential between the two comparable sets.   
Figure 2.4 A,B showed the orthogonal coefficient plots for pH and zeta potential and 
the most significant factors were clearly the DCP and cholesterol which are graphically 
presented in figure 2.8. More detail of the effect of the two components is shown in 
figure 2.9 which shows response surface and contour plots of DCP content against 
cholesterol content and the effects on pH and zeta potential. Figure 2.9 illustrates that 
the interaction of the two components DCP and cholesterol has an impact upon the pH 
where it ranges from a low of 3.5 to a high of 8.5 and zeta potential which has a range 
of -38 to -64 mV depending upon the lipid content within the vesicle. 
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Figure 2.8: The effect of DCP content against cholesterol content on the zeta potential of the bilosome 
vesicles. Low DCP = 0.1 ratio and high DCP = 0.3 ratio. NB. Chol and DCP together should add to 0.5 
therefore the red lines show predictions of the design. 
The pH can be closely linked with the zeta potential in terms of DCP and cholesterol as 
figure 2.9B shows that when DCP is used in its highest ratio with cholesterol at its 
lowest the pH becomes more weakly acidic with a pH of 5.01 and below. When 
compared to the zeta potential (Figure 2.9D) the same ratios of lipids results in a less 
negative zeta potential occurring with a reading of -40 mV. As the two lipid contents 
change, the relationship of pH and zeta potential are linked with a general trend 
resulting in the more alkaline the pH the more negative the zeta potential. Studies by 
Junyaprasert et al, (2008) show that DCP inclusion to salicylic acid at a pH of 5 showed 
greatest stability with the highest zeta potential compared to niosome vesicles prepared 
at pH 3 which had reduced surface charge (Junyaprasert et al., 2008). Zeta potential can 
help reveal the degree of repulsion between vesicles of a similar charge. In addition, the 
presence of DCP resulted in a charged interface thus causing electrostatic repulsion 
between adjacent bilayers, resulting in an increased distance between the bilayers 
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hence, causing rise of the internal aqueous compartment of MLVs (Kulkarni et al., 
1995). The presence of a positive or negative zeta potential implies that the suspension 
is more likely to be stable and may also prevent aggregation of vesicles due to repulsive 
forces between the vesicles (Freitas and Müller, 1998, González-Rodríguez and 
Rabasco, 2011). 
 
Figure 2.9:  Response surface plots for cholesterol and DCP content against pH and zeta potential. A) 
Response surface plot showing the effect of DCP and cholesterol content on the pH, B) Contour plot of 
DCP and cholesterol effects on the pH, C) Response surface plot showing the effect of DCP and 
cholesterol content on the zeta potential, and D) Contour plot of DCP and cholesterol effects on the zeta 
Potential. All response plots are taken where bile salt content is at 100mM as bile salt content does not 
influence pH or zeta potential. Due to restrictions on software all ratios add up to 1 (ie. A ratio of 4 for 
cholesterol would appear as 0.4 on the diagrams, MPG is kept constant on the design at a ratio of 5 which 
is 0.5) 
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2.3.1.5 Optimisation of bilosomes for oral vaccine delivery  
The use of DoE allows a database to be generated which allows the use of high 
throughput screening of specific parameters that are being investigated. For oral vaccine 
delivery, an optimum vesicle size range of 4-10 µm is required for vesicles to retain 
within the target site of the Peyer's Patches (Eldridge et al., 1990), a highly negative 
zeta potential (Norris et al., 1998), and as high an antigen loading as possible. As a 
result these optimum response parameters were programmed into the DoE database and 
as a result the surfactant combination which best fits these responses were given as a 
5:4:1 MPG:Chol:DCP respectively with 70-120 mM bile salt for maximum coverage to 
meet all criteria (Figure 2.10). Bile salt levels above 120 – 200 mM result in a reduction 
in coverage to meet criteria (figure 2.10). The red sections indicate the optimum 
concentrations where all criteria are met and the increase in bile salt results in less 
criteria being met hence the reduction in red zone and increased coverage within other 
zones.    
 
Figure 2.10: Sweet spot plot representing optimal DCP and Cholesterol ratio with 70-200 mM bile salt. 
(Parameters set, Size- 4-6 µm, pH 7-9, zeta potential -55 - -65mV, Peptide entrapment 40-60%).  
 
 
Chapter 2: Optimisation of Non-Ionic Surfactant vesicles for Oral Vaccine Delivery  
 
94 
 
To further examine the trends observed in section 2.3.1, an in depth study was 
undertaken where MPG and cholesterol content were kept constant at a ratio of 5:4 
respectively with 100 mM Bile salt based on the optimisation using sweet spot plot 
(Figure 2.10) with the DCP content changing from a molar ratio of 1 to 3. This study 
was used to indicate to what extent the DCP lipid influences the pH and zeta potential 
of the bilosome formulations and validate the DoE model.  
2.3.2 Validation of DoE responses 
So far, the results have shown that from the design of experiments study in section 2.3.1 
where three excipients (cholesterol, DCP and bile salt) are varied there are specific 
trends that can be linked to certain excipients. It is crucial to isolate these trends to 
individual excipients hence the rationale for the next study was to maintain three 
constant parameters and change the fourth. An example of this included keeping 
MPG:Chol at a ratio of 5:4 with bile salt concentration constant at 100 mM and then to 
change the ratio of DCP from 1-3 in increments. The aim of the study was to determine 
whether the trends in the DoE study (Section 2.3.1) can be repeated but by changing 
only one variable. Once again the parameters looked at were pH, vesicle size and zeta 
potential. 
2.3.2.1 The effect of DCP content within bilosomes on pH and zeta potential  
From the design of experiments study, an in depth study regarding the effect of DCP as 
an individual lipid on the pH, zeta potential and vesicle size was carried out. Within this 
study the MPG and cholesterol ratios were kept constant at a ratio of 5:4 respectively 
with the bile salt content also being constant at 100 mM. Results in figure 2.11 show 
that pH decreases and the zeta potential becomes less negative when there is an increase 
in DCP content (from 10 to 25 mol%) which is comparative to the design of 
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experiments study where cholesterol and bile salt were changed (Figure 2.9). A 
potential cause of this could be due to the degree of ionisation of DCP, an amphiphilic 
molecule, when incorporated in to the bilosomes. DCP (Figure 2.11B) has an OH group 
which is present in the non-dissociated form, but when in solution the H
+
 ion can be 
released. The removal of this H
+
 ion gives the DCP its negative charge, and hence 
anionic zeta potential, when in solution and in turn the H
+
 ion gets taken up by the 
sodium bicarbonate buffer which is present in the formulation. As the DCP ratio is 
increased within the formulations, there are more H
+
 ions within the formulation which 
are being taken up by the buffer, however, there is a buffering capacity. The sodium 
bicarbonate (Na2CO3) buffer when split up becomes 2Na
+
 + CO3
2- 
, hence for every 
mole of buffer there would need to be 2 moles of DCP. As a result, when the DCP is in 
a ratio of 25 % there becomes a 2:1 ratio of DCP:H
+
 ions in relation to the buffer. 
Hence, this is the point at which buffer capacity is lost and there becomes a reduction in 
pH due to excess H
+
 ions and no buffer to take them up. Between 10-18 % DCP ratio 
the pH remains constant (Figure 2.11A), However as the DCP concentration is 
increased the pH drops due to the excess H
+
 ions now in the formulation. The DCP 
molecule has a pKa of ≤ 2.6 (Uchegbu, 2000) thus, ionisation of the phosphate group 
takes place at pH ≤ 2.6  resulting in the large change in surface charge as represented in 
figure 2.11C. This acidic environment could inhibit further dissociation of DCP, 
therefore limiting its ability to impart an anionic charge into the vesicles. This can 
explain why with increasing DCP content, a reduction in the anionic zeta potential was 
noted rather than an increase in negative charge as would be expected (Figure 2.11). 
The impact of DCP on a vesicles suspension’s pH were also shown by Manosroi et al, 
(2003) when developing a liposome formulation for tranexamic acid (TA) with various 
lipid compositions including negatively charged DCP lipid and a positively charged 
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stearlyamine lipid (Manosroi et al., 2003). One of the features of their study showed 
that negatively charged lipids (including DCP) gave low pH values ranging from 3.4-
7.1 compared to the positively charged lipids (pH 7.6-7.9).  The addition of TA to the 
negatively charged lipids results in a rise in pH due to the neutralisation of the DCP 
hydronium ion from the hydroxyl ion released from the ionisation of the TA. The 
negative charge resulting from DCP also resulted in smaller liposomes due to the 
neutralisation of charges with the TA hence producing smaller vesicles with a 10 % 
entrapped TA To confirm the direct link between the pH of the bilosome suspension 
and the measured zeta potential, bilosomes of negative zeta potential and high pH were 
subjected to acid titrations and the effects of pH on zeta potential investigated (Figure 
2.11C). 
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C 
Figure 2.11: A) Effect of changing DCP content on the pH and zeta potential of the bilosomes. B) 
Structure of the anionic DCP lipid and C) A pH titration graph of 5:4:1 ratio of MPG:Chol:DCP 
respectively with 100 mM bile salt containing peptides showing the effect of pH upon the zeta potential 
of the bilosomes n=3. 
Figure 2.11C involved making a batch of bilosomes with a 5:4:1 ratio of 
MPG:Chol:DCP respectively with 100 mM bile salt and peptides with a starting pH of 
approximately 9.4. This study was carried out on a Malvern zetasizer ZS and a MPT-2 
Auto titrator. Three titrant vials were added to the instrument which were 1 M HCl, 0.1 
M HCl and a 1 M NaOH solution where the software was set up and designed to lower 
the pH of the bilosome formulation by 0.5 units at a time and then the zeta potential to 
be measured. So far in previous studies we have shown that an increase in DCP content 
results in a more acidic pH. By carrying out this study, bilosomes were exposed to 
specific pH levels and the zeta potential measured (Figure 2.11C). The results show that 
as the pH is raised from 1 to 10, the zeta potential of the vesicles changes from 
approximately -15 mV to -120 mV confirming the controlling role of pH on the anionic 
nature of the bilosomes (Figure 2.11C). Therefore by varying the DCP content in the 
bilosome formulations, this modulates the pH of the suspension system which in turn 
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impacts on the zeta potential of the bilosomes, thereby confirming that a continued 
increase in anionic surfactant content may not always promote increasing anionic zeta 
potential of vesicles. 
In terms of how this impacts on biological responses, the zeta potential has been shown 
to influence the uptake of bilosomes in studies by Tomizawa et al, (1993) who have 
shown that negatively charged vesicles are preferably taken up by the Peyer's patches 
(Tomizawa et al., 1993). Therefore, by incorporating appropriate levels of DCP into the 
formulation, it gives the bilosomes their negative charge, which can be retained 
throughout the various pH ranges of the GIT (Figure 2.11C) suggesting that this will aid 
in the uptake of the bilosomes by the Peyer's patches at the range of pH seen across the 
GIT.  
To summarise, the intentions of the study were to confirm the previous studies and the 
design of experiments work (Section 2.3.1) and to determine how well design of 
experiments can be applied for the current formulations. This study of DCP content on 
pH confirms some of the early findings of the study (Section 2.3.1) by showing a 
similar trend to the design of experiments study, however in terms of absolute values 
there is no overlay of the results. This shows that design of experiments by factorial 
design is useful in showing trends of specific lipids to the system but it was not absolute 
in this study. The change in pH is closely linked with the zeta potential of the vesicles. 
In terms of vesicle size, which remains unchanged as DCP content is increased suggests 
that the addition of DCP does not alter the vesicle size (data not shown) except when no 
DCP is used. This concept of pH and zeta potential are important factors in the delivery 
of bilosomes as they are delivered orally and are subjected to extreme pH environments 
along the GIT. It is crucial that at this stage that the bilosomes are stable and intact at 
low pH’s most importantly with the antigen being protected and stable. The aims of 
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non-ionic surfactant vesicles are to protect the antigen under extreme pH conditions and 
from the intestinal bile to allow vesicle and antigen to remain intact upon entry at the 
target site.   
2.3.2.2   Effect of bile salt concentration on the vesicle size  
The vesicle size range is crucial as it determines the end location of the vesicle within 
the gastro intestinal tract (GIT). The target for bilosomes is the immuno-competent cells 
within the gut, which are known as Peyer’s patches. Studies by Eldridge et al, (1990) on 
vesicle size uptake in the Peyer's patches show that uptake is dependent on the vesicle 
size and hydrophobicity. The results from their experiments indicate that a vesicle size 
of 10 µm or less is taken up by the Peyer’s patches, however particles with a size less 
than 4 µm can traffic to other tissue cells by a process of lymphoid drainage (Eldridge 
et al., 1990). As a result, particles larger than 4 µm reside within the Peyer's patches. 
Therefore, the target size for bilosome formulations designed for oral vaccination would 
be approximately 4-6 µm so that they can reside within the Peyer's patches and to exert 
their therapeutic effect.  
Given that the design of experiments study previously demonstrated (Section 2.3.1) that 
the most important factor controlling vesicle size is the bile salt, a new set of 
formulations were prepared where all formulations in this study were made with a 5:4:1 
ratio of lipids (MPG: cholesterol: DCP) but with the bile salt concentration changing. 
The bile salt concentrations used were 0 mM, 100 mM, 200 mM, 400 mM and 800 mM. 
It is to be noted that working with the 800 mM bile salt was difficult as the bile salt 
solution became very viscous.  
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A 
 
B 
Figure 2.12: Niosome vesicles containing bile salts showing the A) Effect of bile salt content on mean 
vesicle size distribution (VMD) with span and B)  Number frequency of the formulations with increasing 
bile salt content in relation to the VMD (n=3).  
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Figure 2.12A shows that as the bile salt concentration is increased the vesicle size 
decreases. A previous study incorporating bile salt within lipid vesicles by Chen et al, 
2009 have also shown the same trend of decreasing vesicle size upon increased bile salt 
concentration; this was attributed to enhanced flexibility and a lowering of surface 
tension between the vesicles when bile salts were present (Chen et al., 2009). An 
increase in the flexibility of the lipid bilayer causes a softening effect to occur, which 
impacts upon the stability of the vesicles such as multilamellar vesicles (MLV). The 
vesicles in the study are in microns which fit into the MLV category and with the 
increase in fluidity the MLV are susceptible to form small vesicles upon an external 
force.  
This notion of smaller vesicles forming from MLVs due to the increased fluidity, hence 
causing instability of the MLV, can be visualised in figure 2.12B which shows the 
number distribution of the vesicles upon increasing bile salt concentration. Figure 
2.12B shows the number frequency of the vesicles at the specific vesicle sizes within 
the formulation. As the bile salt content is increased, the number of smaller vesicles 
also increases, suggesting that as we lose the bigger vesicles we are gaining an increase 
in smaller vesicles (Figure 2.12B).   
The niosome formulation (0 mM bile salt) shows a density distribution towards a larger 
vesicle population as represented by the number frequency of these vesicles in relation 
to the formulations containing bile salt. By examining the 200 mM bile salt formulation 
there is a shift of the density distribution curve towards the smaller vesicle size range. 
In addition to the shift, the peak is higher suggesting that there are more vesicles of that 
size range within the formulation. The formulation containing the highest bile salt 
concentration of 800 mM shows the highest peak, further suggesting that there are more 
numbers of smaller vesicles within the formulation. The addition of bile salts to the 
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5:4:1 formulation shows a decrease in mean vesicle size as shown in figure 2.12A, 
however also shows an increase in the smaller vesicles obtained as shown in figure 
2.12B.  
In general, there needs to be an optimal concentration of bile salt to be incorporated 
within the vesicles without influencing vesicle uptake within the Peyer’s patches. This 
present study shows that across the bile salt concentration range tested, the formulated 
bilosomes were generally in the 4-6 µm particle size range therefore should reside 
within the Peyer's patches as required for oral vaccine delivery. 
2.3.3 Vaccine efficacy challenge study using ferret model 
After optimising the 5:4:1 (MPG:Chol:DCP respectively) with 100 mM bile salt 
formulation for oral vaccine delivery, bilosomes containing the synthetic peptides 
directed against influenza viruses were administered to ferrets orally on days 0, 3, 14, 
and 17, and 14 days and later challenged with a clinical rHA isolate of influenza (Figure 
2.13).  To investigate the efficacy of the vaccine and comply with 3R protocols, the key 
correlate of protection, the median temperature differential was measured to follow 
protection against fever and inflammatory cell counts in nasal washes (Figure 2.14 and 
2.15). 
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Figure 2.13: Dose regime for oral vaccination of a ferret challenge study. (Studies were carried out at 
Variation Biotechnologies, Canada). 
The bilosome vaccine incorporating the synthetic peptides shows a reduced median 
temperature differential change compared to a dose of empty bilosomes and the 
commercial vaccine administered intramuscularly (IM) suggesting that the antigen 
containing bilosomes via the oral route show strong results in providing effective 
protection from fever (Figure 2.14).  
 
Figure 2.14: Median temperature differential change after challenge using a clinical isolate of Influenza 
A. (Studies were carried out at Variation Biotechnologies, Canada). 
After analysing nasal washes for inflammatory cells, the bilosome formulation 
containing the synthetic peptide vaccine compared to empty bilosomes resulted in a 
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reduction in viral cell load counts compared to bilosomes administered without antigen 
(Figure 2.15). Moreover, the bilosome vaccine was comparable to the commercial 
vaccine administered IM.  Thus the bilosome formulation containing the influenza 
vaccine has protected against fever and suppressed lung inflammation to extents 
comparable to the commercial vaccine (IM) showing promising results for vaccine 
delivery via the oral route.  
 
Figure 2.15: Inflammatory cell counts after nasal washes of the three formulation groups. (Studies were 
carried out at Variation Biotechnologies, Canada). 
 
Research has shown that, when delivering antigen alone via the oral route, this is not 
sufficiently immunogenic and thus requires the use of adjuvants and carriers to enhance 
immunogenicity (Azizi et al., 2010). In addition, the reduced immunogenicity can be 
accounted by the lack of control of the antigen reaching intestinal surfaces which can be 
due to milieu of the GIT and the poor uptake by the epithelial cells (Devriendt et al., 
2012). The oral biodistribution of an influenza antigen to be further investigated within 
the GIT will compare free antigen dose with formulating the antigen with the bilosome 
vesicles which has the potential of allowing increased antigen at the target site by 
offering uptake via specialised M cells within the Peyer’s patches. Previously, Amorij 
et al, (2007) have shown that the intragastric delivery of recombinant H3N2 antigen 
alone induced low HI titres, significantly lower than the antigen delivered IM (Amorij 
et al., 2007). The use of bilosomes as vaccine carriers with antigen, has shown effective 
mucosal immunity, compared to the delivery of free antigen, where a study by Shastri et 
 
 
Chapter 2: Optimisation of Non-Ionic Surfactant vesicles for Oral Vaccine Delivery  
 
106 
 
al, (2012) have also shown that formulating antigen into microspheres offers higher 
mucosal antibody production compared to free antigen delivered via the oral route 
(Shastri et al., 2012). The use of a potent adjuvant or delivery system is critical in 
obtaining a sufficient immune response which is comparable to a corresponding 
response IM (Amorij et al., 2007). Once again, the use of a delivery system offers a 
more targeted approach of delivery and renders antigens more immunogenic as they 
offer antigen protection against degradation and have a longer residence time within the 
GIT.  
2.4  Conclusions 
An optimisation study by the use of design of experiments has been successful in 
suggesting possible lipid interactions upon specific responses measured. This lead to 
further in depth studies on individual lipids and from the results it can be concluded that 
the pH and zeta potential are linked together and are controlled by the anionic DCP 
lipid which is used in bilosomes to give the net negative charge to allow uptake and 
vesicle formulation. In terms of vesicle size which remains unchanged as DCP content 
is increased, suggests that the addition of DCP does not alter the vesicle size. However, 
the bile salt contributes to the decrease in vesicle size and increase in smaller vesicles 
which can be due to increased fluidity within the bilayer causing slight instability hence 
the formation of smaller vesicles. DoE is a useful tool to understand trends and give an 
insight into process parameters; however, the absolute values predicted by the software 
out of the experimental range were not consistent with those of formulations prepared.  
Thus, the optimised formulation predicted by the software was validated and 
reproduced on several occasions showing reproducibility of vesicle size, pH, zeta 
potential and antigen loading. The 5:4:1 of MPG:Chol:DCP respectively containing 100 
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mM bile salt was subsequently formulated (assuming full incorporation of all the 
excipients) with the synthetic peptides for an oral challenge study in the ferret animal 
model. The results of the study were comparable to the commercial vaccine 
administered IM thus showing a promising platform into the delivery of vaccine 
antigens via the oral route to induce mucosal immunity. 
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3.1 Introduction 
3.1.1 Preparation of non-ionic based vesicles 
Non-ionic vesicles can be prepared through a range of methods, including the lipid 
hydration method (Azmin et al., 1985, Baillie et al., 1985), the reverse evaporation 
technique (Guinedi et al., 2005), the dehydration-rehydration method (Brewer and 
Alexander, 1992) and the molten-lipid emulsification method (Mann et al., 2004).  
Whilst the last method offers the advantages in terms of easy of scale up, any thermal 
induction methods to support the emulsification of lipids presents the risk of enhanced 
degradation promoted by thermal energy hence, it is vital to understand analytically the 
thermal properties of the surfactants used in addition to characteristics such as vesicle 
size and charge.  
To further investigate the manufacture of non-ionic based vesicles via the molten-
emulsion method, the surfactants used to form niosomes were at set ratios which were 
optimised in chapter 2. Previous studies on niosome vesicles, which also employed a 
ratio of 5:4:1 of MPG:Chol:DCP respectively to produce vesicles, have suggested that 
this mixture can be melted at 120 °C or 140 °C which is below the melting point of 
cholesterol (150 °C) (Bennett et al., 2009, Mann et al., 2004). To understand the 
thermal events occurring during the process, there are a range of techniques available. 
3.1.2 Differential Scanning Calorimetry for thermal Analysis 
Differential Scanning Calorimetry (DSC) has been widely used in its application in 
understanding the thermal characteristics of materials (Bouzidi et al., 2005) where  an 
insight into a range of thermal properties including phase transitions including glass 
transition (Tg) and heat capacity changes are presented. The output of data is measured 
as an endothermic or exothermic transition as a function of temperature. An example a 
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typical thermogram is shown in Figure 3.1 where the MPG surfactant was used on a 
controlled heat cool heat cycle.   
 
Figure 3.1: A typical DSC thermogram of a powdered surfactant. MPG surfactant showing melting upon 
heating and then crystallisation upon cooling. Isotherm shows Endothermic going up hence melting peaks 
are up (Scan rate = 10 °C/min). 
 
DSC works on the principle of measuring the difference in heat energy of a sample pan 
against a reference pan under the same experimental method and atmospheric 
conditions (Demetzos, 2008). Hence when analysing powders the reference pan is 
empty and when analysing liquid vesicle formulations the reference pan should be of 
the same aqueous buffer the vesicles are formed from. This is vital as any 
thermodynamic events that take place due to the buffer, the sample pan will also detect 
the same changes hence will not interfere with the heat enthalpy.  
As a result, phase transitions which are key factors in the production of a range of drug 
delivery systems including bilayer vesicles can be determined by DSC which provides 
an insight into the gel to liquid phase transition of bilayer vesicles. The application of 
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thermal energy to lipid bilayer vesicles such as liposomes and niosomes results in a 
change in state which is known as the gel crystalline – gel liquid phase transition. This 
phase transition is represented Figure 3.2 which shows the major transitions that take 
place when heating bilayer vesicles. 
 
Figure 3.2: Schematic representation of phospholipid arrangement above and below the transition 
temperature.  
The formation of liposomes results in the production of rigid bilayered vesicles below 
the transition temperature of the lipid(s) used. The rigidity of the vesicles is attributed to 
the properties of the hydrocarbon tails of the phospholipids which crystallise below the 
main phase transition temperature (Figure 3.2). Upon heating to the phase transition 
temperature, these crystalline tails effectively “melt” and become fluidic tails thus 
giving rise to the gel liquid state. The main phase transition of bilayer vesicles depends 
upon the phospholipids used and the addition of any other components to the vesicles 
such as cholesterol, which is known to remove the main phase transition temperature 
and change bilayer fluidity (Oldfield and Chapman, 1972). Addition of cholesterol has 
shown to increase the retention of fluorescent dyes hence resulting in increased stability 
of vesicles and preventing leakage of entrapped material from the vesicles (Kirby and 
Gregoriadis, 1980). As a result, by knowing the phase transition temperature of bilayer 
vesicles by the use of DSC techniques, this helps in the manufacture of vesicles as they 
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need to be formed above the transition temperature. Furthermore, the properties of 
bilayer vesicles can be controlled and manipulated to achieve the desired effect. 
3.1.3 Aims and Objectives 
In this chapter, the aim was to investigate the temperatures required in the process of 
forming vesicles using the melt method as first outlined by Conacher et al, (Conacher et 
al., 2001). The objectives were to determine: 
 Whether the melting of non-ionic surfactant vesicles (NISV) can take place 
prior to homogenisation at lower temperatures preventing degradation of 
surfactants.  
 Whether DSC, TGA and Langmuir models can provide a rationale to determine 
whether this is possible and then niosome vesicles will be prepared by melting 
the surfactants at different temperatures prior to homogenisation.  
 The formulations will be analysed for physico-chemical instabilities over a 
period of time after storage of the formulations at 4 °C, 25 °C and 40 °C. Empty 
niosomes and niosomes formulated with OVA were also tested for a period of 
28 days. 
3.2 Materials and Methods 
3.2.1 Surfactants 
A range of non-ionic surfactant based bilayer vesicles were prepared by high shear 
homogenisation and analysed using several materials and methods. The surfactants used 
in the study were Monopalmitoyl glycerol (MPG) (Larodan Labs, Sweden), Synthecol 
(Chol) (Sigma Aldrich, UK) and Dicetyl Phosphate (DCP) (Sigma Aldrich, UK). The 
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aqueous buffer sodium bicarbonate (Sigma Aldrich, UK) was buffered to pH 7.6 using 
a 1 M sodium hydroxide solution (Sigma Aldrich, UK).  
3.2.2 TGA of surfactant blends at the two melting temperatures 
Thermogravimetric analysis (TGA) was also employed to understand thermal 
degradation and lipid/surfactant decomposition when elevating the temperature of the 
samples (Skala et al., 1997). The surfactants were assessed prior to formulation of the 
vesicles as the results would provide an indication of an initial melting temperature to 
be used to form the vesicles with.  
A 5:4:1 ratio of surfactants (MPG:Chol:DCP respectively) were weighed and placed 
into a glass vial and mixed. A sample of this mixture was placed onto the Perkin Elmer 
TGA and analysed to 95 °C, 120 °C or 140 °C and held isothermally for 10 minutes at 
each of the three temperatures respectively. 120 °C and 140 °C were chosen to replicate 
currently published melting temperatures whilst 95 °C was chosen to determine the 
effects at a lower melting temperature. All samples were repeated in triplicate to 
determine degradation and reproducibility, and all formulations were carried out using 
nitrogen gas and air. 
3.2.3 DSC of individual surfactants and the surfactant blend 
The surfactants were analysed individually in the solid state using a TA Instruments 
Q200 Thermal Analysis DSC. The DSC was calibrated using sapphire and indium for a 
cell constant and temperature calibration based on the heat flow and type of cooler in 
place on the system. The individual surfactants were weighed using an analytical 
balance into T-Zero aluminium pans and then hermetically sealed ensuring the weight 
between the triplicate samples was kept constant to ensure accurate enthalpy data. All 
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experimental runs were started at an initial temperature of 20 °C purged under nitrogen 
gas with a scan rate of 10 °C /minute to 120 °C. 
After the individual surfactants were analysed for melting, different blends of the 
surfactant mixtures were further analysed based on a design of experiments template 
created where the ratio of surfactants was changed. The surfactants were weighed in the 
correct ratios into a glass vial and mixed. A sample of this blend was placed into the 
pan to see the overall melting temperature of the surfactant blend together. The method 
used for DSC had a heating rate of 10 °C/min over a temperature range from 0-160 °C 
with the purge gas being nitrogen.  
3.2.4 Preparation of non-ionic surfactant based vesicles 
To prepare the bilayer vesicles the surfactants in the powder form (307.5 mg) were 
mixed at the appropriate ratio (5:4:1 of MPG:Chol:DCP respectively), melted in an oil 
bath at 120 °C for 10 minutes, and while maintaining the molten lipid mix, vesicles 
were created by the addition of 5.45 mL of 25 mM sodium bicarbonate (Sigma Aldrich, 
UK) buffer pH 7.6 (60 °C) and homogenised for 5 minutes using a Silverson machines 
homogeniser model #L4RT. After 5 minutes a pre-incubated (60 °C) solution of OVA 
(0.55 mL) was added to the vesicles and further homogenised for 5 minutes. Upon 
cooling, the niosome formulation was incubated for 2 hours in an incubating mini-
shaker (VWR) with gentle shaking at 220 rpm.  
3.2.5 Preparation of monolayers using Langmuir trough system 
Langmuir monolayer studies have been widely used to understand the packaging of 
surfactants and lipids when mixed together by spreading the insoluble amphiphilic 
molecules in chloroform onto an aqueous water subphase (Gopal and Lee, 2006). The 
purpose of the Langmuir is to generate surface pressure isotherms to determine whether 
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the surfactants will form uniform monolayers and relate these findings to bilayers when 
formed as niosome vesicles.  
Monolayer studies of the individual surfactants (MPG, Chol and DCP) and a mixture of 
surfactants in the ratio 5:4:1 of MPG:Chol:DCP respectively were carried out using a 
KSV mini trough Langmuir system (KSV Instruments Ltd, Helsinki, Finland) equipped 
with a platinum Wilhelmy plate in an isolated area. Ultrapure water 18 Ω (Milipore, 
UK) formed the subphase used within these studies and the temperature of the trough 
was kept constant at 20 ± 1 °C using an external water circulation system. Stock 
solutions of the individual surfactants were prepared at a 0.5 mg/mL in chloroform and 
a mixture was also prepared in chloroform at the set ratio. The method used was 
adapted from Ali et al, (2010) where 20 µL of the surfactant stock solutions was spread 
onto the air/water interface using a glass Hamilton syringe precise to ± 0.2 µL (Ali et 
al., 2010). Upon spreading of the samples onto the interface the chloroform was left to 
evaporate and the hydrophilic barriers were set to close at a speed of 10 mm/min to 
form monolayer isotherms. Each sample was run once until it reached its collapse 
pressure and then triplicates of the sample were taken by thoroughly cleaning the trough 
with chloroform and then restarting the experiment. The data was analysed on the KSV 
instruments software. 
3.2.6 Determination of vesicle size and zeta potential 
The vesicle size distribution was determined using laser diffraction on a sympatec 2005 
(Helos/BF) cuvette analyser. 20 µL of the bilosome suspension was diluted into the 
cuvette with 40 mL double distilled water. The zeta potential, which is an indirect 
measurement of the vesicle surface charge, was measured in 1.5 mL double distilled 
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water at 25 °C on a Zeta Plus Brookhaven Instrument. 15 µL of the niosome suspension 
was mixed in 1.5 mL double distilled water and then analysed.  
3.2.7 Determination of OVA entrapment 
The OVA loading was determined in the vesicles after separation via centrifugation, 
produced by the addition of 300 µL of the niosome sample in a 3.9 mL Beckman 
centrifuge tube filled with double distilled water for a period of 40 minutes at 354,000 
X g (TLN-100 rotor), using the Ninhydrin assay at a wavelength of 560 nM. Following 
centrifugation, supernatant was removed with a pipette and pelleted OVA loaded 
vesicles were re-suspended and 100 µL of the sample used for the assay is placed into a 
1.5 mL polypropylene micro-centrifuge tube (in triplicate). The tubes were then dried at 
110 °C on a digital heat block (VWR) and when dry, hydrolysed by 150 µL of 13.5 M 
NaOH (Sigma Aldrich, UK) to each tube.  
The tubes were then heated at 110 °C for 20 minutes and then cooled to room 
temperature. 250 µL glacial acetic acid (Fisher Scientific, UK) was added to the 
samples to neutralise the NaOH and 500 µL ninhydrin (Sigma Aldrich, UK) solution 
was added to each tube, vortexed and then placed on the digital heat block for 20 
minutes at 110 °C. 250 µL aliquots of the samples from these tubes were transferred to 
fresh micro-centrifuge tubes containing 750 µL of propan-2-ol: water (Fisher Scientific, 
UK) (1:1 in v/v) and vigorously vortexed. The 1 mL sample was transferred into a 
semi-micro cuvette and the absorbance was read and recorded at a wavelength of 560 
nM on a Jenway 6405 UV/Vis spectrophotometer. The amount of peptide present 
(μg/mL) is determined from a standard curve which is also made at the same time as 
carrying out the ninhydrin assay of the samples. 
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3.2.8 Appearance and morphology 
Images of the formulations in their glass vials were taken on a digital camera to 
visualise the appearance of the formulation at the time intervals. A Zeiss Axiovert A1 
upright light microscope using a 40x objective lens is used within this study to capture 
images to represent the morphological changes to the vesicles over a time period. 15 µL 
of the sample is placed onto a glass slide with a cover slip on top and is then analysed 
using Axiovision software 36A. Scale bars within the article represent 10 µm and a 40x 
objective is used throughout the stability study. 
3.2.9 Stability study 
Batches of niosomes were prepared by method stated in section 3.2.4 either by melting 
the surfactants in an oil bath set at 95-98 °C or 120-125 °C. Upon formation of vesicles 
the formulation was split into three glass vials with 2 mL of formulation in each. 6 
formulation batches were prepared from fresh for the OVA loaded vesicles and 3 
formulation batches were prepared for the control. Each formulation was split and 
placed into 4 °C, 25 °C and 40 °C incubators and were analysed for vesicle size after a 
10 second vortex, zeta potential and pH at time points for a period of 28 days. 
3.3 Results and discussion 
3.3.1 TGA of components and mixture 
TGA is an analytical technique that is performed on the surfactants to determine 
changes in weight in relation to change in temperature. TGA depends on three main 
measurements which include weight, temperature and the temperature change. TGA 
studies for the components was conducted to determine whether there was any 
decomposition or weight loss at the temperatures employed in the manufacture of the 
vesicles (Skala et al., 1997). It is essential that the components do not degrade at the 
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temperatures of use, as this could lead to impurities within the formulation or by-
products which could be toxic as the end goal is to test the formulations in vivo. 
Therefore, it is necessary to establish that all of the components used are stable and can 
withstand the temperatures used during production methods and these are studied in 
figure 3.3.  
 
 
 
 
A 
B 
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Figure 3.3: TGA Isotherms of the individual surfactants from 30-250 °C showing % degradation. A) 
MPG, B) Cholesterol, C) DCP and D) 5:4:1 (MPG:Chol:DCP) mixture where red line ramp to 90 °C and 
hold for 10 min, green line ramp to 120 °C and hold for 10 min and blue line ramp to 140 °C and hold for 
10 min (Scan rate = 10 °C/min) n=3. 
Figure 3.3 A-C show the replicate TGA isotherms of the individual surfactants MPG, 
cholesterol and DCP respectively. The heating range was taken from 30 °C to a final 
temperature of 250 °C which exceeds the working temperature range used to produce 
niosomes. The results show that the individual components show no degradation up to 
temperatures of approximately 180 °C (Figure 3.3 A to C), which is above the 
C 
D 
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temperatures used in the manufacturing method (120 °C) outlined in Section 3.2.4. 
However, when combining the surfactants into a 5:4:1 mixture of MPG:Chol:DCP 
respectively (Figure 3.3D), the surfactant mixture shows degradation at temperatures 
lower than the individual components with changes in weight being measured at 120 °C 
(Figure 3.3D). Previous studies have melted the surfactant mixtures at temperatures of 
120 °C and 140 °C (Mann et al., 2004, Mann et al., 2009). However, Figure 3.3D 
suggests that this may have an impact on the surfactants integrity if they are held at this 
temperature for extended periods, as the TGA isotherms show that when heating the 
mixture to 140 °C and holding for 10 minutes there is a resultant weight loss of the 
mixture of 2.3 % (Figure 3.3D). Furthermore, when heating to 120 °C and holding 
isothermally for 10 minutes a weight loss of 0.6 % is observed. Studies by Othman et 
al, (2011) on the thermal effects of addition of corn starch to polyvinyl alcohol (PVOH) 
blends also demonstrates that different ratios of the mixtures significantly impact the 
thermal properties (Othman et al., 2011). TGA analysis showed that at 385 °C the pure 
PVOH showed maximum weight loss, and upon addition of corn starch to the PVOH 
this temperature significantly decreased to 374 °C and upon further substitution to 225 
°C, thus showing that composite mixtures suppress the thermal stability of the initial 
PVOH due to the molecular interactions between the compounds (Othman et al., 2011). 
It is unclear whether this loss of the mixture plays an important role in the formulation 
of vesicles; however, this can be avoided by melting the component mixture between 
95-98 °C which shows a mixture weight loss of 0.01 % after holding isothermally for 
10 minutes at 95 °C (Figure 3.3D).  
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3.3.2 DSC of components and mixture 
To further investigate the thermal characteristics of these mixtures, they were also 
investigated by DSC to determine the melting properties and to identify what 
temperatures could be employed to melt the lipid mixture without degrading the 
components. Figure 3.4 A, represents the thermograms of the individual components in 
their solid state, and a mixture blend of a 5:4:1 ratio of MPG:Chol:DCP respectively, 
also in the solid state. From Figure 3.4, the DCP component has a melting onset 
temperature of 74.23 °C with a Tmax of 77.32 °C, followed by the MPG component 
with a melting onset of 74.92 °C with a Tmax of 79.06 °C. The cholesterol component 
shows a melting onset greater than the components MPG and DCP of 148.74 °C with a 
Tmax at 150.05 °C. Based on these component thermodynamic properties, it would 
suggest that to achieve a molten mixture of a blend they would need to be melted at a 
temperature in excess of 150 °C to allow for the cholesterol to melt.  
A
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B  
Figure 3.4: DSC thermogram of the surfactants and the corresponding mixture. A) Individual surfactants 
showing melting upon heating and a mixture of the 5:4:1 (MPG:Chol:DCP) powder blend. B) 
Thermogram of cholesterol, DCP and the 5:4:1 (MPG:Chol:DCP) mixture between 30-60 °C showing pre 
transitions. Isotherm shows exothermic going up hence melting peaks are down (Scan rate = 10 °C/min 
samples run in triplicate). 
The results (Figure 3.4A) show that the cholesterol component has the highest melting 
point of 150 °C, whilst MPG and DCP melt at 79 °C and 77 °C respectively. However, 
when these three lipids were mixed at a 5:4:1 weight ratio (MPG:Chol:DCP), the 
mixture has a melting onset temperature of 72.26 °C with a complete melt (Tmax) at 
79.40 °C (Figure 3.4A). An initial study was carried out where the surfactant mixture 
was taken to 160 °C and no thermal events occurred after 100 °C suggesting that 
complete melting of the mixture has occurred below this temperature. Figure 3.4B 
represents the thermogram for DCP, Synthecol and the mixture of 5:4:1 weight ratio 
MPG:Chol:DCP respectively and reproducible pre transitions/ slow sub-gel transition 
within the components are visible which are much smaller than the main transition and 
in cases cannot be characterised in molecular terms (Biltonen and Lichtenberg, 1993). 
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When analysing the samples under hot stage microscopy at these pre transitions, 
movement of the components occur and slight changes in the structure are noted 
(Figure 3.7). 
Figure 3.5: Hyper DSC thermogram of the mixture of 5:4:1 (MPG:Chol:DCP) n=3. 
To determine whether cholesterol melted or solubilised within the solid state lipid 
mixture upon heating prior to formulation into vesicles, hyper DSC was used on the 
surfactant mixture MPG:Chol:DCP (5:4:1 respectively) to try to separate the 
thermodynamic events from any kinetic events, such as dissolving at a scan rate of 500 
°C/min. The results from the hyper DSC give rise to a large broad melting peak which 
contains multiple peaks representing the surfactant mixture with no presence of a 
melting peak at the cholesterol melting point temperature (149 °C), indicating that the 
cholesterol integration has taken place prior to its melt (Figure 3.5). Faster heating rates 
are employed to provide insufficient time for dissolution/ solubilisation to take place, 
therefore should represent clear endotherm peaks at the melting points of the individual 
components (Gramaglia et al., 2005). This result would indicate that the scan rate of 
500 °C/min was not fast enough as the rate of dissolution of cholesterol took place at a 
much faster rate than 500 °C/min. The use hot stage microscopy (section 3.3.3) further 
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looks into the melting of the surfactant blend where cholesterol is in contact and not in 
contact with the surfactant blend and the subsequent effect of temperature on melting. 
To understand this reduction in melting temperature observed in figure 3.4A, ratios of 
synthecol and DCP were further studied using DOE whilst MPG was kept constant. A 
design of experiments study was carried out using a D-optimal design using the DoE 
software (MODDE), and the ratios of the worksheet are presented in Table 3.1. No 
constraints were placed on this design which allowed the cholesterol to be used in any 
ratio with the DCP hence effects of the individual components could be analysed for 
melting onset temperature, melting enthalpy, crystallisation enthalpy and reheat 
enthalpy. MPG was always kept constant at a ratio of 5.  
Results (Table 3.1) show that when the ratio of cholesterol was increased relative to the 
MPG and DCP, the onset of overall melting point decrease. This trend can be explained 
by the decrease in overall enthalpy which takes place when cholesterol is increased, as 
the mixture requires less energy for the melting event to occur upon increased 
cholesterol levels as represented in figure 3.6.   
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Table 3.1: Effect of varying cholesterol content on the melting onset temperatures of the 
surfactant blend mixtures. Runs 6, 2 and 5 are represented from the design of experiments table 
where the MPG and DCP are kept constant. 
 Run 
Order 
Molar Ratio 
MPG:Chol:DCP  
  
Melting 
Onset (oC) 
Melting 
Enthalpy 
(J/g) 
Crystallisation 
Enthalpy (J/g) 
Reheat 
Enthalpy 
(J/g) 
N1 1 5 : 2 : 0 Mean 74.94 164.6 96.25 136.63 
    SD 0.40 6.5 18.83 6.48 
N2 7 5 : 3 : 0 Mean 73.46 147.8 44.22 106.38 
      SD 0.65 12.9 3.35 6.98 
N3 9 5 : 4 : 0 Mean 73.29 129.5 33.78 100.73 
    SD 0.44 4.8 3.82 2.19 
N4 6 5 : 2 : 1.5 Mean 74.17 175.3 67.01 85.24 
      SD 0.49 3.6 2.78 7.05 
N5 2 5 : 3 : 1.5 Mean 73.54 139.0 42.43 60.01 
    SD 0.74 8.8 11.47 14.87 
N6 5 5 : 4 : 1.5 Mean 71.98 145.5 33.60 46.29 
      SD 0.80 8.4 7.92 4.71 
N7 11 5 : 2 : 3 Mean 73.69 168.9 64.75 92.05 
    SD 2.07 19.6 6.83 14.12 
N8 4 5 : 3 : 3 Mean 73.63 170.3 83.52 111.03 
      SD 0.89 10.5 9.05 8.30 
N9 3 5 : 4 : 3 Mean 73.50 159.4 67.47 95.34 
    SD 0.67 10.6 16.30 16.54 
N10 8 5 : 3 : 1.5 Mean 71.16 153.6 44.21 55.25 
      SD 0.62 5.5 1.94 4.49 
N11 12 5 : 3 : 1.5 Mean 73.64 167.9 59.78 79.84 
    SD 0.87 5.9 3.05 6.84 
N12 10 5 : 3 : 1.5 Mean 72.17 157.1 52.36 67.42 
      SD 0.69 6.5 2.76 4.76 
 
Figure 3.6: Contour plots showing the thermodynamic effects of DCP and cholesterol upon 
melting. A) The effect of cholesterol and DCP on the onset of melting (°C) and B) the effect of 
cholesterol and DCP on the melting enthalpy (J/g) of the mixture. MPG surfactant kept constant 
ratio of 5 for each ratio of DCP and cholesterol varied (Scan rate = 10 °C/min). 
A B 
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Table 3.1 shows that as the cholesterol ratio is increased from a ratio of 2 to 4 in runs 6, 
2 and 5 respectively the onset of melting determined by DSC decreases from 74.17 ± 
0.49 °C to 71.98 ± 0.80 °C respectively. This trend is also represented in Figure 3.6A, 
which shows the overall effect of cholesterol based on all of the formulations tested. 
Cholesterol has an onset melting point of 148 °C (Figure 3.4A) and as a result in the 
presence of MPG and DCP the total mixture is able to melt at 72-95 °C (Figure 3.4A). 
The cholesterol itself does not melt; however, it becomes miscible with the molten 
MPG/DCP mixture. Studies by Brostow and Datashvili, (2007) show that melting point 
depression of low density polyethylene occurs upon addition of different ratios of 
melamine formaldehyde indicating miscibility between the two components (Brostow 
and Datashvili, 2007).  When analysing the combined melting of MPG and DCP a 
single melting peak with an onset temperature of 72.98 ± 0.17 °C and enthalpy of 204 
J/g is obtained. By analysing the individual melting onsets and the heat energy required; 
DCP has a melting onset of 74.23 °C with a heat enthalpy of 222.6 J/g and MPG also 
has a very similar melting onset of 74.93 °C and a heat enthalpy of 194.8 J/g. The 
melting onsets of both are very similar and when used in ratio together at (5:1 
MPG:DCP respectively) the melting onset reduces to 72.98 ± 0.17 °C with enthalpy of 
204 J/g. Therefore, when the two surfactants are used in combination the melting onset 
temperature is reduced; however, the enthalpy of melting remains average of the two 
components. This can be explained in figure 3.4B, where the DCP shows a small 
transition at 43.34 °C and this event being the cause for interdigitation between MPG 
and DCP hence the lowering of the melting point. This is very common when using 
multiple component blends that two solids will co-melt together and cause a melting 
point depression with a broadening of the melting peak (Rice et al., 2011, Tran et al., 
2004). For example, Tran et al, (2004) demonstrated that with the addition of just 2 mol 
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% cholesterol to DSPC liposomes both the transition temperature was depressed and 
enthalpy values resulting in broader melting peaks (Tran et al., 2004). 
In the case of the 3 component mixture being investigated in these studies, Figure 3.6B, 
shows that as the DCP content is increased, the melting enthalpy increases suggesting 
more energy is required to melt the DCP. The DCP requires the highest melting 
enthalpy of 222 J/g and hence increasing the concentration will require more energy to 
melt. There is no difference in onset of melting observed as the structure still remains 
the same, but due to the increased DCP content the energy required to complete the 
melt increases. The incorporation of cholesterol at a ratio of 2 with MPG (5) and DCP 
(1) as shown in Figure 3.6 B, shows that the maximum heat enthalpy required to melt 
the mixture was 164 J/g (Melting onset 73.9 °C, Figure 3.6A) hence the inclusion of 
cholesterol has lowered the heat enthalpy further than that of the MPG:DCP (5:1) 
mixture whilst maintaining the melting onset. A further increase of cholesterol to a ratio 
of 4 with MPG:DCP (5:1) results in an enthalpy of melting at approximately 135 J/g 
which is considerably lower than that of the MPG:DCP mixture (204 J/g). This 
reduction in enthalpy has lowered the melting point onset further of the mixture to 
72.26 °C. When the cholesterol content is increased the heat enthalpy required to break 
the bonds and allow for melting of the mixture decreases. Figure 3.4B, shows a 
thermogram of the mixture with a scan of cholesterol and DCP overlaid. The 
cholesterol shows a melting event at 35.66 °C which has an end point of approximately 
60 °C suggesting that some of the cholesterol is possibly already in a molten state. As 
previously mentioned the lowering of melting point of a MPG and DCP mixture is 
caused by the DCP pre-melting event which associates itself within the MPG and DCP 
matrix resulting in bond weakness upon heating meaning that melting takes place at a 
lower temperature.  
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DSC studies by Othman et al, (2011) on the thermal effects of addition of corn starch to 
polyvinyl alcohol (PVOH) blends demonstrate that the addition of corn starch enhances 
the miscibility of the PVOH due to the molecular interactions which occur between the 
two components (Othman et al., 2011). Thus, lowering the melting point temperature by 
disrupting the crystalline structure of the PVOH as the addition of corn starch causes 
the enthalpy for melting to decrease in addition to reducing the melting temperature of 
the blend. Hence, the addition of cholesterol further enhances this miscibility process as 
the mixture requires even less enthalpy for melting due to the addition of cholesterol. 
The cholesterol content also influences the enthalpy for melting and the transition 
temperature upon formed vesicles. Eg, Cho et al, (2007) show that increasing 
cholesterol content within phosphatidylcholine liposomes broadens and reduces the 
melting onset and transition temperature and that this lipid to lipid interaction in the 
bilayer is dependent on the cholesterol content within the bilayers (Cho et al., 2007). 
The increase in cholesterol ratio results in a greater surface area of cholesterol within 
the mixture and interferes with the MPG and DCP lipid matrix which results in 
interference with the crystalline structures hence further reducing the enthalpy of 
melting which is shown in Figure 3.6B.  
In conclusion, the thermogram in Figure 3.4A, shows that compete melting of the blend 
occurs between 95-98 °C and that when melting these components a temperature range 
of 120 °C can be avoided as the mixture is able to melt at a lower temperature. The 
results obtained indicate that the high melting point cholesterol is miscible with the 
other two molten surfactants where they impact on the crystalline structure of 
cholesterol thus allowing the powder blend to be melted at less than 100 °C preventing 
degradation of the component mixture which was confirmed by TGA and hot-Stage 
microscopy.  
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3.3.3 Hot stage microscopy confirming results of DSC 
Hot stage microscopy was used to confirm the observations and conclusions from the 
DSC analysis in section 3.3.2. The hot stage was set up in a similar way to the DSC in 
that the program start temperature and end temperatures were maintained in the same 
way; however, a slightly slower scan rate of 6 °C/ min were employed due to the 
resolution and accuracy of the recording software. Figure 3.7 shows two image reels, A 
and B, which both comprise of the three component mixture. 
Figure 3.7A shows that at 111 °C crystals remain present on the glass slide, which are 
presumably cholesterol. These cholesterol crystals are not in contact with the molten 
MPG/DCP and thus would require the hot stage to go to 150 °C to complete the melt of 
those cholesterol crystals, which was confirmed by an individual scan of cholesterol. 
However in Figure 3.7B the lipids were layered with MPG was placed on the bottom, 
followed by DCP and then cholesterol. The result shows that just before the complete 
melt (Tmax) at 80 °C there are still crystals present and that complete melting occurs at 
81 °C which corresponds to the DSC thermogram of the mixture. This result confirms 
that the cholesterol is able to dissolve into the molten MPG/DCP mixture and that this 
acts as a solvent for the cholesterol to dissolve in. Hence, when manufacturing at a large 
scale the order of addition of the components could increase melting efficiency by 
enabling melting to take place at lower temperatures, in turn preventing degradation of 
the surfactants at high temperatures. This idea of co-solvency to aid in melting point 
depression was also observed by Grandelli et al, (2012) where the melting point of the 
drug Piroxicam was significantly depressed when mixed with carbon dioxide (CO2) or 
mixtures of CO2 with co-solvents such as ethanol (Grandelli et al., 2012).  
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Figure 3.7: DSC thermogram of the surfactant mixture showing corresponding microscopy. A) MPG:Chol:DCP placed onto a glass slide randomly, B) 
Ordered mixture with MPG placed on bottom followed by DCP followed by cholesterol (Scan rate = 6°C/ min).  
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3.3.4 Langmuir monolayer isotherms 
Before preparing the vesicles Langmuir monolayer studies were carried out to 
investigate how the surfactants interact with each other, potentially giving an insight 
into their interfacial properties with an aqueous subphase. The monolayer isotherm for 
the individual surfactants and the mixture of the surfactants is shown in Figure 3.8. 
Table 3.2 represents the values of the study showing the deviations for all experiments 
as n=3 and it is observed the deviation from the ideal extrapolated area at zero pressure 
is minimal of 0.9 % which is in line with the ideal extrapolated area.  
The scan of MPG (Figure 3.8) shows that the surfactant isotherm exhibits several phase 
changes prior to collapsing when the surface pressure is increased. At 65 - 50 
A
2
/molecule there is a gaseous phase, followed by a liquid expanded and gaseous phase 
from 50 - 35 A
2
/molecule. At 35 - 22 A
2
/molecule a liquid condensed/ liquid expanded 
phase is present followed by a short liquid condensed phase to 20 A
2
/molecule where a 
sharp solid phase up to 16 A
2
/molecule is reached where the surface collapse pressure 
of 51.6 ± 1.5 mN/m is reached. In terms of cholesterol (Figure 3.8) the phase changes 
upon increasing surface pressure differ to those of the MPG surfactant. The cholesterol 
starts from a gaseous phase from 40 - 35 A
2
/molecule followed by liquid condensed 
phase from 35 - 30 A
2
/molecule. After 30 A
2
/molecule sharp solid phase occurs up to 
27 A
2
/molecule at a surface collapse pressure of 46.6 ± 0.5 mN/m. Upon studying the 
DCP lipid, the isotherm is very similar to the cholesterol molecule where a gaseous 
phase exists between 50 - 40 A
2
/molecule until a liquid condensed phase is achieved 
between 40 - 36 A
2
/molecule until a final collapse pressure is reached of 53.8 ± 0.9 
mN/m at 34 A
2
/molecule. 
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The mixture of 5:4:1 molar/weight (308.5 mg) ratio of MPG:Chol:DCP respectively 
was prepared and the experiment was carried out in the same way as the individual 
components. The mixture exhibits a gaseous phase from 38 - 31 A
2
/molecule where a 
liquid condensed phase occurs at 31 - 28 A
2
/molecule followed by a sharp solid 
condensed phase at 24 A
2
/molecule with a collapse pressure of 51.9 ± 0.1 mN/m 
(Figure 3.8). When extrapolating the mean molecular are at zero surface pressure for 
the mixture, based on the molecular weights and ratios of the components the ideal 
extrapolated molecular area was calculated to be 28.3 ± 1.5 A
2
/molecule. Upon 
completion of the experiment the mixture resulted in an ideal extrapolated mean 
molecular area of 29.19 ± 0.19 A
2
/molecule which showed no significant difference 
based on the ideal experimental calculated values. This shows that when the surfactants 
are in the 5:4:1 ratio of MPG:Chol:DCP they are forming uniform monolayers and the 
dispersion within the monolayer of the surfactants is even around the trough.  
 
Figure 3.8: Langmuir monolayer isotherms of the individual components and the 
corresponding mixture 5:4:1 (MPG:Chol:DCP). All experiments were carried out in triplicate 
and at 20 °C. 
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Table 3.2: The experimental and ideal extrapolated mean molecular area and surface area 
compression pressure of mixed and pure monolayers at the air/water interface (at 20 °C). MPG, 
Chol, DCP and a mixture of ratio 5:4:1 (MPG:Chol:DCP respectively). All results are 
represented by n=3. 
Component 
Extrapolated area at 
Zero pressure 
(A2/molecule) 
Ideal Extrapolated 
area at Zero pressure 
(A2/molecule) 
Deviation 
from Ideality 
(%)  
Collapse pressure 
(mN/m) 
MPG 21.2 ± 0.4 - - 51.6 ± 1.5 
Synthecol 37.1 ± 0.4 - - 46.6 ± 0.5 
DCP 37.5 ± 0.5 - - 53.8 ± 0.9 
Mixture (5:4:1) 28.3 ± 1.5 29.19 0.9 51.9 ± 0.1 
Langmuir isotherms are reviewed extensively by Moghaddam et al, (2011) where 
cholesterol and DCP, as used within this study, are shown under compression to move 
from a gaseous state to a liquid condensed state, and upon further contraction of the 
barriers forms a solid phase, until the monolayer of the surfactants collapses 
(Moghaddam et al., 2011a). The small molecules, cholesterol and DCP (without 
branching acyl chains), in this study show highly condensed surface pressure monolayer 
isotherms which are in line with studies carried out by Shah and Schulman (1968) 
(Shah Dinesh and Schulman Jack, 1968).  However, the MPG isotherm shows different 
properties to those of Chol and DCP: where in Figure 3.8 the data shows that with the 
MPG surfactant there are more phases with a larger gaseous phase that occurs which 
includes a liquid expanded and gaseous phase prior to achieving a liquid condensed 
phase, which is common for saturated single chain molecules.  
The cholesterol collapse pressure and extrapolated mean molecular area at zero pressure 
(46.5 ± 0.5 mN/m and 37.1 ± 0.4 A
2
/molecule at Zero pressure; Table 3.2) are in line 
with previous studies (Dynarowicz-Latka et al., 2003, Slotte, 1992, Florence, 1981). For 
the combination of MPG:Chol:DCP (5:4:1 molar/ 308.5mg ratio), the ideal calculated 
mean molecular area is 29.19 A
2
/molecule and the experimental value for the mixture is 
28.3 ± 1.5 A
2
/molecule (Table 3.2) suggesting that the surfactants are forming a 
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uniform monolayer and that they have equal properties where no one surfactant is more 
rigid or dominant over the others which is often seen with cholesterol. Furthermore, the 
presence of unsaturated fatty acyl chains or cholesterol has shown to liquefy DCP 
monolayers when mixed together and when applying the additivity rule of working out 
deviation from ideal molecular area, the monolayers of cholesterol-DCP follow the rule 
and show no deviation (Shah Dinesh and Schulman Jack, 1968). The cholesterol 
incorporation within the bilayer of high transition lipids has been shown to increase 
bilayer planarity affecting the bilayer packing density allowing uniform vesicles to form 
which become smaller and spherical and are better suited for laser diffraction (van Hal 
et al., 1996). However, the presence of cholesterol within low or no transition lipids 
such as phosphatidylcholine has shown to increase membrane mechanical rigidity and 
cohesiveness thus increasing the stability of liposome vesicles by reducing the 
permeability of the bilayers in the gel liquid state (McMullen et al., 2004, Kirby and 
Gregoriadis, 1980). The ability of cholesterol to interact with surfactants to reduce their 
transition temperature can also be studied using DSC. Liposomes were prepared with 
and without cholesterol and analysed by DSC (Figure 3.9). The Hydrophobic tails of 
the DSPC liposomes crystallise into a rigid-crystalline phase hence upon heating the 
tails become flexible giving rise to a transition temperature (Moghaddam et al., 2011a, 
Taylor and Morris, 1995). The DSPC scan in figure 3.9, represents one clear distinct 
transition peak with a smooth baseline which is an indicator of a pure liposome sample 
with no impurities segregated within the plane of the membrane hence a good indicator 
of the quality of the liposome sample prepared (Biltonen and Lichtenberg, 1993). 
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Figure 3.9: DSC thermogram of liposomes and niosomes. DSPC and DSPC:cholesterol liposomes 
prepared by lipid hydration were analysed for phase transition. A niosome preparation of 5:4:1 
(MPG:Chol:DCP) shows no transition. Isotherm shows exothermic going up hence melting peaks are 
down the aqueous buffers were used as the reference (Scan rate = 10 °C/min samples run in triplicate). 
The incorporation of cholesterol within the formulation allows the cholesterol to 
uniformly spread between the monolayers and insert itself between the lipids or 
surfactants hence preventing crystallisation of the hydrophobic tails. The presence of 
increasing cholesterol within lipid bilayers are to broaden and reduce the enthalpy of 
the liquid crystalline and gel phase eliminating it entirely at 50 mol % cholesterol 
(McMullen et al., 2004, Demel et al., 1972, Gregoriadis and Perrie, 2001, Oldfield and 
Chapman, 1972). Zuidam et al, (1995) further confirm that high mole fractions of 
cholesterol within lipid based vesicles remain physically stable and resist hydrolysis 
due the abolishment of the gel-liquid crystalline phase transition (Zuidam et al., 1995). 
Thus, our study confirms that the presence of cholesterol within the niosome vesicles 
results in an abolished transition temperature which was observed when analysed by 
DSC (both 95 °C and 120 °C preparations) as presented in Figure 3.9, thus indicating 
that the niosome vesicles should be physically stable and resist hydrolysis.  
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3.3.5 Stability study initial characteristics  
As a result based on the information obtained about the surfactant mixtures by DSC, 
Hot stage Microscopy, TGA and Langmuir, vesicles were produced at two temperature 
ranges with an oil bath either set between 95-98 °C or 120-125 °C and upon 
manufacture the formed niosomes were investigated to elucidate if lower temperatures 
could be adopted in their manufacture. Within this study, the effect of temperature and 
storage were analysed by determination of vesicle size, zeta potential, suspension pH 
and by light microscopy. All of the formulations were tested on day 0 and a control 
study of empty niosomes alongside niosomes formulated with the model antigen, OVA, 
was carried out. The average vesicle size, surface charge and entrapment for the 
stability study in section 3.3.5 is represented in table 3.3 and the confirmation of the 
vesicles is visualised by the light microscopy images presented in figure 3.10. 
Table 3.3: Initial vesicle size, zeta potential and antigen entrapment for the stability study. 
OVA niosomes n=6, empty niosomes n=3. 
 Temperature (OVA NISV) Temperature (Empty NISV) 
 95 °C  120 °C  95 °C  120 °C  
Size (µm) 6.15 ± 0.1  6.52 ± 0.5  6.25 ± 0.04  6.58 ± 0.25  
Span 1.73 ± 0.08  1.73 ± 0.05  1.81 ± 0.02  1.76 ± 0.01  
Zeta (mV) -63.23 ± 9.51  -61.69 ± 8.36  -81.48 ± 9.39  -80.17 ± 9.55  
OVA 
entrapment (%) 
23.51 ± 2.05  23.31 ± 1.18  -  -  
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Figure 3.10: Light microscopy images of the niosome formulations with and without OVA at T=0. A) 
Preparation 95 °C empty, B) Preparation 120 °C empty, C) Preparation 95 °C OVA loaded and D) 
Preparation 120 °C OVA loaded. Scale bar represents 10 µm. 
An average vesicle size of 6 µm is produced whether forming the vesicles by melting 
the surfactants at 95 °C or 120 °C (Table 3.3). As an initial observation no significant 
differences are present in terms of vesicle size when reducing the melting temperature 
of the surfactant mixture (Table 3.3). In terms of surface charge, zeta potential is the 
nearest experimental approximation of surface potential as both the surface potential 
and stern potential are difficult to measure. Thus the zeta potential is the potential at the 
surface of the shear plane which is measured by electrophoresis and is a good indicator 
of stability of colloidal suspensions or emulsions. The zeta potential is measured to 
understand aggregation and dispersion of vesicles within the formulation giving an 
insight into stability requirements. In terms of stability, the more negative the zeta 
A B 
C D 
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potential, the more likely the formulation is to be stable as the charged vesicles will 
repel each other hence avoiding aggregation (du Plessis et al., 1996). The initial zeta 
potential readings are presented in table 3.3 which are highly negatively charged 
indicating good stability (Freitas and Müller, 1998). The optical light microscopy 
images represented in figure 3.10 confirm the vesicle size distributions of the 
formulations alongside the zeta potential values mentioned in previous sections. The 
images show that the vesicles are well dispersed around and no aggregates are visible. 
The distribution of vesicles from large to small vesicles are visible on the images and 
are represented by the span values in Table 3.3.  
 
The OVA entrapment in the niosomes was calculated by a direct method using the 
ninhydrin assay mentioned in section 3.2.7. The ninhydrin assay is used as the presence 
of surfactants do not interfere within the assay in comparison to the Bradford, Lowry 
and Pierce Bicinchoninic Acid (BCA) assay (Brewer et al., 1995). Results of the 
entrapment studies show that the vesicles produced when the surfactants are initially 
melted at 95 °C have an entrapment of 23.5 ± 2.05 % (Table 3.3) and the vesicles 
produced with initial melting at 120 °C have an entrapment of 23.3 ± 1.18 %. Although 
the state of the protein is unknown, for vaccines confirmation is less important; 
however, it can be confirmed that the antigen is present and entrapment shows 
consistency between the two initial melting temperatures of the surfactants and is 
reproducible (n=6).  
3.3.6 The effect of storage temperature on the stability of the niosome 
preparations 
The aim of the stability study carried out on storage conditions is to see whether there 
are any significant differences in the vesicle characteristics by changing the initial 
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melting temperature of the surfactants. As observed in section 3.3.5 the pre-
characteristic data shows no variable differences in the niosome formulations produced 
with either an initial melting temperature of 95 °C or 120 °C. The pH of all of the 
suspensions were all in the range of 9.47 ± 0.15 (results not shown). The formulations 
were prepared and subjected to different temperature storage conditions. Figure 3.11 
represents the vesicle size and zeta potential for each storage temperature over a period 
of 28 days. 
 
From the results the formulations stored at 4 °C (Figure 3.11A) increase in vesicle size 
at a faster rate than when stored at 25 °C or 40 °C (Figure 3.11B and C respectively). 
For example, the comparison of vesicle size of the OVA loaded vesicles at day 14 for 
the different storage temperatures varied greatly with niosomes having a VMD of 25.84 
± 1.22 µm at 4 °C, compared to 11.95 ± 1.09 µm and 10.07 ± 1.18 µm at 25 °C and 40 
°C respectively (Figure 3.11). The physical appearance of these formulations is 
represented in figure 3.11 which shows the OVA loaded vesicles at day 14 and at the 
different storage temperatures. The formulation at 4 °C shows signs of aggregation as 
there remains a sediment layer on the bottom of the vial when turned to its side 
whereas, the formulation at 25 °C or 40 °C do not show signs of sedimentation or 
aggregation at day 14. The niosomes kept at 4 °C after day 14 tend to show increased 
viscosity when physically agitating the vial in relation to the formulations stored at 25 
°C and 40 °C which maintained fluidity.  
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Empty OVA loaded 
 
Figure 3.11: Characteristics of vesicle size and zeta potential of the formulations for a period of 28 days where the empty vesicles represent n=3 and 
the niosomes loaded with OVA represents n=6. Formulation vials out of the storage incubators to visually determine the appearance of the niosome 
preparations at day 14 A) 4 °C storage chamber showing corresponding light microscopy images, B) 25 °C storage chamber and C) 40 °C storage 
chamber. 
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Of each of the storage temperatures studied, the vesicles stored at 40 °C show better 
stability of the niosomes over a period of 28 days when compared to vesicles stored at 
25 °C or 4 °C. The vesicles however within the formulation at 40 °C undergo 
morphological and structural changes into hexagonal shapes (Figure 3.12C/D).  These 
shapes are visualised greater in the formulations stored at 25 °C (Figure 3.12A/B) from 
day 21 onwards hence suggesting that the niosomes when stored at higher temperatures 
are maintain their structure and shape for a longer time period.  
 
Figure 3.12: Day 28 formulations representing morphological rearrangement analysed by light 
microscopy at 40 x objectives. A) Empty niosome formulation stored at 25 °C, B) OVA 
niosome preparation stored at 25 °C,  C and D) OVA niosome preparation stored at 40 °C, 
Scale bar represents 10 µm in all images and taken on a 40x objective. 
When analysing the formulations prepared at 95 °C and 120 °C they showed the same 
properties in terms of sedimentation at each storage temperature (Figure 3.11) hence 
indicating that the initial melting temperature of the surfactant blend has little 
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implication on the physical properties of the formulations. The increased rate of 
sedimentation and destabilisation can be related to the slight differences in zeta 
potential of the formulations at the different storage temperatures (Figure 3.11). At 4 °C 
the zeta potential varies and heads towards the -30 mV range which results in 
destabilisation of the vesicles hence leading to aggregation and sedimentation. The zeta 
potential of the formulations stored at 25 °C and 40 °C show zeta potential of -50 mV 
with the deviations reaching -40 mV and still exhibit good stabilisation of the vesicles. 
Studies by Du Plessis et al, (1996) also show that over an extensive period of time at 4 
°C and 25 °C storage of positively charged multi lamellar liposomes resulted in 
aggregation and increase in the vesicle mean diameter upon reduction in zeta potential 
(du Plessis et al., 1996). In addition, Uchegbu and Florence (1995) show that the 
presence of a charged lipid is vital in preventing aggregation when subjecting the 
vesicles into an isotonic solution (Uchegbu and Florence, 1995). 
The DCP used within this study provides the net anionic charge to the vesicles hence 
resulting in a negative zeta potential (Chupin et al., 2002). The inclusion of a negatively 
(DCP) or positively charged (stearylamine) within vesicle bilayers stabilises the 
vesicles against fusion, aggregation and agglomeration (Barakat et al., 2009, Jadon et 
al., 2009). Studies show that optimum zeta potential should be greater than 60 mV for 
full electrostatic stabilisation for a positively charged moiety (Heurtault et al., 2003). 
Hence for a negatively charged vesicle, a highly negative charge of -60 mV would 
provide full electrostatic stabilisation. The zeta potential results of the vesicles to be 
used in the stability study in Table 3.4 are highly negative hence, are well dispersed 
within the suspension and are less likely to undergo aggregation hence showing 
excellent stability (Figure 3.10).  The ‘empty’ vesicles show a greater negative charge 
to the vesicles containing OVA which could be due to the free OVA masking the 
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charge of the vesicles. In addition, the OVA could be inserting itself within the bilayer 
also masking the charge of the vesicle as studies by Chupin et al, (2002) have shown 
(Chupin et al., 2002). However, whilst not significantly different, the group sizes within 
these studies shows that there is a trend. 
When comparing the formulations in figure 3.11 it is visible that the empty 
formulations at 4 °C show a faster rate of aggregation in relation to the formulations 
containing OVA. This trend is only observed at 4 °C and not at the other two storage 
temperatures. There is a possibility that due to the drop in surface charge which is from 
the DCP this may be an indicator of DCP leaving the vesicles and thus causing the 
aggregation and breakdown of the vesicles. Furthermore figure 3.11 confirms that there 
is a difference between the empty formulations and the OVA loaded niosomes at 4 °C. 
Figure 3.11 A at 4 °C shows that the formulations are very viscous and practically 
sediment to the bottom of the vial in relation to the OVA loaded vesicles in figure 3.11 
B, which still show signs of fluidity. These samples were examined via light 
microscopy (Figure 3.11) where two sections of the same sample were screened to 
show that there are regions where there are intact vesicles in addition to regions where 
there are clusters or aggregates of degraded vesicles. At day 14, the empty vesicles 
show greater clusters and regions where the niosomes have disintegrated and are 
forming needle like structures. 
Previous studies by Arunothayanun et al, (1999) on polyhedral niosomes have shown 
that niosomes are sensitive to temperature (Arunothayanun et al., 1999). The study 
shows that when niosomes held below the transition temperature form polyhedral 
niosomes which resemble the vesicles in this study (Figure 3.12). Furthermore, 
Arunothayanun et al, (1999) discuss that when polyhedral niosomes are present the 
viscosity of the samples increase in relation to the more spherical niosomes due to the 
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presence of rigid gel shapes (Arunothayanun et al., 1999). This effect can be related to 
our study where fewer polyhedral shapes are visible within the formulations held at 40 
°C and are represented by the minimal vesicle size change (Figure 3.11C) as these 
remain less viscous when stored at higher temperatures (40 °C). Whereas, the niosomes 
stored at room temperature show an increased presence of polyhedral shapes as the 
storage time increases so does viscosity in relation to the samples stored at the higher 
temperatures (40 °C) which is in line with the studies carried out by Arunothayanun et 
al, (1999). As a result, vesicles stored over time start to undergo bilayer transformations 
and change shape resulting in the increased viscosity of the formulations. At 4 °C 
(Figure 3.11) there are no signs of polyhedral niosomes or any shapes of this 
description. The formulations in figure 3.12 show the viscosity of the samples at the 
low temperature of 4 °C is at its greatest and shows destruction of the vesicles when 
analysed visually (Figure 3.11).  
Although the vesicles were initially prepared at 50 °C, resulting in spherical niosomes, 
the cold storage temperatures over the period of 28 days has shown vesicle destruction, 
whereas the vesicles stored at higher temperatures show increased stability and 
retention of spherical vesicles for a longer period of time. Furthermore, studies on 
vesicles by Vangala et al, (2006) also show that liposome vesicles prepared from DDA 
showed an increase in vesicle size when stored at 4 °C over a period of 7 days, 
eventually leading to precipitation of the vesicles by day 28. In addition, the 
incorporation of TDB in the DDA liposome vesicles showed that over a period of 28 
days there was no significant increase in vesicle size (Vangala et al., 2006). The OVA 
present within the formulations seems to stabilise the vesicles from breakdown at 4 °C 
(Figure 3.11B) for a longer period of time up to day 14; however, at day 28 the empty 
vesicles and the OVA loaded vesicles look the same under the microscope and the 
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evident size result shows that the size distribution between the niosomes with and 
without OVA end up to be the similar (Figure 3.11).  
3.4 Conclusion 
Overall, the purpose of this study was to determine whether the mixture of surfactants 
can be initially melted at a lower temperature than stated in the literature to prevent any 
degradation occurring of the surfactants at the elevated temperatures. The study shows 
that the use of analytical techniques such as DSC and TGA confirm that the surfactant 
mixture is able to melt at a lower temperature hence, vesicles were prepared and tested 
for physico-chemical properties over a period of 28 days and compared to vesicles 
prepared at the literature values. Results show that when melting the lipids at 95 °C or 
120 °C there are no significant differences to vesicle size, zeta potential or pH. Hence, 
niosome vesicles can be prepared at a lower melting temperature thus preventing 
degradation of surfactants and in turn allowing the cost of manufacturing to be lowered 
due to the decrease in melting temperature. In regards to future preparations, as there is 
no significant difference in physico-chemical characteristics between the two 
preparation temperatures formulations will be melted at 120 °C to speed up the melting 
process as the degradants formed had no impact upon the immune response (confirmed 
by VBI).  In terms of temporary storage, niosome vesicles should preferentially be 
stored in the fridge for a maximum of three days and stored at either 25 °C or 40 °C for 
a maximum of 24 hours to see no significant change in vesicle size. However, it is 
recommended that for long term storage stability, the niosomes should preferentially be 
lyophilised in order to maintain stability during storage.  
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4.1 Introduction 
All of the currently licensed vaccines are sensitive to heat, thus requiring the use of cold 
chain environments for storage during transport. On the other hand, many vaccines such 
as hepatitis B are sensitive to freezing temperatures (Braun et al., 2009, Chen et al., 
2009a). Therefore, vaccines are stored with a temperature range specified at 2-8 °C to 
maintain their potency. However, protecting the vaccines from excessive heat and 
freezing during transport and storage can be difficult in developing countries (Matthias 
et al., 2007, Nelson et al., 2007, Techathawat et al., 2007) and studies have shown that 
temperature deviations for vaccines are more likely to occur after delivery of the 
vaccines  to storage centres, or immunisation clinics, rather than at the production sites 
(Setia et al., 2002, Matthias et al., 2007). For example, a study in Hungary confirmed 
that 4 % of the vaccines were compromised due to the summer heat and 38 % 
compromised by the winter freeze (Lugosi and Battersby, 1990). Other issues related to 
consequences of compromised vaccines include, insufficient training, power shortages 
and human errors (Setia et al., 2002). As a result, the consequences of failures during 
cold chain transportation/storage can result in the increase of immunisation costs and 
local vaccine strategy plans due to vaccine wastage and inadequate protection of those 
unidentified products. 
Therefore, the thermostability of vaccines is critical in providing effective prevention of 
disease and currently the approaches to overcome the issues of vaccine stability include 
the use of particulate delivery systems. Thermal stability of components required to 
produce vaccines in solution is strongly influenced by factors such as pH, osmolarity, 
ionic strength and the presence of excipients (Brandau et al., 2003). Currently non-ionic 
surfactant vesicle carrier systems, such as niosomes or bilosomes, are being employed 
to encapsulate/ associate vaccine antigens and to promote their effective delivery via the 
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oral route. However, the methods used to form these vesicles can require antigens to be 
heated to 60 °C or be subjected to several freeze thaw cycles to prepare the vaccine 
delivery systems (Conacher et al., 2001, Mann et al., 2009). This can have a major 
impact on the integrity of the vaccine; for example, Statens Serum India have shown 
that after three freeze thaw cycles toxoid vaccines such as Tetanus, Diphtheria and 
Pertussis lose up to 60 % potency and this freeze damage is sustained (Kartoğlu, 2006). 
Given that the potency of a vaccine can be decreased by exposure to excess 
temperatures it is essential to maintain vaccine components at their ideal temperatures 
for maximum potency (Plotkin and Fletcher, 1996, Galazka et al., 1998). Yet this can 
be costly, thus the development of a thermostable vaccine presents the ideal solution to 
this problem.  
4.1.2 Aims and Objectives 
Therefore, the aim of the work outlined within this chapter was to develop a novel 
method of preparing niosome vesicles which can protect the vaccine antigen against 
elevated storage conditions for a portion of its shelf life. This was carried out by 
preparing Fluzone associated niosome vesicles and after lyophilisation transporting 
them to Variation Biotechnologies (Canada) and determining if the developed method 
gives a response in vivo compared to a commercial vaccine (Fluzone). Upon 
determination of the ability of the proposed method of production to induce an immune 
response the niosome vesicles were to be subjected to storage at 40 °C and 4 °C for 3 
months prior to in vivo administration to determine thermostability compared to the 
commercial vaccine and the current method of niosome production. 
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4.2 Materials and Methods 
4.2.1 Surfactants 
A range of non-ionic surfactant based bilayer vesicles were prepared by high shear 
homogenisation and analysed using several materials and methods. The surfactants used 
in the study were Monopalmitoyl glycerol (MPG) (Larodan Labs, Sweden), Synthecol 
(Chol) (Sigma Aldrich, UK) and Dicetyl Phosphate (DCP) (Sigma Aldrich, UK). The 
aqueous buffer sodium bicarbonate (Sigma Aldrich, UK) or phosphate buffered saline 
(PBS) was buffered to pH using a 1 M sodium hydroxide solution (Sigma Aldrich, UK) 
or 0.1 M hydrochloric acid (Fisher Scientific, UK).  
4.2.2 Radio-labelling of H3N2 antigen 
The H3N2 antigen (Immune Tech, USA) stock solutions were prepared as 100 µg of 
purified protein (1 mg/mL) in PBS stock and 40 µL (40 µg) placed into an iodination 
tube (Pierce Biotechnology) with 2 Mbq of 
125
I (Perkin Elmer, Belgium) for 1 hour. A 
separation column was pre-prepared by firstly, heating Sephadex G75 (Sigma Aldrich, 
UK) beads for 3 hours at 90 °C and left to cool, during that time the column was 
prepared by placing glass wool at the bottom to prevent any Sephadex beads from 
falling through the column. The column was then packed using the pre heated and 
swollen Sephadex G75 prepared earlier. It is important that the gel remains hydrated 
with the PBS buffer which is used for labelling. It is essential to optimise the flow rate 
based on sample collection and then to match the sample volume collected to the 
correct protocol on the gamma counter.  
Upon packing of the column, just above gel, the solution from the iodination tube was 
added to the top of the column and then rehydrated with buffer and samples were 
collected every 1 minute for 1 hour which results in the collection of 500 µL per vial. 
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The vials were then analysed for 
125I content using a Cobra™ CPM Auto-Gamma® 
counter (Packard Instruments Company inc., IL, USA) individually to prevent any 
backscatter that may occur from neighbouring vials. To confirm presence of protein in 
the vials a micro- BCA assay was carried out and used in parallel with the data obtained 
from the iodination of the protein. 
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4.2.3 Preparation methods of vesicles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Summary of methods for preparing niosome vesicles as presented within the patent by Anderson et al, 2011.
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4.2.3.1    Preparation of niosomes using Aston melt method  
A 5:4:1 molar ratio of MPG, Chol and DCP was weighed out using a balance and 
placed into a 10mL glass beaker ensuring that no lipids stick to the sides of the beaker. 
Before melting the lipids, the aqueous phase was prepared in a 15 mL falcon tube. 25 
mM sodium bicarbonate (pH 7.6) formed the bulk part of the aqueous phase, and 
radiolabelled antigen (Section 4.2.2) was placed in a heated water bath for 10 minutes at 
30-35 °C. Hence this was to be known as the buffered antigen stock solution. 
While the aqueous buffer was preheated, the beaker containing the lipids was placed 
into a hot oil bath (120-125 °C) and melted for 10 minutes. The beaker containing the 
molten mixture was removed from the oil bath and the buffered antigen stock solution 
was immediately added to this beaker and immediately homogenised at 8000 rpm at 30-
35 °C. The mixture was homogenised for 10 minutes and left to shake and incubate at 
220 rpm at 30 °C for 2 hours. 
4.2.3.2   Preparation of niosomes using Strathclyde melt method  
Niosomes were also prepared using a method first developed by researchers within 
Strathclyde university (Mann et al., 2004); a 5:4:1 molar ratio of MPG, Chol and DCP 
was weighed and placed into a 10 mL glass beaker. Before melting the lipids, the 
aqueous phase was prepared in a 15 mL falcon tube. 25 mM sodium bicarbonate (pH 
7.6) formed the bulk part of the aqueous phase. The buffered solution was placed into a 
heated water bath at 60 °C. A 100 µL radiolabelled antigen was then placed in a heated 
incubator for 5 minutes at 37 °C. While the aqueous buffer was preheated, the beaker 
containing the lipids was placed into a hot oil bath (120-125 °C) and melted for 10 
minutes with occasional swirling. The beaker containing the molten mixture was 
removed from the oil bath and the 25 mM sodium bicarbonate buffer is immediately 
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added to this beaker and then immediately homogenised at 8000 rpm at 60 °C for 5 
minutes. Upon 5 minutes total homogenisation time the radiolabelled antigen was added 
to the homogenising suspension and homogenised for a further 5 minutes and then left 
to shake and incubate at 220 rpm at 30 °C for 2 hours. 
4.2.4  Characterisation of vesicles 
The size of the vesicles was determined using laser diffraction on a sympatec 2005 
(Helos/BF) analyser. 20 µL aliquots of the vesicle suspension were diluted into the 
cuvette with 40 mL double distilled water. The zeta potential was measured in 1.5 mL 
double distilled water at 25 °C on a Zeta Plus Brookhaven Instrument. 20 µL of the 
bilosome suspension was mixed in 1.5 mL double distilled water and then analysed. 
The pH of the vesicle suspension was determined using a pH meter where the tip was 
placed into the vesicle suspension and left for a few minutes.  
4.2.5 Quantification of antigen 
For quantification of antigen association, ultra-centrifugation of the formulations was 
required to isolate antigen entrapped vesicles, from non-incorporated antigen. To 
achieve this, 300 µL aliquots of sample were diluted in a Beckman 3.9 mL Polo-
allomer tube and filled up to the neck with double distilled water.  The tubes were 
carefully heat sealed ensuring that there are no air bubbles present within the tube. The 
tubes were then placed accordingly in the TLN-100 rotor and centrifuged at 354,000 X 
g for 45 minutes at 4 °C with the acceleration set at 8 (Slowest) and the deceleration at 
coast. When centrifugation was complete, the tubes were opened and the supernatant 
removed. The sample was resuspended and the centrifugation stage repeated. After the 
second ‘wash’ the antigen loaded vesicles are then re-suspended with 100-200 µL of 
appropriate buffer and transferred all to a clean/labelled 1.5 mL eppendorf tube. 
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4.2.6 Separation of free antigen from associated antigen via gel separation  
The Sepharose CL-4B solution was mixed in a ratio of 75:25 % ratio of Sepharose and 
PBS and shaken to ensure a homogenous mixture of the Sepharose CL-4B beads. Glass 
wool was placed into a 5 mL glass burette column where pre-swollen Sepharose CL-4B 
gel was packed into the column and PBS was allowed to run through the column for up 
to 1 hour to ensure successful packing of the gel. 300 µL of the radiolabelled niosome 
formulation was pre-counted on the gamma counter to obtain an initial count. The 
sample was then taken from the gamma vial and placed onto the top of the gel within 
the column and was then allowed to pass through and the column then rehydrated with 
PBS. The samples were collected at 0.25 mL per two minutes for a period of two hours. 
Radioactive counts were determined using the gamma counter and antigen association 
was calculated. 
4.2.7 Trypsin digestion 
Vesicles were prepared with radiolabelled antigen and an initial antigen association was 
calculated by centrifugation. Trypsinisation studies were carried out by incubating 
aliquots of the sample with 100 µg/mL trypsin for a period of 30 and 60 minutes at 37 
°C to remove any adsorbed antigen. The samples were then centrifuged (Section 4.2.5) 
to determine surface adsorption of the antigen. 
4.2.8 Lyophilisation of niosome vesicles 
Lyophilisation was performed with the Virtis Advantage (Bio Pharma) freeze dryer. A 
400 mM Trehalose solution was prepared and then added 1:1 to the niosome samples to 
be freeze dried and were then stored at -70 ºC. The freeze drying protocol was set for 
primary drying to occur at -40 ºC for 48 hours with a secondary drying cycle set at 20 
ºC for a further 10 hours with a condenser of -75 ºC. The freeze drying cycle is 
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sufficient enough to thoroughly dry the formulations and prevent damage to the 
samples. 
4.2.9 Direct Enzyme-linked immunosorbent assay (ELISA) 
Enzyme-linked immunosorbent assay (ELISA), was used to detect the presence of 
antibody in serum collected from mice. The direct detection method used a labelled 
primary antibody that reacts directly with the antigen. Direct detection could be 
performed with antigen that was directly immobilized on the assay plate or with the 
capture assay format. Diluted antigen in PBS was used to coat a 96 well plate using 100 
μL of solution followed by incubation at 2-8 °C overnight. 300 μL of a diluted goat 
serum in PBS was used as blocking solution. A series of 2 fold dilution of the serum 
sample prepared in a blocking buffer was assayed in a 96 well plate to detect the 
antibody titre. The results were recorded at OD 450 nm and chart was prepared to detect 
the titres of the sample.  
 
ELISA assay was performed on 96 well ELISA plates and were coated overnight at 4 
°C with recombinant protein. The next morning the plates were washed with PBS 
containing 0.05 % Tween 20 and then blocked (1-3 h at 37 °C) with 10 % goat sera in 
PBS. After the incubation time, plates were washed six times in wash buffer (0.05 % 
Tween 20 in PBS). The starting dilution of the sample in 10 % goat sera in PBS was 
prepared and 2-fold serial dilutions were carried out. The sample and the standard were 
added to the 96 well ELISA plates and were incubated for 1.5 h at 37 °C. The plates 
were washed six times in wash buffer and incubated for 1.5 h at 37 °C with a 1/10000 
dilution of a goat anti-mouse IgG-Fc HRP conjugated secondary antibody (Bethyl). The 
plates were washed six times and developed with 100 μL of TMB substrate for 8 min. 
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100 μL of TMB-Stop solution was added to stop the reaction. Absorbance was read at 
450 nm with an ELISA plate reader (Bio-Rad). 
4.3 Results and Discussion 
4.3.1 Development of Aston melt method 
Due to problems of stability of vaccines at excessive heat or freezing temperatures, 
protection methods, such as association with particulate delivery systems and 
subsequent lyophilisation has resulted in increased shelf life protection of the vaccines. 
As previously mentioned, niosome vesicles have shown the potential to both improve 
antigen-specific immune responses and offer increased protection of vaccines (Brewer 
and Alexander, 1992, Walker et al., 1996, Murdan et al., 1999). However, the current 
patented methods of manufacture of niosomes require preparation temperatures of 60 
°C (Figure 4.1; commonly referred to as the Strathclyde melt method) which can be 
detrimental to thermolabile vaccine antigens. As a result, within this chapter  a method 
has been developed that can overcome this barrier and allow the use of thermolabile 
antigens to be incorporated within niosome vesicles. The new method proposed in 
figure 4.1 (referred to as the Aston melt method) has significant differences to the 
previously patented method in section 4.3.2.3 (referred to as the Strathclyde melt 
method). Firstly, the manufacturing temperature is reduced from 60 °C to 30-35 °C 
which in turn, should restrict degradation of antigen during the formulation process. 
Secondly, the antigen is added to the process at the start prior to vesicles being formed 
with the intention of increasing the amount of antigen entrapped within the vesicles 
therefore offering increased protection. To determine whether these changes offer 
differing properties, vesicles prepared using each of the two methods were compared 
for antigen loading and retention after trypsinisation and then subsequent in-vivo 
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immunisation studies. To determine entrapment the H3N2 antigen was firstly 
radiolabelled to determine quantification of antigen studies. 
4.3.2 Radiolabelling of antigens 
Fluzone is a trivalent vaccine comprising of three influenza antigens H1N1, H3N2 and 
Brisbane in the year 2009. All three of the antigens were radio-labelled with 
125
I as 
outlined in section 4.2.2. Figure 4.2 shows the radiolabelling of A) H3N2 and B) 
Brisbane antigens where the radiolabelled antigen elutes first at approximately <7 mL 
(14 min) whilst free 
125
1 elutes > 10 mL. The presence of antigen within the first peak 
was confirmed with a micro BCA assay kit (which turned purple on the detection of 
antigen; Figure 4.2). The aliquots containing the antigen were pooled to form the stock 
solution for the subsequent studies.  
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Figure 4.2: A) The radiolabelling of the H3N2 antigen showing two peaks indicating radiolabelled 
antigen and free 125I  with the confirmation of the antigen present in peak 1 wells 8-10 using  a Micro-
BCA assay kit. B) The radiolabelling of the Brisbane antigen showing two peaks indicating radiolabelled 
antigen and free 125I with the confirmation of the antigen present in peak 1 wells 8-10 using a Micro-BCA 
assay kit. 
4.3.3 Validation of centrifugation protocol 
To remove non-associated antigen from niosome formulations various methods can be 
adopted including centrifugation, column chromatography and dialysis. However, of 
these methods centrifugation offers the most convenient method for formulation 
screening of multiple formulations. Therefore to validate the use of centrifugation to 
remove non-associated antigen from niosomal carriers, studies initially focused on 
comparing the efficiency of non-associated antigen removal using centrifugation 
(Brewer and Alexander, 1992) and column chromatography using Sepharose CL-4B 
(Stuhne-Sekalec et al., 1991, Uchegbu and Florence, 1995). The columns used were 
prepared with Sepharose CL-4B as per protocol in section 4.2.6. The Sepharose Cl-4B 
column has a bead diameter of 40-165 µm enabling the niosomes to pass through the 
column whilst delaying the elution of the free antigen (as this passes through the matrix 
of the gel). In all cases background values on the gamma counter were taken to be 
below 300 cpm. Initially ‘free’ antigen was passed through the column to identify its 
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elution volume. Independent batches of niosome formulations which were tested for 
antigen loading using column separation chromatography antigen loading compared to 
the corresponding association values obtained for the centrifugation method (Figure 
4.3). Niosome vesicles were prepared as outlined by the VBI inverted melt method in 
figure 4.1. 
Figure 4.3 A shows that the free antigen starts to appear from vial numbers 16-18 (4 to 
4.5 mL), however as a small percentage (< 1%) of the initial counts. This could be due 
to possible aggregates of the antigen, hence travelling through the sepharose column at 
a faster rate than the rest of the free antigen which appears as a broad peak from vial 23 
(5.75 mL) onwards. A comparison of niosome-associated H3N2 via centrifugation and 
column separation was also determined by preparing niosome vesicles with the H3N2 
antigen, where 300 µL of the sample was counted and then passed through the column 
as in section 4.2.6. In addition to passing through the column another 300 µL from the 
same batch of niosome vesicles was counted and association was determined using 
centrifugation as per protocol in section 4.2.5.  
The results from both centrifugation and column separation show highly comparable 
results of antigen association with the niosome vesicles. Figure 4.3A shows that the free 
antigen starts to appear from vial number 23 (5.75 mL). In comparison, niosomes with 
associated antigen are eluted from vial number 13 to 18 (from 3.25 mL to 4.5 mL; 
Figure 4.3B and C). The data shows that the reproducibility between the processes is 
around 5 % and that the centrifugation procedure with the H3N2 antigen is valid with 
no indication that the free antigen is spinning down with the antigen associated 
niosomes at a process temperature of 30 °C. 
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Figure 4.3: A) Determination of elution volume for free H3N2 antigen; B) niosome preparations 
incorporating the antigens H3N2; C) confirmation of niosome peaks using the vials after passing through 
Sepharose CL-4B column, and D) corresponding centrifugation antigen-loading results for H3N2.  
 
   
Centrifugation Column Chromatography 
      Batch 1 Batch 2 Batch 1 Batch 2 
 free antigen recovered  14.85 % 16.39 % - - 
antigen associated with niosomes 60.74 % 63.61 % 61.09 % 66.44 % 
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4.3.4 Initial association of antigen with vesicles and digestion with trypsin 
Niosome vesicles containing Fluzone (which included radiolabelled H3N2 antigen) 
were prepared via the Strathclyde melt method and the new Aston melt method as per 
protocol in section 4.2.3. Results indicate that, whilst the vesicles are comparable in 
terms of their initial physico-chemical characteristics (Table 4.1), when comparing the 
initial association values between the two methods there is significant differences in 
antigen association with the Strathclyde melt method having significantly higher (p < 
0.01; ANOVA with post-tukey test) association of antigen compared to the Aston melt 
method (Figure 4.4). However, upon digestion with trypsin for 30 and 60 minutes, the 
Aston melt method gave significantly higher antigen protection (p < 0.01) from 
degradation and in turn having greater antigen entrapped within the vesicles compared 
to the Strathclyde melt method (Figure 4.4). 
After 30 minutes of trypsin exposure antigen-loaded vesicles prepared by the 
Strathclyde method (Section 4.2.3.2), antigen association dropped to ~ 17 % and 
subsequently after 60 minutes trypsin exposure, antigen association dropped to ~ 13 % 
from an initial association of ~ 58 % (Table 4.2). This suggests that 45 % of the 
niosome associated antigen was accessible to digestion, and that this antigen is surface 
bound given that trypsin is unable to cross vesicle bilayers (Kaur et al., 2012) (Table 
4.2). In comparison, the Aston melt method, although initially less antigen (39.21 ± 
1.59 %) is associated to the vesicles compared to the Strathclyde melt method, trypsin 
digestion studies after 30 minutes show that more antigen (31.82 ± 1.59 %) is entrapped 
within the vesicles thus offering significantly (p< 0.01) increased protection and 
recovery of antigen compared to the Strathclyde method (17.35 ± 0.57 %; Table 4.2).  
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Table 4.1: Physicochemical characteristics of the niosome formulations prepared by either Aston melt or 
Strathclyde melt. 
Niosome Vesicle size (µm) Zeta potential 
(mV) 
pH 
Aston melt 4.84 ± 0.16 -102 ± 12 7.4 
Strathclyde melt 5.14 ± 0.11 -103 ± 21 7.4 
 
 
 
Figure 4.4: Digestion of antigen with trypsin after 30 and 60 minutes incubation at 37 °C compared to 
initial association measured with radioactive counts (n=3). 
 
Table 4.2: Initial H3N2 antigen association and protection after trypsin digestion at 37 °C for 30 and 60 
minutes.  
Method Initial % 
Association 
30 min 
Trypsin 
Protection 
% 
60 min 
Trypsin 
Protection 
% 
Aston  39.21 ± 2.72  31.82 ± 1.59 82 30.19 ± 2.32  77 
Strathclyde 58.29 ± 2.48 17.35 ± 0.57 30 13.26 ± 0.66 23 
 
The differences in antigen retention between the two niosome preparation methods 
(Figure 4.4) could be due to difference in when antigen was added in the formulation 
process and the temperatures used. Using the Strathclyde method (Section 4.3.2.3) the 
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antigen is added to preformed vesicles thus potentially promoting increased surface 
adsorption of the antigen, whilst in the revised Aston method, the antigen is added 
during formation of the niosomes, which may promote higher incorporation within the 
vesicles. Secondly, the difference in temperatures between the two preparation 
processes which may influence and potentially denature the antigen thus changing 
niosome/antigen interactions. This effect has been demonstrated by Privalle et al, 
(2011), whereby a phosphinothricin acetyltransferase protein exposed to 60 °C was still 
detectable after exposure however, showed total loss in its enzymatic activity (Privalle 
et al., 2011). The overall increased recovery of antigen within the Aston melt method 
can be attributed to the addition of antigen within the formulation process. The antigen 
is present within the aqueous phase prior to the formation of the vesicles, thus, upon 
vesicle formation there is an increased potential for antigen to be incorporated within 
the vesicles compared to surface adsorption. This is comparable to previous studies 
where antigen was loaded onto the surface of MLV and compared to antigen entrapped 
within vesicles using the dehydration-rehydration method (Kaur et al., 2012). Within 
this study, cationic vesicles were used to deliver a TB sub-unit antigen and it was 
demonstrated that whilst initial loading of antigen was noted to be similar between both 
vesicles preparation methods, vesicles with antigen incorporated within vesicles offered 
higher antigen protection to trypsin digestion compared to liposomes where the antigen 
was surface bound (Kaur et al., 2012). Therefore from the data within Table 4.2 it can 
be seen that the Aston melt method offers increased antigen protection potentially due 
to enhanced entrapment of antigen within the vesicles, and this may be advantageous 
for antigen delivery.  
 
 
 
 
Chapter 4: Development of a novel thermostable vaccines by exploiting non-ionic vesicles 
 
166 
 
4.3.5 Determination of immune response from Aston melt method 
From the data shown so far, the Aston melt method has shown promise as a process for 
vesicles, resulting in increased antigen entrapment within niosome vesicles and offering 
increased protection of the antigen upon digestion with trypsin. Although having 
increased antigen retention and protection shows promise, it is important that these 
attributes facilitate production of an immune response. As a result, niosome vesicles 
were prepared via the Aston melt method with the trivalent Fluzone vaccine, 
subsequently lyophilised and reconstituted prior to administration intramuscularly to 
female Balb/c mice (6-8 weeks old). In general, an intramuscular dose of antigen to 
mice require the dose to be 1/10
th
 the human dose (45 µg). Therefore, the commercial 
vaccine was used as the control formulation and injected at 4.5 µg per dose compared to 
the prepared niosome vaccine which had a reduced 1.35 µg antigen per dose. The 
formulations were administered as 50 µL doses in the right quadricep of the balb/c 
mouse. Blood samples were taken at specific intervals and then immunological analysis 
was carried out by ELISA.  
The physicochemical characteristics of the vesicles used for the immunisation study are 
presented in Table 4.3 where the vesicle size was 4.58 µm with a highly negative 
surface charge of -101 mV and a neutral pH. The consideration of pH is an important 
factor; Influenza antigens within a pH range of 7-9 show no loss of potency, however 
losses in antigen potency have been shown above and below this range (Brandau et al., 
2003).  
Table 4.3: Physicochemical characteristics of the niosome formulation 
 Vesicle size (µm) Zeta potential 
(mV) 
pH 
Aston melt 4.58 ± 0.12 -101 ± 17 7.4 
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Results from the ELISA experiments for the three strains (Figure 4.5) show that by 
incorporating Fluzone with the niosome vesicles, endpoint titres are increased and offer 
a stronger immunological response compared to the commercial Fluzone vaccine. 
When comparing the niosome preparation to the commercial Fluzone control vaccine, 
there were significant differences in the H1N1 strain and the B-Florida strain showing 
that the niosome vaccine offers stronger systemic immunity compared to the 
commercial Fluzone. However, there were no significant differences in immunity for 
the H3N2 strain. 
 
Figure 4.5: Reciprocal HAI endpoint titres of the trivalent Fluzone incorporated into niosome vesicles 
via the Aston melt method compared to the commercial Fluzone vaccine. A) H1N1 strain, B) H3N2 
strain and C) B-Florida strain (n=5). 
The study shows that the development of the Aston melt method is successful in 
inducing systemic immunity against influenza. Based on the results within figure 4.5, 
antigen entrapped/associated within niosome vesicles offers potentially increased 
systemic immunogenicity compared to the commercially available Fluzone vaccine. 
Furthermore, the niosome vaccine prepared, contained a much lower dose than the 
commercial vaccine when administered and still showed increased immunity, thus 
showing the potential of the niosome vesicles to act as a dose-sparing adjuvant. Studies 
by Moon et al, (2012) on the development of a malaria vaccine with the use of PLGA 
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nanoparticles have also demonstrated that conjugation of antigen to the nanoparticles 
results in a significant increase in serum IgG titres compared to the same free antigen 
dose. Moreover, upon significant reduction in antigen dose when conjugated to the 
nanoparticles, antibody levels produced were still significantly higher than the antigen 
only dose, thus showing that the use of carrier systems potentially allows a reduction in 
antigen dose to produce dose sparing vaccines whilst maintaining effective immunity 
(Moon et al., 2012). In addition, Wee et al, (2008) have shown that mucosal immunity 
can be enhanced by the use of H1N1 influenza antigen when administered with an 
ISCOMATRIX system containing cholesterol, phospholipids and saponins. Their study 
showed that pulmonary administration of a significantly dose reduced H1N1 antigen 
from 15- 0.04 µg in the ISCOMATRIX system showed serum antibody responses 
greater than or equal to the standard 15 µg unadjuvanted antigen dose when delivered 
subcutaneously (Wee et al., 2008).  
The use of delivery systems to provide immunogenicity has also been shown by Prego 
et al, (2010) using chitosan based microspheres to encapsulate hepatitis B antigen. 
Results from their studies show that the chitosan based microspheres are able to 
maintain antigen integrity (confirmed by SDS page) after lyophilisation and storage at 4 
°C for a period of three months (Prego et al., 2010). Upon intramuscular administration 
of the Alum adsorbed hepatitis B antigen and the chitosan encapsulated hepatitis B 
antigen microspheres, there was a delay in the immune response for the microsphere 
vaccine compared to the alum vaccine (Prego et al., 2010). However, over time, 
significantly higher levels of IgG titres were produced with the chitosan microsphere 
based vaccine compared to the alum adsorbed vaccine, thus showing the effectiveness 
of encapsulating vaccine antigens with delivery systems to elicit immune responses. 
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4.3.6 Thermostability between the formulations 
Given that the overall aim of this study was to develop potential thermostable vaccines, 
the next stage of this research was to consider the thermostabiltiy of the niosome 
formulations. Therefore, niosome vesicles incorporating the trivalent Fluzone 2009 
antigens were prepared by the Aston melt and Strathclyde melt method and compared 
in terms of their ability to offer thermostability in a freeze-dried format. The niosome 
preparations outlined in table 4.1 were subjected to storage at 4 ± 3 °C and 40 ± 2 °C 
for 3 months and subsequently given as single intramuscular administration to Balb/c 
mice. Sera was collected prior to administration, as well as on day 14 and 
immunogenicity was assessed using the hemaglutination inhibition assay (HI assay) and 
direct ELISA. The commercial vaccine Fluzone was used as a positive control for 
comparison and stored in the same storage conditions as the niosome formulations. 
The HAI assay is a serological technique which is used to detect HA-specific antibodies 
in serum resulting from infection or vaccination with influenza virus antigen; HAI titres 
correlate with protection from influenza in humans and a geometric mean titre (GMT) 
≥40 is considered to be protective (Hobson et al., 1972, Hannoun et al., 2004). The HAI 
method works on the principle of the influenza viruses ability to agglutinate red blood 
cells with agglutination that is inhibited by anti-HA antibodies specific to the viral 
strain. The HAI antibody titres were expressed as the reciprocal of the highest serum 
dilution showing complete hemaglutination inhibition. With reference to the results of 
the preparations at 4 °C and 40 °C and the H1N1 strain (Figure 4.6 A), no significant 
difference in IgG titres were found between the mice immunised with either the 
Strathclyde melt and Aston melt niosome formulations and both formulation methods 
were comparable to the commercial vaccine titres.  
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A
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Figure 4.6: Geometric mean for IgG titres after administration of niosome vesicles at t= 14 days after 
formulations stored for 3 months at 4 °C and 40 °C for A) H1N1 and B) H3N2 (n = 16). ≤40 GMT 
considered protective against Influenza. 
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However, in terms of the preparations at 4 °C and 40 °C, responses against the H3N2 
antigen (Figure 4.6B) were significant different between all three immunisation groups. 
For the mice immunised with the Strathclyde melt method niosomes minimal (< 40 
GMT) IgG titres were measured. In contrast, the Aston melt niosomes promoted highest 
IgG responses (p< 0.01) compared to both the control group and the mice which 
received the Strathclyde method niosomes, after storage at 40 °C, and when stored at 4 
°C the IgG titres were comparable between the Aston melt and the commercial Fluzone 
control (Figure 4.6B). The control vaccine stored at 4 °C for both strains H1N1 and 
H3N2 showed significantly (p< 0.01) higher IgG titres than the control vaccine stored at 
40 °C. These results suggest Aston melt niosomes can support antigen immunogenicity 
to be maintained after storage of the formulation at both 4 and 40 °C for a period of 3 
months prior to administration.  
One of the key changes in the preparation of niosomes implemented within the Aston 
melt method was that the process temperatures were reduced to between 30-35 °C. Both 
niosome preparations (Figure 4.1) were subjected to the same freeze drying protocol 
outlined in section 4.2.8. The freeze drying cycle exploited the lyoprotectant trehalose 
which is a natural alpha linked disaccharide which has known to protect proteins and 
stabilise lipid membranes during freeze drying (Crowe et al., 1987, Arakawa and 
Timasheff, 1982). Studies by Pizzuto et al, (2011) demonstrated that the incorporation 
of trehalose when freeze drying influenza antigens and subsequent storage at 37 °C and 
45 °C for a period of two weeks to mimic failures in transport of antigens shows 
significant improvement in thermostability (Pizzuto et al., 2011). There were no 
significant differences observed in HA median titres of the antigens supplemented with 
trehalose when incubated at 37 °C and 45 °C therefore, improving the heat stability of 
the influenza antigens by maintaining their original HA titres. Therefore this would 
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suggest that the niosomes prepared by the Strathclyde melt were either initially less 
potent as vaccine delivery systems or were less stable during the freeze drying process. 
To confirm this, further studies comparing both niosome preparations pre and post 
formulation are required. However, given that the point of this work was to develop a 
thermostable vaccine protocol, the studies undertaken have demonstrated the niosomes 
prepared using the Aston protocol offer this attribute, at least 3 months. In addition, the 
lyophilisation process of liposome based vesicles with trehalose has been studied by 
Mohammed et al, (2007) where upon freeze drying of liposomes with trehalose has 
shown stability for a period of 42 days, showing retention of vesicle size and drug 
loading (Mohammed et al., 2007). Moreover, Gregoriadis et al, (1999) have 
demonstrated that material-containing liposomal suspensions can be freeze dried in the 
presence of a cryoprotectant (for storage) without significant loss of material from the 
vesicles on reconstitution (Gregoriadis et al., 1999). Within the study reported in Figure 
4.5 the niosome formulation had been lyophilised and subsequently rehydrated prior 
administration and compared against a control formulation. Whilst no comparison to 
non-freeze-dried formulations were conducted, studies by Christensen et al, (2007) have 
previously confirmed that freeze drying of DDA/TDB vesicles when compared with a 
formulation prepared fresh prior to administration had no significant influences on 
antibody responses of the IgG1 and IgG2b isotypes (Christensen et al., 2007). Overall 
they found that freeze drying preserved adjuvant activity and that the antigen was not 
compromised where both a cell mediated and antibody response was produced. 
Therefore, as a result lyophilisation of sub-unit vaccine delivery systems are able to 
elicit immune responses greater than the antigen alone and are comparable to 
formulations prepared fresh.  
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Considering the differences between the strains shown in figure 4.6, studies by Coenen 
et al, (2006) on the stability of influenza sub-unit vaccines outside of refrigerator 
conditions conclude that the degradation rate of haemagglutinin differs between all the 
strains of influenza. For example, the A/Panama strain is susceptible to degradation 6-
12 times faster when stored at 25 °C than at 5 °C (Coenen et al., 2006). Hence within 
this study, figure 4.6 shows that the H1N1 and H3N2 sub-unit antigens are both 
susceptible to storage conditions outside of the fridge (4 °C) where a significant 
reduction in IgG GMT titres is observed thus showing signs of haemagglutinin 
degradation when stored at 40 °C. The ability of the Aston melt method preparations to 
produce such high IgG titres when storing the vaccine at 40 °C for 3 months prior to 
administration has shown a major breakthrough in providing thermostability to 
influenza antigens when stored at elevated temperatures. The Aston melt niosomes 
showed no loss in potency of the two strains when stored at 40 °C and the results were 
comparable to the control vaccine stored at 4 °C.  
4.4 Conclusions 
With growing concern over the thermostability of vaccines globally, this chapter has 
focussed on the development of a vaccine delivery system that promotes thermal 
stability and dose-sparing. The advantage of using delivery systems is that the antigens 
can also be protected after administration (Gregoriadis et al., 1999, Gregoriadis, 1994). 
The revised method of preparing niosome vesicles (Aston melt) has shown to 
incorporate a larger quantity of antigen within the vesicle compared to current methods 
as has been demonstrated by the antigen protection levels. The key aspects of the 
revised method was a lowering of the process temperatures to 30-35 °C and the antigen 
being present prior to vesicle formation with the intention of protecting thermolabile 
antigens and incorporating more antigen within the vesicles. One of the common 
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problems resulting in vaccine wastage in several countries was due to power outages 
thus resulting in vaccines not being able to maintain their cold temperatures (Setia et al., 
2002). The results within this study have shown that the niosome vaccine delivery 
system was able to protect the vaccine with no loss in potency for a period of 3 months 
at 40 °C, thus overcoming the problems associated with power outages and temperature 
increases worldwide. 
The manufacture of thermostable niosomes, were shown to produce the most consistent 
immunological responses in animals for both H1N1 and H3N2 strains compared to the 
commercial Fluzone control vaccine. The results were confirmed by both HAI and 
ELISA techniques for formulations stored at 4 °C and 40 °C whereby the thermostable 
niosome vaccine (Aston melt method) showed its superiority in resulting in increased 
IgG titres. To note, the Strathclyde melt method did not show any immunological 
response against the H3N2 antigen when stored either at 4 °C or 40 °C suggesting that 
the antigen had been compromised. To conclude, this chapter demonstrates that there is 
great scope to use a wide range of antigens/drugs with this proposed method of 
producing thermostable niosomes that offer increased levels of protection and offer 
effective immunity. 
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5.1 Introduction 
5.1.1 Oral vaccination 
The oral route a potentially preferable route of delivery for vaccines due to its non-
invasive nature, ease of administration and lack of infection risk from needle stick 
injuries. Most importantly, the mucosal immunity can be promoted by oral 
immunisation offering strong resistance against many pathogens that infect via the 
mucosal lining (Clark et al., 2001). The target site of such vaccines are the M cells, 
located in the Peyer’s patches, which are responsible for promoting secretory IgA and 
other mucosal responses (Schmucker et al., 1996). However, even though the oral route 
is one of the most accessible routes and has good patient compliance, it is generally not 
feasible to administer vaccines via this route because of problems associated with low 
efficacy, due to the metabolism and degradation that occurs in the GIT. The gastro 
intestinal tract is lined with protease enzymes, such as trypsin and chymotrypsin, and 
this presents stability issues for orally administered proteins and peptides (Delie and 
Blanco-Prieto, 2005, Russell-Jones, 2000). In addition, the residence time of vaccines at 
the immune induction sites within the GIT (the Peyer's Patches) is limited due to GI 
transit. With this latter point, the size of the systems becomes important, as the vaccine 
needs to penetrate the intestinal epithelium with a short exposure time. Due to this 
problem, higher doses or an increased in frequency of dosing are often required to 
supply sufficient antigen to elicit an immune response (Webster et al., 2003). However, 
it is essential avoid dosing in quantities that could potentially lead to sustained low level 
secretion of antigen specific IgA, resulting from an increased systemic tolerance to the 
vaccine (Russell-Jones, 2000, Mowat, 2003). 
To support the delivery of oral vaccines, bilosomes and niosomes have been considered 
to help offer protection in the biological milieu of the GIT and to protect the antigen. 
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However for such systems to promote immune responses both protection and 
appropriate uptake of the antigen is required. To facilitate this, niosomes formulated 
from Monopalmitoyl glycerol (MPG), Synthecol (Chol) and Dicetyl Phosphate (DCP) 
have been investigated (Mann et al., 2006). In addition, Sodium deoxycholate (EMD) 
has also been added to these formulations to further enhance their stability within the 
GIT. These so called bilosomes have been shown to stabilise vesicles against 
detrimental effects of bile acids in the GIT and have shown to provide adjuvant 
properties by inducing systemic and mucosal immunity when administered with 
antigens (Schubert et al., 1983, Mann et al., 2004) .   
5.1.2 Aims and Objectives 
Within this chapter the aim is to determine the effect of the method (Preparation 
temperature) of vesicle formulation, type of vesicle upon its in vivo trafficking and 
immunogenicity. This will be carried out by: 
 Using a dual radio-labelling system where the antigen and the delivery system 
are tracked independently yet simultaneously in vivo and in situ when in the 
GIT.   
 Determining the clearance of free antigen and the effects of niosomes versus 
bilosomes in the distribution of antigen and the delivery system.  
 Looking at the effects of vesicle size and dosing strategy upon oral delivery of 
vaccines.  
5.2 Materials and Methods 
5.2.1 Surfactants 
A range of non-ionic surfactant based bilayer vesicles were prepared by high shear 
homogenisation and analysed using several materials and methods. The surfactants used 
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in the study were Monopalmitoyl glycerol (MPG) (Larodan Labs, Sweden), Synthecol 
(Chol) (Sigma Aldrich, UK), Dicetyl Phosphate (DCP) (Sigma Aldrich, UK) and 
Sodium Deoxycholate (EMD, UK). The aqueous buffer sodium bicarbonate (Sigma 
Aldrich, UK) was buffered to pH 7.6 using a 1 M sodium hydroxide solution (Sigma 
Aldrich, UK).  
5.2.2 Radio-labelling of H3N2 antigen 
The fluzone vaccine is commercially available in PBS and not as a concentrate and 
comprises of additives such as gelatine which interfere in centrifugation and labelling 
(Table 5.1). The fluzone is made up of three recombinant HA antigens which are mixed 
together to form the vaccine. As a result three individual rHA strains were obtained 
which could be used be radio-labelled with 
125
I using a previously described method 
(Henriksen-Lacey et al., 2010a) so to facilitate the quantification and tracking of the 
antigens. The three antigens included within fluzone are: H1N1 (75 kD), H3N2 (75 kD) 
and Brisbane (100 kD) and each of the individual antigens were labelled with 
125
I.  
Table 5.1: Constituents forming Fluzone vaccine 
Component Quantity per dose 
Active substance (Inactivated strains) 45µg HA total 
H1N1 15 µg HA 
H3N2 15 µg HA 
Brisbane 15 µg HA 
Sodium phosphate buffered isotonic solution To appropriate volume 
Formaldehyde ≤100 µg 
Octylphenol ethoxylate ≤100 µg 
Gelatine 0.05% 
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Dual radiolabelling techniques have been used widely within our lab to follow the 
movement of vaccine antigens and their delivery systems (Henriksen-Lacey et al., 
2010a). It enables the antigen to be tracked using one radioisotope and at the same time 
to track the antigen carrier system using a different radioisotope. Dual-radiolabelling 
increases the data output of the study whilst keeping in line with the 3 Rs of reduce, 
refine and replace of animal models.  
The H3N2 antigen (Immune Tech, USA) stock solutions were prepared as 100 µg of 
purified protein (1 mg/mL) in PBS stock and 40 µL (40 µg) placed into an iodination 
tube (Pierce Biotechnology) with 2 Mbq of 
125
I (Perkin Elmer, Belgium) for 1 hour. A 
separation column was pre-prepared by firstly, heating Sephadex G75 (Sigma Aldrich, 
UK) beads for 3 hours at 90 °C and left to cool, during that time the column was 
prepared by placing glass wool at the bottom to prevent any Sephadex beads from 
falling through the column. The column was then packed using the pre heated and 
swollen Sephadex G75 prepared earlier. It is important that the gel remains hydrated 
with the PBS buffer which is used for labelling. It is essential to optimise the flow rate 
based on sample collection and then to match the sample volume collected to the 
correct protocol on the gamma counter.  
Upon packing of the column, just above gel, the solution from the iodination tube was 
added to the top of the column and then rehydrated with buffer and samples were 
collected every 1 minute for 1 hour which results in the collection of 500 µL per vial. 
The vials were then analysed for 
125I content using a Cobra™ CPM Auto-Gamma® 
counter (Packard Instruments Company inc., IL, USA) individually to prevent any 
backscatter that may occur from neighbouring vials. To confirm presence of protein in 
the vials a micro- BCA assay was carried out and used in parallel with the data obtained 
from the iodination of the protein. 
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5.2.3 Preparation methods of vesicles 
5.2.3.1    Preparation of niosomes using Aston melt method  
A 5:4:1 molar ratio of MPG, Chol and DCP was weighed out and placed into a 10 mL 
glass beaker. Before melting the lipids the aqueous phase was prepared in a 15 mL 
falcon tube. 25 mM sodium bicarbonate (pH 7.6) formed the bulk part of the aqueous 
phase and was spiked with radiolabelled antigen (Section 5.2.2) and then placed in a 
heated water bath for 10 minutes at 30-35 °C. This was to be known as the buffered 
antigen stock solution. 
While the aqueous buffer was preheated, the beaker containing the lipids was placed 
into a hot oil bath (120-125 °C) and melted for 10 minutes. The beaker containing the 
molten mixture was removed from the oil bath and the buffered antigen stock solution 
was immediately added, the mixture homogenised at 8000 rpm at 30-35 °C for 10 
minutes, and left to incubate at 220 rpm at 30 °C for 2 hours. 
5.2.3.2    Preparation of bilosomes using Aston melt method  
A 5:4:1 molar ratio of MPG, Chol and DCP was weighed out and placed into a 10 mL 
glass beaker. Before melting the lipids, the aqueous phase was prepared in a 15 mL 
falcon tube. 25 mM sodium bicarbonate (pH 7.6) formed the bulk part of the aqueous 
phase containing 100 mM sodium deoxycholate (bile salt). Radiolabelled antigen 
(Section 5.2.2) was then placed in a heated water bath for 10 minutes at 30-35 °C. 
While the aqueous buffer was preheated, the beaker containing the lipids was placed 
into a hot oil bath (120-125 °C) and melted for 10 minutes. The beaker containing the 
molten mixture was removed from the oil bath and the buffered antigen stock solution 
is immediately added to this beaker and then immediately homogenised at 8000 rpm at 
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30-35 °C. The mixture was homogenised for 10 minutes and is then left to shake and 
incubate at 220 rpm at 30 °C for 2 hours. 
5.2.3.3   Preparation of bilosomes using Strathclyde melt method  
A 5:4:1 molar ratio of MPG, Chol and DCP was weighed out and placed into a 10 mL 
glass beaker. 25 mM sodium bicarbonate (pH 7.6) formed the bulk part of the aqueous 
phase. 100 mM bile salt was prepared in 25 mM sodium bicarbonate buffer. The two 
buffered solutions were placed into a heated water bath at 60 °C. A 100 µL 
radiolabelled antigen was then placed in a heated incubator for 5 minutes at 37 °C. 
While the aqueous buffer was heated, the beaker containing the lipids was placed into a 
hot oil bath (120-125 °C) and melted for 10 minutes. The beaker containing the molten 
mixture was removed from the oil bath and the 25 mM sodium bicarbonate buffer 
added to this beaker and then immediately homogenised at 8000 rpm at 60 °C for 2 
minutes. Upon two minutes homogenisation, 0.55 mL of the 100 mM bile salt solution 
was added and further homogenised for three minutes. Upon 5 minutes total 
homogenisation time the radiolabelled antigen (Section 5.2.2) was added to the 
homogenising suspension and homogenised for a further five minutes and then left to 
shake and incubate at 220 rpm at 30 °C for 2 hours. 
5.2.4  Characterisation of vesicles 
The size of the vesicles was determined using laser diffraction on a sympatec 2005 
(Helos/BF) analyser. 20 µL aliquots of the vesicle suspension was diluted into the 
cuvette with 40 mL double distilled water. The zeta potential, which is an indirect 
measurement of the vesicle surface charge, was measured in 1.5 mL double distilled 
water at 25 °C on a Zeta Plus Brookhaven Instrument. 20 µL of the bilosome 
suspension was mixed in 1.5 mL double distilled water and then analysed. The pH of 
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the vesicle suspension was determined using a pH meter where the tip was placed into 
the vesicle suspension and left for a few minutes.  
5.2.5 Quantification of antigen 
For quantification of antigen association, ultra-centrifugation of the formulations was 
required to isolate antigen entrapped vesicles, from non-incorporated antigen. To 
achieve this, 300 µL aliquots of sample was diluted in a Beckman 3.9 mL Polo-allomer 
tube and filled up to the neck with double distilled water.  The tubes were heat sealed 
ensuring that there are no air bubbles present within the tube. The tubes were then 
placed accordingly in the TLN-100 rotor and centrifuged at 354,000 X g for 45 minutes 
at 4 °C. When centrifugation was complete, the tubes were opened and the supernatant 
removed. The sample was resuspended and the centrifugation step repeated. After the 
second ‘wash’ the antigen loaded vesicles are then re-suspended with 100-200 µL of 
appropriate buffer and transferred all to a clean/labelled 1.5 mL Eppendorf tube. 
5.2.6  Stability of the vesicles in simulated fasted gastric and intestinal medium 
Fasted state simulated gastric media (50 mL) was prepared using a 34.2 mM NaCl 
solution in 50 mL HPLC water at pH 1.2 adjusted with 1 M HCl. Pepsin (40 mg) was 
then added, followed by sodium taurocholate (2.15 mg) and phosphatidylcholine (0.76 
mg) in 50 mL at 37 °C (Vertzoni et al., 2005).  
Fasted state simulated intestinal media (50 mL) was prepared by a 50 mM PBS solution 
in 50 mL HPLC water at pH 8.5, adjusted with 1 M NaOH, and sodium 
glycodeoxycholate (180 mg) and phosphatidylcholine (34 mg) dissolved in the solution 
at 37 °C. To establish the effect of these conditions on vesicle attributes, 400 µL of the 
vesicle formulations was added to 3.6 mL of fasted gastric medium as a 1:10 dilution. 
The formulations were tested for vesicle size and zeta potential at specific time 
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intervals. The gastric to intestinal phase was carried out by centrifuging 3.9 mL of the 
formulations from the gastric period and then resuspending the pellet in fasted intestinal 
fluid and was then tested at the stated time points. To measure antigen retention in these 
conditions, radio-labelled antigen was incorporated within the formulations and antigen 
retention tracked in the above conditions by ultracentrifugation (Beckman, Ultima XP) 
at 354,000 X g. 
5.2.7 In vivo biodistribution protocol 
Inbred female Balb/c (6-10 weeks of age) mice were housed in cages within a laminar 
flow safety enclosure and provided with irradiated food and filtered drinking water. 
Experimentation adhered to the 1986 Scientific Procedures Act (UK). All protocols 
have been subject to ethical review and were carried out in a designated establishment. 
200 µL doses of the formulations, which were washed to remove unentrapped 
radiolabelled antigen, were given orally to Balb/c mice in groups of 4. Animals were 
terminated at various time points, organs collected and analysed for both 
125
I (to 
measure antigen) and 
3
H, which was used as a radio-active tracker for vesicles by 
incorporating 
3
H-cholesterol in the formulation (Figure 5.1).  
Gamma vials were pre-labelled and individual tissues/organs were weighed and 
individually placed into the gamma vials. To the gamma vials 1.5 mL of solvable 
(Perkin Elmer, UK) was added to digest the tissues. Once the solvable was added to the 
vials they were then placed onto the gamma counter to record the 
125
I-antigen levels. 
The vials were then placed into an incubator at 50 °C overnight to dissolve the tissues. 
Once the tissues had dissolved the contents of the gamma vials were transferred to 20 
mL scintillation vials where 200 µL hydrogen peroxide (Sigma Aldrich, UK) was added 
to each vial to bleach the samples. The vials were left overnight once again to wait for 
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gas to disappear and 10 mL of Ultima Gold scintillation fluid (Perkin Elmer, UK) was 
added to form an emulsion. The vials were then counted on the scintillation counter 
which will represent the counts for the vesicles at each site. 
5.2.8  Calibration of Radioisotope equipment 
The presence of 
125
I in scintillation vials results in interference within the scintillation 
counter when counting for tritium; hence, a calibration was carried out where known 
iodine concentration counts were serially diluted and counted on both counters to 
confirm the readings. The calibration curves were merged together and an equation 
formed hence allowing recalculation of the final counts (Figure 5.2). 
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Figure 5.1: Biodistribution regime showing plan of termination and extraction of GI organs at the various time points. 
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A
 
Figure 5.2: Calibration of Radioactivity counters: A) serial dilution of 125I dose for calibration on gamma 
counter and B) Calibration curves for 125I against interference on scintillation counters (n=3). 
5.2.9 Statistical analysis 
The results within this study are given as the geometric mean ± S.D. unless stated 
otherwise. The statistics were carried out using ANOVA and a probability factor of less 
than 0.05 (p< 0.05) was considered to represent statistically significant difference. 
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5.3 Results and Discussion 
5.3.1 Physical characteristics of vesicles when subjected to fasted-state GI fluids 
Non-ionic surfactant based vaccine vesicles have provided effective immunity in 
various animal models such as mice and ferrets after oral administration (Brewer and 
Alexander, 1992).  The oral route provides a challenging environment for delivery of 
antigens  including low pH, digestive/ gastric enzymes the poor absorption and the 
rapid transit (Singh and O'Hagan, 1998). As a result, it is important to ensure that the 
antigen and carrier system remains intact during its transit through the GI tract until it 
reaches the target site. Therefore, vesicles were subjected to simulated gastric (pH 1.2) 
and intestinal media (pH 8.6) and at various time points the vesicles were analysed for 
vesicle size and zeta potential. 
The formulations of niosome and bilosomes were analysed for vesicle size (Figure 
5.3A) and zeta potential (Figure 5.3 B) when placed into 1) fasted gastric media, 2) 
fasted gastric to intestinal fluid (GSIF), and 3) fasted intestinal fluid (SIF). Results 
(Figure 5.3A) demonstrate that niosomes formulated by the Aston melt method show a 
significant (p< 0.05) decrease in overall VMD from 6.54 ± 0.04 µm at t=0 to 5.46 ± 
0.05 (after 1 h gastric media) to 3.57 ± 0.03 µm after a period of 4 hours in the GSIF 
medium (Figure 5.4 A). In contrast, the Aston bilosome vesicles significantly increase 
in VMD (p< 0.05) from 6.19 ± 0.04 µm (t=0) when in gastric medium to 9.13 ± 0.31 
µm (t=1 h) and then return to their original vesicle size when in GSIF to 6.11 ± 1.27 µm 
(t= 4 h) which could be due to flocculation of vesicles within the gastric medium. In 
comparison, the Strathclyde bilosomes vesicles follow a similar trend as the Aston 
bilosomes vesicles. However, the extent of the increase in vesicle size is significantly 
larger (p< 0.05) in the gastric medium of a VMD of 11.9 ± 0.57 µm in relation to the 
Aston bilosomes of 9.13 ± 0.31 µm.  
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In addition, the study of zeta potential surface charge (Figure 5.3B) was carried out of 
the vesicles in the various media. A sample of the formulation was taken at each 
timepoint and suspended into a 100 fold diluted medium of gastric or intestinal fluid 
depending upon which sample was being analysed. Results show that when in the 
stomach the zeta potential at pH 1.2 results in a significant decrease (p< 0.05) in surface 
charge around -35 mV and when in the duodenum region of pH 6 surface charge 
significantly (p< 0.05) returned to -80 mV (as represented by the pH titration graph in 
Chapter 2) and then finally when at the site of uptake where the pH in the fasted state is 
8 the zeta potential returns to its original value of -100 mV. This trend is observed for 
all three formulations and is represented in figure 5.3B. Hence, the drop in zeta 
potential within gastric conditions for all formulations could potentially encourage 
flocculation, however, the niosome vesicles showed no increase in vesicle size. Thus, 
suggesting that the bilosome preparations which increase in vesicle size, reduce in zeta 
potential when in gastric media flocculate as this trend is reversible when in intestinal 
media suggesting that the bile salt component could be promoting flocculation. 
It is important that the vesicle size and surface charge remain stable and are fit for 
purpose as studies have shown that the proposed transparacellular uptake of particles 
within the Peyer's patches is restricted to particulates below 10 µm (O'Hagan, 1996, 
Eldridge et al., 1990, van der Lubben et al., 2001). Furthermore, the retention within the 
Peyer's patches has been demonstrated for vesicles between 3 -10 µm, whilst vesicles 
below 3 µm translocate into the lymphoid tissue (Eldridge et al., 1990, Ebel, 1990). In 
addition, a study using microspheres by Tabata et al, (1996) have shown that particles 
within the 5-10 µm induced a mucosal immune responses whereas smaller vesicles 
migrated into the lymphatics resulting in systemic immunity (Tabata et al., 1996). As a 
result this study proves that the vesicles prepared for the delivery of antigens fall within 
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an acceptable range for uptake and retention within the Peyer's patches so when 
incorporated with antigen will induce a mucosal immune response. Although the 
vesicles vary in size and charge upon exposure to the milieu within the GIT they do 
however, fall within acceptable ranges for uptake by the Peyer’s patches. In addition to 
the vesicle size and charge, a key parameter is whether the antigen remains associated 
to the vesicles throughout the transit within the GIT and to determine how much is 
prematurely released or lost before reaching the target site. 
5.3.2 Antigen retention of vesicles when subjected to fasted GI fluids 
For therapeutic application, it is essential that the antigen is retained within the delivery 
system to enhance targeting. Given that GI conditions were shown to impact on vesicle 
size and zeta potential, this is an important factor as this could influence antigen 
retention whether the antigen is entrapped or surface adsorbed to the vesicles. Therefore 
to investigate the ability of the vesicles to retain antigen during GI transit, vesicles 
containing antigen were subjected to a full simulation of GI conditions as previously 
conducted (section 5.3.1) but for the determination of antigen release. This is critical for 
the oral route, as the surface of the vesicles is exposed to the internal milieu of the GIT 
and is exposed to changes in pH, digestion enzymes and mucous proteins.  
H3N2 antigen was radiolabelled and incorporated into the niosome and bilosome 
vesicles (see section 5.2.3) and antigen retention studies were carried out (section 5.2.5) 
where the vesicles were centrifuged to determine total antigen association. Entrapment 
shows that initial antigen loading was significantly higher (p< 0.01) in niosomes 
compared to bilosomes (39.21 ± 2.72 % vs 32.5 ± 2.9 %; Figure 5.4 respectively). 
Results show that just after 15 minutes in gastric media the niosome preparation 
significantly decreases (p< 0.05) in antigen retention to 28.04 ± 0.95 % whilst the 
bilosome preparations maintain antigen retention with no significant loss. 
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An in depth look into the antigen retention within the vesicles for the three formulations 
showed that overall, antigen retention decreased in all formulations with the greatest 
reduction in the Strathclyde bilosome formulation and Aston niosome formulation 
(Figure 5.4). Figure 5.4A shows that the niosome preparation has lost antigen retention 
whilst the two bilosome preparations maintain their loaded antigen at all times within 
the gastric media. However, upon subjecting the vesicles to GSIF from the gastric 
media (Figure 5.4B), antigen retention significantly decreases (p< 0.05) for all 
formulations. Antigen retention when in SIF media is greatest within the niosome 
formulation which could be due to the initial higher antigen association than that of the 
two bilosome formulations (Figure 5.4C). The sharp decline in antigen retention with 
the Strathclyde bilosome formulation (Figure 5.4C) when placed into the SIF of 2-4 % 
compared to the Aston bilosome significantly higher recovery (p< 0.05) of 12 % at the 
same conditions could be an indication of where the antigen resides within the vesicles; 
due to their differences in preparation the antigen in the Strathclyde melt preparation 
could be surface adsorbed to a greater extent than that of the Aston melt preparations. 
Due to this surface adsorption, the intestinal medium could be degrading the antigen 
located on the surface or outer regions of the vesicles hence resulting in 2-4 % antigen 
retention when in the fasted intestinal fluid. Kaur et al, (2012) also demonstrated that 
antigen surface adsorbed to DDA:TDB liposome vesicles were only able to retain 20.8 
± 7.8 % antigen after trypsin digestion compared to vesicles prepared by a dehydration- 
rehydration method; where antigen was able to entrap itself within the bilayers thus 
offering protection from enzyme digestion with 66 ± 1.2 % antigen retained (Kaur et 
al., 2012). Hence, location of antigen within bilayer vesicles are able to dictate antigen 
retention levels where antigen which is not surface bound is potentially protected from 
enzymatic degradation.  
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This suggests that the antigen content is consistent within the aqueous core of the 
vesicles as when formulating the vesicles via the Aston melt method where, the antigen 
is in the aqueous phase pre homogenisation hence having a greater chance to be 
incorporated within the aqueous core in comparison to the Strathclyde method where 
the antigen is added at a later stage during the homogenisation procedure. Thus, the 
incorporation of antigen within the buffer used to form the vesicles and at the revised 
lower manufacturing temperature (30 °C) is a good opportunity to increase antigen 
concentration at the target site and to allow the use of thermolabile antigens within this 
delivery system.  
The use of carrier delivery systems have been shown in several studies to protect drugs/ 
antigens thus aiding in stability, biodistribution, drug transport and release via the oral 
route (Mane and Muro, 2012, Torchilin, 2009, des Rieux et al., 2006). Within this 
study, it has been shown that the redesigned niosome and bilosome method offers 
increased antigen protection in vitro than the previous published bilosome method. 
Mane and Muro, (2012) also demonstrate that degradation of IgG in vitro at various pH 
conditions is significantly higher than when incorporating the IgG with nano-carriers 
(Mane and Muro, 2012). Furthermore, Shukla et al, (2011) demonstrate that bilosome 
vesicles entrapping diphtheria toxoid offer protection through the GIT and increased 
uptake by the M cells (shown by confocal microscopy) compared to the free dose 
(Shukla et al., 2011). These simulated GI conditions within this study have shown that 
the vesicles are able to withstand the harsh environment and that antigen can be 
protected and retained within the vesicles from exposure to the external milieu of the 
GIT, thus offering increased antigen bioavailability when reaching the target site. As a 
result, the vesicles and antigen were fluorescently labelled to track the vesicles within 
the GIT and to determine whether they reach the target site intact.  
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5.3.3 Confocal laser scanning microscopy of vesicles 
Within this study we have shown that the vesicles remain within the desired size range 
5-10 µm after subjecting to simulated gastric and intestinal conditions. To obtain a 
greater understanding of antigen location within the vesicles, confocal laser light 
microscopy of the Aston niosome vesicles was carried out. The bilayers of the vesicles 
were fluorescently labelled with a lipid dye- Dil-C and the antigen was fluorescently 
labelled with a flourophore dye. Figure 5.5 represents the imaging process from 
manufacturing of the vesicles to the site of uptake of the vesicles/ antigen in vivo.  
As represented within figure 5.5, the bulk labelled antigen (labelled blue with 
Flammaflour) resides within the aqueous core of the Aston niosome vesicles as 
distinguished between the red bilayers and the blue core in figure 5.5 compared to the 
niosomes without loaded antigen which shows an empty clear aqueous core (Figure 
5.5). Due to the limitations of the microscopy technique the high laser intensity results 
in rapid photo-bleaching of the antigen fluorescence so attempts to zoom into the 
bilayer regions and the surface of the vesicles to locate any surface bound antigen 
proved to be difficult.  
The fluorescently labelled vesicles were administered via oral gavage (0.2 mL dose) 
and after 30 minutes tissues were excised and analysed via microscopy to locate the 
vesicles. Figure 5.5 shows the procedure start to finish in terms of how the vesicles 
appear under confocal microscopy after centrifugation and once they have been 
administered orally. The figure shows that upon excising of the Peyer's patch the 
vesicles are intact, spherical and between 5-10 µm.   
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Figure 5.5: Confocal laser light microscopy images of niosome vesicles labelled with a lipid Dil-C dye and antigen labelled with a Flammaflour FPR 648 dye. 
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The vesicles can be observed in large numbers when on a low magnification and upon 
increased magnification and 40 µm deep within the tissue a 5 µm vesicle is clearly 
visible hence suggesting that the Peyer's patches take up the vesicles. Moving from the 
Peyer's patches to the underlying mesenteric lymph tissue once again fluorescence is 
visible with a green autoflourescence (from collagen within the capillary network) 
within the mesentery. As a result, this study shows that vesicles are able to penetrate 
and reside within the Peyer's patches.  
In terms of clearly distinguishing between the vesicle and the antigen this was a 
challenge as the limitations of the confocal result in a multiphoton laser being emitted 
which shows excitation at all wavelengths and in doing so the antigen and vesicle are 
not distinguishable. Furthermore, it is also undistinguishable whether the fluorescence 
is from clusters of vesicles or whether the vesicles are destroyed and distorted. 
Therefore to further investigate in vivo trafficking of the vesicles and antigen a dual 
radiolabelling technique was used to determine the antigen/vesicle retention at sites 
across the GIT. 
5.3.4 Biodistribution of mucosal vaccines 
It is important to understand the biodistribution of mucosal vaccines administered orally 
as they are subject to dilution in mucosal secretions, capture within the mucus and 
attack by the mucosal proteases and enzymes with the largest obstacle of exclusion by 
the epithelial barriers (Neutra and Kozlowski, 2006). Within this study, the location and 
biodistribution of H3N2 antigen (
125
I) and the vesicle carrier system (
3
H- Chol) was 
used to understand the uptake of vesicle and antigen and to determine the residence 
time of the vaccine within the GIT. An oral gavage volume of 0.2 mL was used based 
on an upper limit of oral dosing of 20 mL Kg
-1
 (McConnell et al., 2008, Wolfensohn 
and Lloyd, 2003). 
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The results from the study are presented in Figure 5.6, where the 
125
I
 
counts represent 
the tracking and movement of the H3N2 antigen and the 
3
H-chol represents the tracking 
and movement of the vesicle. Figure 5.6 represents the Aston bilosomes, Aston 
niosomes and Strathclyde bilosomes formulations at time intervals of 30 minutes, 1 
hour and 4 hour termination of the test subjects. The 1 hour time point also includes the 
free antigen which was administered in the same way as the formulation by oral gavage. 
The general trend observed from figure 5.6 shows that the blood, spleen, kidneys and 
liver have trace amounts of antigen and vesicle recovery with the majority of the 
recovery coming from the stomach, small intestine, and the colon and cecum, 
suggesting minimal systemic absorption of particles.  
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Figure 5.6: Antigen recovery after dissection and removal of organs based on initial radioactive 
dose counts , A) time point 30 minutes, B) time point 1 hour and C) time point 4 hours (n=4). 
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The overall recovery of formulated antigen decreases as the antigen loaded vesicles 
undergo their transit within the GIT from 30 minutes to 4 hours with levels dropping 
from 58 % (Figure 5.6A) to 55 % (Figure 5.6B) to finally 44 % (Figure 5.6C). 
However, for the  unformulated antigen in all of the organs collected after 1 hour, 
recovery of free antigen (38.5 ± 5.6 %; Figure 5.6B) was significantly (p < 0.01) lower 
than antigen formulated within Aston niosomes (59.8 ± 6 %), Aston bilosomes (67.7 ± 
7 %) or Strathclyde bilosomes (50.5 ± 7 %) respectively (Figure 5.6B). In particular, the 
free antigen within the small intestine (5.8 ± 1.8 %) resulted in significantly (p < 0.01) 
lower levels compared to antigen delivered in Aston niosomes (25 ± 10 %), Aston 
bilosomes (49 ± 18 %) or Strathclyde bilosomes (30 ± 10 %)  (Figure 5.6B). Figure 
5.6C after the 4 hour time point reflects the transit of the vesicles within the GIT, where 
the antigen has translocated from areas within the GIT such as the stomach and small 
intestine to show increased levels of recovery within the colon and cecum which is the 
latter part of the GI system. Overall, these results shows that the vesicles entrapping the 
antigen offer longer residence time of the antigen within the GIT (t=1 h) and thus do not 
transit along the GIT to the cecum or colon at a faster rate compared to administering 
the free antigen dose alone.  
Considering between the formulations, there was no significant difference in the antigen 
recovery in most of the organs at the various time points (Figure 5.6) the niosome 
formulation showed antigen presence within the cecum after 1 hour which was not 
apparent for the two bilosome preparations. The presence of antigen within the cecum 
(t=1 h) from the niosome preparation can be correlated with the in vitro GI media 
transit study carried out in section 5.3.2 where the niosome vesicles showed a resultant 
loss in antigen content of ~ 13 % when in the gastric media (Figure 5.4). The loss of 
antigen from the vesicles mimics the transit of the free antigen dose where after 1 hour 
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~ 7.4 % of the free antigen dose was recovered from the cecum and ~ 8 % of the 
antigen from the niosome dose was recovered compared to no antigen from the 
bilosome preparations.  
The antigen recovery alongside the vesicle recovery is presented together in figure 5.8 
to determine the overall trend whether the antigen remains with the vesicles along the 
GI transit. In general, when comparing the vesicle and antigen recovery for all of the 
organs together (Figure 5.7) the results show that the antigen stays with the vesicles and 
that the results are comparable between the bilosomes and niosomes at the time points 
considered. The vesicles in all three formulations (Figure 5.7) within the stomach 
decrease up to the 4 hour time point which shows that vesicles remain within the 
stomach for a period of up to 4 hours with vesicle recovery significantly decreasing (p< 
0.05) from ~10 % (t= 30 min) to ~2 % (t= 4 h). The only exception to this general trend 
is that the vesicle recovery (~6 - 14 %) in the small intestine at 4 hours is significantly 
higher (p< 0.05) than the antigen recovery (~2 %). A possible suggestion could be that 
the vesicles may be adhered within the mucous of the intestine and potential 
degradation of the vesicles from the various enzymes within the mucous thus releasing 
the antigen from the vesicles. 
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Figure 5.7: A) Aston bilosome preparation showing antigen and vesicle recovery, B) Strathclyde 
bilosome preparation showing antigen and vesicle recovery and C) Aston niosome preparation showing 
antigen and vesicle recovery (n=4). 
As previously shown, after 1 hour antigen delivered with the niosomal vesicles is 
recovered within the cecum, compared to the two bilosome preparations. Once again, 
this could be due vesicle breakdown, and translocation to the cecum at a faster rate than 
the bilosome vesicles which is confirmed by the recovery of vesicles within the cecum 
after 1 hour (Figure 5.7C). Studies by Bhavsar and Amiji, (2007) show that 
radiolabelled gelatin nanoparticles were rapidly degraded within the stomach and small 
intestines due to the presences of proteolytic enzymes thus rapidly clearing ~85 % of 
the dose from the GIT after 1 hour (Bhavsar and Amiji, 2007a). However, upon 
incorporation of the nanoparticles-in-microspheres (NiMOS) of less than 5 µm in size, 
more than 50 % of the dose was recovered within the small intestine indicating that the 
microspheres were stable and offered longer residence time within the GIT (Kriegel et 
al., 2012, Bhavsar and Amiji, 2007a). In addition, they also found that trace levels of 
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radiolabelled gelatin nanoparticles were recovered from organs such as the blood and 
liver indicating minimal systemic absorption of particles (Bhavsar and Amiji, 2008, 
Bhavsar and Amiji, 2007a). These findings are comparable to the findings within our 
study where un-associated antigen is rapidly cleared to the cecum and colon after 1 hour 
(Figure 5.6B) with antigen recovery levels of 5 % within the small intestine compared 
to an average of 40 % antigen recovery within the small intestine when associating the 
antigen with vesicles. 
Within the Peyer's patches, the vesicle recovery between 1 hour and 4 hours for all 
formulations showed no significant differences; however, the antigen retention within 
the Peyer's patches significantly decreased from 1 hour to the 4 hour time point 
suggesting that antigen is migrating away from the vesicles (Figure 5.8A). This effect 
has also been observed by Henriksen-Lacey et al, (2010) where a biodistribution study 
using charged DDA:TDB liposomes were injected intramuscularly were shown to retain 
vesicles at the site of injection for a period of 4 days with no significant change 
however, antigen content decreased significantly from days 1 to 4 whereas increased 
antigen levels were found in the draining popliteal lymph nodes (Henriksen-Lacey et 
al., 2010b). Henriksen-Lacey et al, (2010) also confirm that the charged liposomes are 
retained for longer periods of time at the site of injection and that antigen adsorbed to 
the vesicles also offer better retention (Henriksen-Lacey et al., 2010b). The increased 
bioavailability and antigen retention is also confirmed within this study, where the 
association of antigen with niosome/ bilosome vesicles resulted in significantly higher 
(p< 0.05) vesicle/antigen recovery levels compared to administration of the free antigen 
dose, which was rapidly cleared from the GIT. Therefore, this study confirms the 
advantage of associating antigen with niosome/bilosome vesicles as antigen is protected 
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from the external milieu of the GIT and in turn offers increased residence time of the 
vaccine within the GIT. 
5.3.5 Peyer's patch targeting  
Within the mouse model, there were approximately 8 to 11 Peyer's patches recovered 
which are in line with literature (6-12 patches; (Yeh et al., 1998)). In terms of targeting 
to the Peyer's Patches, figure 5.8A shows that there was no significant difference 
between uptake and retention of the free antigen and antigen entrapped within the 
vesicles. The Peyer’s patches are located at the antimesenteric border of the intestine 
where they appear as nodular white masses (1.5 – 3.0 mm) and are key to antigen 
uptake and induction of immunity (Yeh et al., 1998). The Peyer's patches are an 
attractive route for targeted delivery as this provides a direct route for antigen to reach 
the lymphatic system where first pass metabolism is avoided and the chances of cellular 
rejection are reduced due to the M cells not expressing P-glycoprotein efflux pumps 
(Hunter et al., 2012, Florence, 1997). Furthermore the Peyer's patches, in comparison to 
the rest of the GI mucosa, possesses minimal mucosal coating where transcytotic 
activity is high (Frey et al., 1996, Plapied et al., 2011). The results show that the uptake 
of vesicles within the Peyer's patches showed uptake within the range of 1-5 % (Figure 
5.8A) and after studying the vesicle size after exposure to simulated GI fluids, the 
vesicles still remain within the size range 3-10 µm which are suited for uptake and 
retention within the Peyer's patches. Furthermore, the study presented in section 5.3.5 
has also shown that vesicles within this size range show increased uptake and retention 
compared to vesicles of a smaller size range of 2 µm. 
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Figure 5.8: Recovery of antigen and vesicles based on initial dose within A) Peyer's patches and B) 
Mesenteric Lymph Tissue (n=4). 
Antigen recovery within the Mesenteric lymph tissue as presented in figure 5.8B for the 
niosome/bilosome formulations is significantly greater (p< 0.01) than that of the free 
antigen administered dose. The results show that even after 4 hours the antigen recovery 
of the niosome/bilosome vesicles within the mesenteric tissue is still greater than the 
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recovery of free antigen after 1 hour. The data indicates that the vesicles and the antigen 
are able to penetrate and reside within the lymph tissue for a period of 4 hours without 
any change in the recovery levels. This is beneficial as the vesicles which remain in the 
Peyer's patches offer increased mucosal immunity whereas the increased antigen and 
vesicle within the mesentery is more likely to induce systemic immunity, thus offering 
both mucosal and systemic immunity (Tabata et al., 1996). In addition, Neutra and 
Kozlowski (2006) determine that antigens delivered to mucosal sites within the small 
intestine offer greater IgA secretions which are a characteristic of mucosal immunity. In 
comparison to antigen delivery via routes such as the nasal route promote a systemic 
antibody response, due to the migration of antigen to the draining lymph nodes (Neutra 
and Kozlowski, 2006).  
In terms of comparing niosomes and bilosomes, there were no significant differences 
between the uptake within the Peyer's patches and the mesenteric lymph tissue (Figure 
5.8). This prompted further studies to consider the impact of dose concentration on 
antigen recovery within the Peyer's patches. 
5.3.5.1  In vivo Saturation study with bilosome preparation 
Given that the biodistribution study in section 5.3.4 showed that uptake in the Peyer’s 
patches and mesenteric lymph tissue remained constant and then decreased slightly over 
the time period from 30 minutes to 4 hours (Figure 5.6, Figure 5.8A), a question arose; 
is uptake by the Peyer’s patches limited in terms of saturation of antigen or vesicle 
uptake? To address this a study considering varying doses of the vaccine was carried 
out which involved four groups of a) double dose (antigen 180 µg/mL, lipid 27 
mg/mL), b) normal dose (antigen 90 µg/mL, lipid 13.5 mg/mL), c) half dose (antigen 
45 µg/mL, lipid 6.75 mg/mL) and d) quarter dose (antigen 22.5 µg/mL, lipid 3.375 
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mg/mL) was designed to determine uptake of vesicles and antigen throughout the GIT 
in particular attention to the target site Peyer’s patches and Mesenteric lymph tissue. 
Based on the biodistribution study the organs removed for the following study focussed 
specifically on the GI tract which included the stomach, Mesenteric lymph tissue, 
Peyer’s patches, small intestine, colon and cecum, where the data is presented for 
antigen and vesicle in figure 5.9.  
Results from the study (Figure 5.9) show no significant differences in percentage 
antigen recovery or vesicle recovery between different dose concentrations in the 
organs collected after a 30 minute time point (Based on each dose initial counts).  The 
overall percentage recovery of antigen is comparable (40-70 %) between all doses 
administered based on the initial dose count (Figure 5.9A). The vesicle recovery (Figure 
5.9B) between the organs when changing dose concentrations is also comparable with 
no significant differences suggesting that the clearance rate and the gastric emptying 
time is not formulation dependent. Gastric emptying time has been attributed to the fed 
or fasted state of the GIT, where the gastric emptying time T ½ in the fasted state is up 
to 2 ± 1 min compared to a fed state t ½ of 17± 2 min (Roda et al., 2010).  However to 
consider if the amount of lipid and antigen was influenced by the dose given, the results 
were also analysed in terms of mass of antigen and lipid (Figure 5.10). 
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Figure 5.9: In vivo saturation study of various dose concentrations representing antigen and vesicle recovery within the organs selected. A) Antigen recovery, B) 
Mesenteric tissue and Peyer's Patches antigen recovery, C) Vesicle carrier recovery  and D) vesicle carrier recovery within the Mesenteric tissue and the Peyer's patches 
(n=4). 
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Figure 5.10: Representation of dose recovery per mL at site of uptake for various dose concentrations of 
the formulation within Peyer’s patches and mesenteric lymph tissue. A) Antigen dose and B) Lipid dose. 
(n=4). 
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A closer look at the Peyer’s patches and mesentery in figure 5.10A shows that the 
higher the antigen dose administered the higher the antigen recovery levels within the 
organs however, there was no significant difference between the double dose and 
normal dose administered. Hence suggesting that saturation point is being reached 
within the Peyer's patches and mesentery which is confirmed by figure 5.10B where the 
increase in lipid dose also shows no significant difference between the normal and 
double dose. This effect of saturation based on dose has been observed by Nograles et 
al, (2012) where 50, 100 and 150 µg doses of pDNA-loaded alginate microspheres 
carrying a green fluorescent protein (GFP) were orally administered. Upon the delivery 
of a plasmid DNA vector to determine GFP expression (Intestinal cells) 24 hours post 
administration, the 100 µg dose yielded higher GFP expressing cells compared to a 50 
µg dose. However, saturation had been reached as the increment of dose to 150 µg 
yielded lower GFP expressing cells than the 50 µg dose suggesting dose controlling is 
important (Nograles et al., 2012). Therefore, controlling dose is vital as a strategy of 
increasing dosing could potentially lead to reduced secretion of antigen specific IgA 
levels, due to increased systemic tolerance to the vaccine (Mowat, 2003). 
5.3.6 Size reduction implications on uptake within GIT for bilosomes 
To consider the impact of vesicle size on biodistribution vesicles were prepared as 
mentioned in section 5.2.3 where bilosomes were produced using the Strathclyde 
method. The vesicles were then probe sonicated for two periods of 30 seconds to reduce 
the overall VMD of the vesicles and were then centrifuged to remove the un-entrapped 
antigen and then administered to 5 female Balb/c mice. 
Table 5.2 shows that the reduction in vesicle size was successful and that an overall 
smaller range of vesicles was produced. These samples then underwent an in vivo 
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biodistribution study and were compared to a normal dose in the previous study in 
section 4.3. The antigen and lipid recovery data suggests that the majority of the 
formulation after 30 minutes is present within the small intestine, with approximately 
10 % in the stomach. These results (Figure 5.11A) are in line with previous studies 
where the vesicles were un-sonicated and show good overall recovery (Figure 5.9B). 
When looking at the Mesenteric lymph tissue, the results from the two formulations 
shows no significant differences in the antigen uptake (Figure 5.11B); however when 
looking at the Peyer’s patches, antigen recovery is significantly (p< 0.05) higher when 
delivered with the larger vesicle population. There is also a greater recovery of vesicles 
within the Peyer's patches of the larger vesicles in comparison to the sonicated smaller 
vesicle formulation (Figure 5.11B).  
This would suggest that it is advantageous to keep the larger vesicle sized formulations 
as the vesicles which remain in the Peyer's patches offer increased retention time and 
hence can stimulate the dendritic cells to produce the effective immunity. Considering 
the target site uptake of antigen and carrier into the Peyer’s patch and mesenteric lymph 
tissue (Figure 5.11B), significantly higher (p< 0.01) levels of the larger vesicles was 
found in the Peyer’s patches compared to the smaller vesicle size formulation (Figure 
5.11B). However this did not translate into significantly increase the levels of bilosomes 
or antigen in the mesentery. A similar trend has been observed by Ebel (1990), who 
compared the uptake of 9 µm and 2 µm polystyrene latex beads via the Peyer’s patches 
and mesenteric lymph nodes. The results showed that the larger particles retained 
within the Peyer’s patches with no presence in the mesenteric lymph nodes, whereas the 
smaller particles were more noticeable in the mesenteric lymph nodes (Ebel, 1990).
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Table 5.2: Overall VMD and size distribution of the administered vesicles. 
 Vesicle Size (µm) Span 
No Sonication 6.44 ± 0.05 1.75 
Sonication 1.88 ± 0.37 2.45 
 
 
 
 
 
 
A   B 
Figure 5.11: Influence of vesicle size: A) In vivo biodistribution data for antigen and vesicle (tritium) for the organs selected from the GIT and  B) A closer look into the 
mesenteric lymph tissue and Peyer’s patches for the smaller vesicle formulation and for the normal sized formulation (n=4).  
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Furthermore, in terms of immune response, this trend has also been observed by other 
studies where, a summary by Oyewumi et al, (2010) also suggests that in terms of oral 
vaccine delivery using lipid vesicles, the larger vesicle sizes (400–2500 nm) induced 
significantly higher IgG2a titres and IFN-g responses than the smaller vesicles 
(Oyewumi et al., 2010). A study directly comparing immune responses to antigens 
delivered orally with 200, 500 or 1000 nm PLGA particles showed the largest particle 
group to be the most effective, suggesting that although the smaller particles would be 
more readily absorbed, their lack of targeting to the Peyer’s patches reduces their 
immunogenicity (Gutierro et al., 2002). In addition, studies using PLA for oral delivery 
of vaccines have shown that the optimum vesicle size for induction of an IgG response 
is 4 μm. Moreover, Eldridge et al, (1990) noted that uptake was restricted to particles 
less than 10 µm. However, whilst particles between 5 and 10 µm remained within the 
Peyer’s patches, the majority of microspheres less than 3 µm were transported through 
the efferent lymphatics within macrophages, suggesting that this pattern of absorption 
and redistribution may determine the type of immune response elicited by the vaccines 
(Eldridge et al., 1990). Within their paper they predict that microspheres below 3 μm 
would induce a predominantly circulating antibody response, while those above this 
size would stimulate a mucosal (IgA) immune response. Mladenovska et al, (2002) 
further confirm that their 7 μm BSA loaded gelatin microspheres were adsorbed 
through the M cells into the Peyer's patches where higher local antigen concentration 
was observed and upon decreasing particle size, higher recovery of BSA loaded 
microspheres was found in the liver and spleen via the mesenteric lymph nodes 
(Mladenovska et al., 2002). Thus, the results obtained from the biodistribution study of 
the unsonicated formulations (VMD- 6.44 μm) which show increased vesicle and 
antigen recovery within the Peyer's patches offer a greater chance to increase mucosal 
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immunity. This study confirms that it is important to understand the vesicle size 
characteristics in relation to the desired site of uptake depending on the route of 
delivery thus potentially influencing the type of immunity produced.  
5.4 Conclusions 
The proposed method of producing vesicles to protect thermolabile antigens by 
lowering the process temperatures (Aston melt) shows that antigen can be associated 
and entrapped within non ionic surfactant vesicles. Confocal laser scanning microscopy 
confirmed that the vesicles are spherical in nature and the vesicles meet the criteria of 
being within the optimum size range and charge for increased uptake within the target 
site of the Peyer's patches. On average 1.5 % antigen is taken up by the Peyer's patches 
based on initial dose administered after 30 minute time point. This is the highest point 
of uptake within the Peyer's patches, after this time antigen levels stay the same or 
decrease over time. Based on the saturation studies, the dose concentration can be 
increased but once again only an average of 1.5 % antigen (based on dose) is recovered 
within the Peyer's patches and although an increase in antigen concentration is 
calculated this is not significantly different to the normal dose that would be 
administered. The presence of the vesicles show increased retention of antigen within 
the mesenteric lymph tissue and overall recovery during transit compared to 
administering free antigen alone thus increasing the chances of uptake. To conclude, 
this study shows that it is important to control and understand dosing and antigen 
concentrations administered as increased dose concentration would not be 
commercially viable with the higher chance of reduced immunity due to oversaturation 
and  increased systemic tolerance. Furthermore, larger vesicles are able to reside within 
the Peyer's patches compared to the corresponding smaller vesicles thus is an indicator 
of providing increased mucosal immunity.  
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6.0 Introduction 
Oral liquid vaccines have previously been shown to enhance immunity and show 
comparative data to commercial vaccines when administered intramuscularly (Chapter 
2). In the development of an oral vaccine generally the dosage form would be in a 
liquid state. However, in terms of long term shelf stability, storing vaccines as liquid 
dosage forms is not ideal due to stability issues. Hence, the development of a solid 
dosage vaccine platform which was initially formulated as a liquid is the desire in 
overcoming stability and storage issues. 
Freeze drying has been widely used as a standard method for enhancing the stability of 
liposomal preparations. Freeze drying of liposomes is used to prevent hydrolysis and 
physical degradation of the phospholipids used within the vesicles during extended 
storage (van Winden, 2003, Bridges and Taylor, 2001). However, the process of 
freezing and resultant dehydration of the formulation can exert stress onto the vesicles 
thus affecting the integrity of the vesicles. Freezing may result in ice formation thus 
disrupting the bilayers and result in phase transition changes (Stark et al., 2010). Upon 
dehydration, an increase in solute concentration can occur which may initiate chemical 
destruction of vesicles thus losing integrity, causing bilayer fractures, subsequently 
leading to vesicle aggregation, changes in vesicle size, and loss of entrapped 
antigen/material (Crowe et al., 1985, Crowe et al., 1986, Stark et al., 2010).  
The associated problems with freeze drying of bilayered vesicles can be minimised by 
the inclusion of cryo- and lyoprotectants which include disaccharide carbohydrate 
sugars within the formulation prior to freeze drying. Protectants such as trehalose or 
sucrose are characterised by their non-eutectic nature, thus protecting the vesicles by 
forming an amorphous matrix around the vesicles. The addition of trehalose to a vesicle 
suspension inhibits vesicle fusion and aggregation during the freezing process 
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(Abdelwahed et al., 2006, van Winden et al., 1997). The mechanism of action of such 
cryoprotectants has been examined by Crowe et al, (1996) where they found that the 
sugar molecules are able to interact with the head groups of the phospholipids, thus, 
preventing membrane disruption by counteracting fusion (Crowe et al., 1996). In 
addition to adding a cryoprotectant to the suspensions, other excipients have also been 
known to aid in the lyophilisation process offering protection of the product (Table 6.1). 
Table 6.1: Excipients and their functions within the lyophilisation process. 
Parameter  Function  Example excipients  
Bulking agents  When concentration of 
product is low it is useful 
to add bulking agents to 
freeze-dry the system.  
Hydroxyethyl starch, trehalose, mannitol, 
lactose, and glycine  
Buffers  Some buffers alter pH 
after freeze-drying  
Phosphates, Tris, citrates  
Stabilisers  Protect product through 
freezing stages  
Sucrose, lactose, glucose, trehalose, glycerol, 
mannitol, sorbitol, glycine, alanine, lysine, 
polyethylene glycol, dextran, and polyvinyl 
pyrrolidone  
Isotonicity 
modifiers  
Controls isotonicitity  Mannitol, sucrose, glycerol  
Increase collapse 
temperature  
Allows higher drying 
temperatures  
Dextrans, PEG, PVP,  
The oral route offers increased patient compliance and the possibility of providing herd 
immunity is increased if the vaccine is easily administered. Tablets and capsules are 
considered to be dosage forms which offer the high patient compliance. In addition 
there are options of fast melt tablets for paediatrics, geriatrics, patients who may 
struggle with swallowing (after stroke or renal failure patients) or patients with 
dysphasia (Lindgren and Janzon, 1991, Wilson et al., 1987, Gupta, 2010). In terms of 
vaccine solid dosage forms, this resolves the issue of storage and is a more cost 
effective way to carry out bulk immunisation as tablets can be distributed worldwide 
without the use of trained personnel.  
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6.1.1 Aims and Objectives 
The aim of this project was to exploit excipients used for lyophilisation (Table 6.1) to 
formulate an oral vaccine solid dosage platform which, upon rehydration or ingestion 
releases the vesicles containing the antigen. These vesicles should also maintain their 
integrity, potency and function as they would in a liquid dosage form. The studies 
involved: 
1. preparing a powdered sachet which a user could mix with water prior to 
administration;  
2. producing a fast melt tablet that, upon contact with water immediately 
redisperses to form vesicles. This table could either be placed in some water to 
drink or directly into the mouth; 
3. producing an oral chewable dosage form which will release contents within the 
mouth and expose the vesicles to mucosal sites along the Mucosa associated 
lymphoid tissue; 
4. developing a vaccine capsule which protects the contents against the stomach 
acids and then release the contents closer to or within the small intestine. 
6.2 Materials and Methods 
To form the vesicles the surfactants Monopalmitoyl glycerol (MPG; Larodan AG, 
Sweden), Synthecol (Chol), Dicetyl phosphate (DCP) (Sigma-Aldrich, UK) were used. 
The buffers were made up of sodium bicarbonate (Sigma-Aldrich, UK) at pH 7.6, 
where hydrochloric acid and sodium hydroxide (NaOH) (Sigma-Aldrich, UK) was used 
for pH adjustments. For the antigen a recombinant H3N2 sub-unit protein (Immune 
Tech, USA) was used. 
6.2.1 Preparation of niosomes for lyophilisation 
A 5:4:1 molar ratio of MPG, Chol and DCP was weighed and placed into a 10 mL glass 
beaker ensuring that no lipids stick to the sides of the beaker. Before melting the lipids 
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the aqueous phase was prepared in a 15 mL falcon tube. 25 mM sodium bicarbonate 
(pH 7.6) formed the aqueous phase and was then placed in a heated water bath for 10 
minutes at 30-35 °C. Whilst the aqueous buffer was preheated, the beaker containing 
the lipids was placed into a hot oil bath (120-125 °C) and melted for 10 minutes with 
occasional mixing. The beaker containing the molten mixture was removed from the oil 
bath and the buffered stock solution was immediately added and homogenised at 8000 
rpm at 30-35 °C. After homogenising for 10 minutes, the homogenisation speed was 
reduced to 4000 rpm to act as a mixer and dextran (Sigma Aldrich, UK) was added and 
mixed into the solution for a minute followed by mannitol (Sigma Aldrich, UK) for 
another minute of mixing.  
A 400 mM trehalose solution was prepared and then added 1:1 of niosome mixture: 
trehalose in a bijoux tube which formed the mould for the tablets and were then pre-
frozen in the -70 ºC freezer until the freeze drying cycle was ready to begin. 
6.2.2 Lyophilisation cycle  
Lyophilisation was performed with the Virtis Advantage (Bio Pharma) freeze dryer. 
The samples to be freeze dried were stored at -70 ºC and the freeze drying protocol was 
set for primary drying to occur at -40 ºC for 48 hours with a secondary drying cycle set 
at 20 ºC for a further 10 hours with a condenser temperature set at -75 ºC. The freeze 
drying cycle was sufficient enough to thoroughly dry the formulations and prevent 
damage to the samples. 
6.2.3 Freeze fracture microscopy of niosome vesicles 
A 5 µL drop of each incubation mixture was placed on a ridged, gold specimen support 
or was sandwiched between two copper plates for fracture in a double replica device. 
Samples were frozen by rapid plunging into a constantly stirred mixture of 
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propane:isopentane (3:1) cooled by liquid nitrogen. Fracture was performed on a 
Balzers BAF 400D apparatus at a temperature of −110 °C. Replicas were floated free 
on distilled water and cleaned in 40 % chromic acid. Images were then viewed using a 
Jenway transmission electron microscope. 
6.2.4 TGA of freeze dried tablet samples 
A small sample of the tablets were broken and the sample was placed onto the Perkin 
Elmer TGA apparatus and was weighed and then analysed. The method set, heated the 
sample to 110 °C and moisture content was determined as a % weight loss of the 
sample. All samples were repeated in triplicate to determine moisture content and 
degradation. All formulations were carried out using nitrogen and air as the purge 
gasses. 
6.2.5 Mechanical strength 
The mechanical properties (Hardness) of the tablets were analysed by a Tinius Olsen 
texture analyser (Hounsfield, UK) equipped with a 50 N load cell. The instrument was 
calibrated with standard weights and the tablets were placed individually on a platform. 
The hardness was expressed as the peak force (N) after a 2 mm penetration of a 5 mm 
diameter probe at velocity of 6 mm/min was applied. The average of five batches was 
taken as replicates. 
6.2.6 Disintegration time  
Disintegration time was measured using the USP apparatus (Erweka, ZT3) test for 
disintegration where 800 mL distilled water was kept at constant temperature of 37 °C. 
A basket with a wire mesh was raised up and down within this 800 mL media at an 
interval of 30 cycles/ min. Samples were run individually and were tested in triplicate. 
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6.2.7 Determination of vesicle size and zeta potential 
The vesicle size distribution was determined using laser diffraction on a sympatec 2005 
(Helos/BF) cuvette analyser. 20 μL of the niosome suspension was diluted into the 
cuvette with 40 mL double distilled water. The zeta potential which is an indirect 
measurement of the vesicle surface charge, was measured in 1.5 mL double distilled 
water at 25 °C on a Zeta Plus Brookhaven Instrument. 15 μL of the niosome suspension 
was mixed in 1.5 mL double distilled water and then analysed.  
6.2.8 Labelling and quantification of antigen 
Initially the H3N2 antigen was incubated with the fluorescent flamma fluor FPR-648 
(Bio Acts) marker and a conjugation buffer was added and left at 30 °C for 4 hours to 
conjugate. After this period the unbound fluorescence was removed by centrifugation 
through an amicon P-10 centrifugal 10 kD MWCO filter tube. The remaining 
fluorescent antigen was made back to volume and then a spike of this was used per 
formulation as listed above. The H3N2 spike was placed into the aqueous phase prior to 
homogenisation. Initially a calibration curve was constructed on the same plate as the 
formulations after rehydration and all conditions for all formulations was kept constant 
(Figure 6.1). 
Chapter 6: Development of an alternative dosage platform for oral vaccine delivery using freeze drying 
 
222 
 
 
Figure 6.1: Calibration of Fluorescent H3N2 antigen at 648 nm emission and 672 nm excitation. Initial 
antigen concentration within niosome 6 mL was 13.6 µg (n=3). 
Vesicles were prepared incorporating the fluorescent antigen and freeze dried. For 
quantification of antigen association, ultra-centrifugation of the formulations was 
required to isolate antigen entrapped vesicles, from non-incorporated antigen. To 
achieve this, freeze dried samples were rehydrated and 300 µL aliquots of sample were 
diluted in a Beckman 3.9 mL Polo-allomer tube and filled up to the neck with double 
distilled water.  The tubes were heat sealed ensuring that there were no air bubbles 
present within the tube. The tubes were then placed accordingly in the TLN-100 rotor 
and centrifuged at 354,000 X g for 45 minutes at 4 °C with the acceleration set at 8 
(Slowest) and the deceleration at coast. When centrifugation was complete, the tubes 
were opened and the supernatant removed. The sample was resuspended and the 
centrifugate stage repeated. After the second ‘wash’ the antigen loaded vesicles were 
then re-suspended with 100-200 µL of appropriate buffer and transferred to a black 
microplate for reading fluorescence.  
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6.3. Results and Discussion 
6.3.1 Optimisation of freeze drying cycle 
It is vital to develop an economical freeze drying cycle, which is dependent on 
formulation, surface area, freezing process, pressure and temperature. Lyophilisation is 
a time-consuming and energy intensive process thus optimisation of a cycle is vital 
(Hilleman and Hurni, 1982). The first step of freeze drying is the thermal treatment of 
the sample ie, pre-freezing, where the liquid suspension is cooled and ice crystals are 
formed. The water present within the formulation freezes and forms crystals, thus 
increasing the viscosity of the suspension. As previously mentioned, the presence of ice 
crystals may disrupt bilayers and lead to vesicle instability (Stark et al., 2010). In 
general, fast freezing results in smaller ice crystals being produced compared to slow 
freezing which results in large crystals and pores. As a result, pre freezing of the liquid 
suspensions can be carried out by freezing at -70 °C to overcome the issue of producing 
large vesicles and larger pores. When optimising the freeze drying cycle the 
sublimation rate of the ice during primary drying is the most crucial stage and this 
depends upon several factors such as surface area, pressure and temperature. There are 
four main features of primary drying which have been highlighted and summarised in 
figure 6.2 (Abdelwahed et al., 2006, Bridges and Taylor, 2001, Pikal et al., 1990). 
Figure 6.3A and B represents the samples loaded within the freeze dryer containing the 
thermocouples ready to start the cycle and the sublimation rate is presented in figure 
6.3C which demonstrates that the sublimation of the ice crystals takes place from the 
surface to the bottom of the vessel. 
The freeze drying cycle, consists of two phases which include primary drying and 
secondary drying (Williams and Polli, 1984). Figure 6.3C represents primary drying 
where sublimation of the ice from the frozen sample is taking place.  
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•Transfer and conduction of heat from the shelf 
to the frozen solution through the vial to the 
sublimation front. 
•Sublimation of ice and the water vapour passes 
through the dried surface of the sample 
•Water vapour then transferred from the dried 
product surface to the condenser 
•Water vapour condenses on the condenser 
 
 
Primary 
Drying 
 
 
•Removal of adsorbed water from the dried product 
which did not become ice during initial freezing 
Secondary 
Drying 
 
 
 
 
Figure 6.2: Summary of primary and secondary drying during a standard lyophilisation procedure. 
Initially, the lyophilisation procedure for lipid based vesicles within this study was 
obtained from the development of a freeze drying protocol for TB vaccines based on 
DDA:TDB liposomes within the Aston university group (Mohammed et al., 2006, 
Mohammed et al., 2007). Within these studies, it was found that PC: cholesterol 
liposomes at a 16:4 µmol ratio when pre frozen at -70 °C followed by 10 hours primary 
drying at -50 °C with 24 hours secondary drying at -30 °C was a stable protocol with 
the inclusion of a cryoprotectant, determined by the vesicle size after rehydration 
(Mohammed et al., 2006). The preparation of niosome vesicles includes the use of 
significantly higher lipid concentrations within the formulations compared to liposome 
vesicles hence, based on the protocol developed by Mohammed et al, (2006) the 
lyophilisation cycle was further optimised for drying times. 
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Figure 6.3: Samples undergoing lyophilisation where: A) Demonstrates samples removed from the -70 °C pre storage conditions, B) Samples are in process during a 
freeze drying cycle. C) Sublimation taking place within a vial containing the niosome formulation. Temperature probes are constantly monitoring internal temperature 
over the time period of the lyophilisation cycle. 
Dried lipid product 
Frozen sample 
SF 
A B 
C 
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This was carried out as presented in figure 6.3 where thermocouples were added to vials 
containing niosome vesicles. Figure 6.4 presents this data where the shelf temperature 
was kept constant at -40 °C and the change in temperature based on the thermocouples 
recorded the temperatures with and without a cryoprotectant. Figure 6.4 shows that 
there was no deviation in temperature change between 30 -75 hours of primary drying, 
implying that the temperature within the lipid cake is constant thus suggesting that a 
primary drying cycle should be chosen implementing primary drying time between this 
time point. Figure 6.4 also demonstrates that the addition of a cryoprotectant (200 mM 
sucrose) allows primary drying to take place at a much higher temperature (-20 °C) as 
presented by the yellow line on the graph. 
 
Figure 6.4: Key stages during a freeze drying cycle taken using a thermocouple placed inside niosome 
vials with and without sucrose. 
The final optimised protocol (Table 6.2) for niosome/ bilosome vesicles was optimised 
for primary drying to occur for 48 hours with a shelf temperature of -40 °C to ensure 
that the lyophilisation cycle was efficient and allowed for maximum number of vials for 
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large scale drying to be successfully carried out. Freeze fracture images (Figure 6.5) 
confirm the presence of niosome vesicles prior to and after freeze drying, where figure 
6.5A represents vesicles prior to freeze drying and figure 6.5B representing rehydrated 
vesicles after freeze drying with the corresponding characterisation data in table 6.2B. 
Table 6.2: A) Final optimised parameters for lyophilisation of niosome vesicles with condenser 
temperature set at -75 °C and B) Characterisation data for niosome vesicles prior to and after 
lyophilisation. 
A Temperature (°C) Time (h) 
Pre- freezing -70 1h minimum 
Primary drying -40 48 
Secondary drying +20 10 
 
B Pre lyophilisation After lyophilisation 
Vesicle size 6.12 ± 0.09 5.85 ± 0.31 
Zeta potential -64.5 ± 6.9 -66.8 ± 9.7 
 
 
 
 
 
 
 
A 
 
 
 
 
 
 
B 
Figure 6.5: Freeze fracture images of niosome vesicles taken on a Balzers apparatus at -110 °C where 
images were then taken on a Jenway transmission electron microscope where: A) represents vesicles 
prior to freeze drying and B) rehydrated vesicles after freeze drying. 
Chapter 6: Development of an alternative dosage platform for oral vaccine delivery using freeze drying 
 
228 
 
6.3.2 Oral sachet 
Freeze drying a niosomal vaccine suspension results in the formation of a light 
powdered cake which upon rehydration results into the original liquid dosage form 
which can either be injected or administered orally. Freeze drying single doses within 
glass vials for mass production can cause an issue in terms of logistics as they occupy a 
large surface area and this is a less cost effective procedure. As a result, to overcome 
this issue, an innovative freeze dried vaccine heat sealed aluminium pouch, as presented 
in figure 6.6, was trialled for suitability to contain a freeze dried vaccine product. An 
advantage of using aluminium heat sealed pouches are that they are able to convect and 
conduct the ‘heat’ transfer process at a faster rate than if the energy was being passed 
through glass or plastic thus improving drying times.    
 
Figure 6.6: Packaging options for the niosome vaccines including moisture free pouches and tablet 
blister packs. Images taken from Amcor and Daklapack group.  
Figure 6.6 shows moisture protective heat seal or spout aluminium bags which are ideal 
to prevent moisture from entering the product. Niosomes were prepared in a 5:4:1 ratio 
of MPG:Chol:DCP respectively and after formulation mixed 1:1 with 400 mM 
trehalose as the protectant based on the freeze drying protocol developed at Aston 
university (Figure 6.4 and Table 6.2) as part of a contract research patent (Anderson et 
al., 2012). The pouches were filled with 20 doses and then pre frozen at -70 °C for 1 
hour prior to running the freeze drying cycle. Table 6.3 shows that the vesicle size prior 
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to freeze drying resulted in a consistent vesicle size to all previous studies of 6.22 ± 
0.12 µm with a surface charge of -68.5 ± 8.6 mV.  
Table 6.3: Characterisation data for 20 niosome vaccine doses (each dose 0.5 mL) of 5:4:1 
MPG:Chol:DCP respectively demonstrating vesicle size and surface charge prior to and after freeze 
drying from pouches (n=3). 
 Pre freeze drying Post freeze drying 
Vesicle size (µm) 6.22 ± 0.12 5.82 ± 0.25 
Zeta potential (mV) -68.5 ± 8.6 -62.3 ± 10.2 
 
The freeze drying process resulted in a light fluffy cake being produced within the 
pouches which were then sealed. Upon vigorous handling of the pouches it was noticed 
that the cakes would crumble into a light fine powder and upon opening of the pouch a 
small percentage of powder would form a dust cloud and leave the pouch. Lyophilised 
products are subject to being poorly stable under stressed conditions in terms of 
physical properties such as fragility, rendering conventional packaging unsuitable 
(Shukla et al., 2009, Fu et al., 2004). As a result, the second pouch was carefully 
opened and rehydrated to see if the vesicles were still present and the vesicle size of 
5.82 ± 0.25 µm and surface charge of -62.3 ± 10.2 mV (Table 6.3) was not significantly 
different to the size or surface charge prior to freeze drying.  
Studies by Mohammed et al, (2006) also demonstrate that freeze drying of cationic 
liposomes with trehalose and subsequent sterilisation of the lyophilised cake showed no 
significant differences after rehydration in vesicle size, zeta potential, pH and dynamic 
viscosity (Mohammed et al., 2006). The vesicles remained intact as was confirmed by 
light microscopy of the formulations prior to and after freeze drying. The use of the 
cryoprotectants such as trehalose preserve functionality and activity of liposome 
vesicles thus increasing shelf life of the product (Mohammed et al., 2006, Zurbriggen et 
al., 2010). This process of having small sachets containing the vaccine which can be 
added to a glass of water offers several advantages to mass vaccinations and increased 
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patient compliance due to needle free vaccines. The setback to this preparation method 
is that due to the freeze drying products being of a light flaky powdered nature this 
could result in incorrect dosing issues as there is a chance of the vaccine being lost upon 
opening of the sachet. Therefore, an alternative solid dosage form was investigated.  
6.3.3 Development of a rapid disintegrating tablet 
As previously shown (Section 6.3.2), the niosome vesicles are able to undergo the 
freeze drying process with a protectant and no significant changes in vesicle size or 
surface charge were noted upon rehydration. The underlying problem to the sachet was 
the nature of the final product was very delicate and needed to be handled with care to 
not lose any dose. As a result, a more robust final product is required which is able to 
resist handling and mechanical stresses. Therefore as an alternative option, this section 
involved the development of a freeze-dried tablet formulation using mannitol as an 
additive which has known to have bulking and stabilisation properties on the final 
freeze dried product (Seager, 1998). Mannitol is also water soluble and non-
hygroscopic which provides a cooling sensation when in the mouth (Jeong et al., 2008). 
In addition, sucrose will be used as a comparison with trehalose to determine any 
effects of protectant on the final product characteristics in table 6.4. The cryoprotectant 
was initially prepared at a 200 mM concentration which resulted in a final concentration 
of the sample and cryoprotectant being 100 mM.  
Initial indications (Figure 6.7) showed that two out of five samples for the niosomes 
protected with sucrose collapsed during freeze drying (Figure 6.7 vials 2C and 2D). The 
other three sucrose samples and the trehalose formulations all formed nice tablet shaped 
cakes. The collapsing of the niosomes was a result of a low final concentration of 
cryoprotectant which should have started off at 400 mM resulting in a final 
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concentration of 200 mM. Future studies rectified this issue and a repeat study showed 
the use of 200 mM final concentration resulted in no collapse of the tablet cakes. 
Redispersion of the samples (Table 6.4) was carried out with 2 mL water into the vials 
and gently agitated where the resuspension time was less than 5 seconds. The dispersion 
time of the tablets was rapid due to the matrix being prepared from water soluble sugars 
(sucrose/trehalose) thus, rendering the moulded tablets to rapidly disintegrate and offer 
improved taste (mannitol). The presence of mannitol to the tablets offers high aqueous 
solubility and sweetness, offering taste masking resulting in a pleasant feel within the 
mouth (Jeong et al., 2008, Mizumoto et al., 1996). However, these moulded tablets 
resulted in poor mechanical strength where figure 6.6 demonstrated that removal of the 
tablets from the moulds, handling was compromised.  
Table 6.4: Niosome formulations and pre characterisation data. (5:4:1 niosomes of MPG:Chol:DCP 
respectively, with protectant final concentration 100 mM) 
   Pre Freeze drying After Freeze drying 
Niosome  Additives Protectant Vesicle 
Size (µm) 
Zeta 
potential 
(mV) 
Vesicle 
Size (µm) 
Zeta 
potential 
(mV) 
1 5% w/v 
Mannitol 
Trehalose 5.88 ± 
0.05 
-68.54  ± 
6.4 
6.55 ± 
0.12 
-59.8  ± 8.9 
2 5% w/v 
Mannitol 
Sucrose 5.88 ± 
0.05 
-68.54  ± 
6.4 
8.42 ± 
0.45 
-54.8  ± 
12.1 
3 N/A Trehalose 5.65 ± 
0.08 
-70.82  ± 
6.4 
6.45 ± 
0.22 
-65.7  ± 4.8 
 
These initial freeze drying techniques showed that tablet shaped cakes (Figure 6.7) were 
formed which were able to redisperse back into vesicles upon the addition of an 
aqueous phase. Table 6.4 shows that the addition of sucrose as the cryoprotectant 
resulted in a significant (p< 0.05) increase in vesicle size after rehydration compared to 
trehalose formulations with no significant difference in zeta potential. The underlying 
problem with the sucrose and trehalose tablets within this preliminary study was the 
low final concentration of protectant within the formulations and hence required double 
the concentration. In addition, for a more robust tablet ie. a very hard lyophilised cake 
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the addition of a binder to the formulations which does not interact with the vesicles to 
change their morphology was examined based on the excipients listed in table 6.1. This 
formed the basis of the next studies which introduced the use of a binder such as 
dextran or gelatin to the niosome formulations prior to lyophilisation to provide 
structural integrity of the tablets.  
In general, freeze dried tablets such as Claritin
®
 RediTabs
®
 have highly porous inner 
structures which results in immediate disintegration and dissolving of the tablets upon 
the tongue (Fu et al., 2004). The highly porous nature of the freeze dried tablets results 
in their fragile properties. To increase, handling of the tablets, either binders or other 
excipients can be used or the preparation method can be altered. In terms of inducing 
hardness, Benadryl
®
 Fastmelt
TM
, using the WOWTAB
®
 technology (Pfizer) reduce 
tablet porosity by direct compression of the tablets resulting in harder tablets (Fu et al., 
2004, Dobetti, 2000).       
6.3.4 Introduction of a Binder 
Formulations prepared previously (Section 6.3.3) had shown the ability to form a nice 
cake (Figure 6.7); however, structural integrity was lacking and handling was a 
fundamental weakness. As a result a suitable agent to increase hardness and manual 
handling of the tablets was investigated. The tablets were prepared based on table 6.3 
and after lyophilisation were tested for hardness, disintegration time and upon 
rehydration, characterised for vesicle size and zeta potential. To increase the hardness 
of the tablets, excipients including dextran and gelatin were chosen (Table 6.3).  
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Figure 6.7: Final lyophilised tablets of niosomes (5:4:1 of MPG:Chol:DCP respectively) containing 5% w/w mannitol representing appearance and handling protected 
with 100 mM final concentration of either A) trehalose and B) sucrose (n=5). 
1A 1B 1C 1D 1E 2A 2B 2C 2D 2E 
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Results show that the presence of mannitol caused in a slight reduction although not 
significant of the zeta potential (Table 6.6) which was most likely due to its presence 
around the stern layer when measuring the zeta potential. This was also demonstrated 
by Budai et al, (2009) where the addition of glucose and mannitol to liposome vesicles 
was shown to possibly mask the liposomal vesicle charge (Budai et al., 2009). In 
addition, the presence of salt within liposomal formulations influences the surface 
(Moghaddam et al., 2011b). Upon rehydration the dextran and mannitol formulations 
appeared to have no significant difference in terms of vesicle size and zeta potential and 
showed that after rehydration the vesicles returned to their original characteristics 
(Figure 6.8A). When using the gelatin excipient within the formulations, it was only 
soluble in water at elevated temperatures where the gelatin had to be pre-heated at 45 
°C and left to dissolve. An aliquot of this solution was then added to the vesicle 
formulation. When working with gelatin it was noted that upon cooling back down to 
room temperature the gelatin was prone to precipitating back out of solution and 
becoming viscous prior to use, thus potentially causing problems with temperature 
sensitive vaccine antigens. Furthermore, the incorporation of gelatin to the niosome 
formulations after freeze drying, resulted in a significant reduction (p< 0.05) in vesicle 
size (< 4 µm) upon rehydration (Figure 6.8A).  
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Table 6.5: Formulation design study including the use of dextran and gelatin in combination with mannitol added to 5:4:1 niosomes of MPG:Chol:DCP respectively 
(n=3). 
Niosome formulation Additives Cryoprotectant final concentration 
4 Mannitol 5 % w/v, Dextran 10 % w/v  200 mM Trehalose 
5 Dextran 10 % w/v 200 mM Trehalose 
6 Gelatin Final Conc 0.5 % w/v  200 mM Trehalose 
7 Gelatin 0.5 % w/v, Mannitol 5 % w/v  200 mM Trehalose 
 
 
 
 
 
 
 
 
Figure 6.8: The impact of dextran and gelatin in combination with mannitol added to preformed niosome vesicles on: A) vesicle size and zeta potential pre and after 
freeze drying and B) the hardness and disintegration times of the tablets (n=5). 
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In addition, the inclusion of mannitol within the formulations after freeze drying 
resulted in harder tablets (Figure 6.8B), represented by the hardness results which were 
carried out by a Hounsfield machine which applied a force 2 mm into the tablet where 
resistance to indentation produced the hardness result. The addition of mannitol has 
previously shown to induce crystallinity within the lyophilised cake thus imparting 
rigidity and preventing collapse of the structure (Sastry et al., 2000). Studies have 
shown that the matrix of freeze dried tablets that consist of polymers such as gelatins, 
dextrans or alginates provide structural strength and saccharides such as  mannitol or 
sorbitol provide crystallinity, hardness and elegance (Sastry et al., 2000). This trend is 
apparent in the dextran and gelatin formulations, where the presence of mannitol has 
significantly (p< 0.05) improved hardness of the tablets (Figure 6.8B). 
In terms of disintegration time, the inclusion of mannitol significantly (p< 0.05) 
increased the time of the tablets to disintegrate from 4-6 seconds to 9 seconds which 
was related to the increased hardness of the tablets thus requiring a longer period of 
time to disintegrate (Figure 6.9B). All tablets produced within this study are categorised 
within the rapid disintegrating tablets class based on the criteria by the FDA where 
rapid disintegrating tablets should disintegrate in less than 30 seconds (McLaughlin, 
2009, FDA, 2008). After assessing the tablets produced within this study the dextran 
and mannitol based combinations formed the basis of the next studies with the aim to 
improve hardness by determining optimum concentrations of the excipients. The gelatin 
formulations were discarded due to the inclusion of extra preparation steps which 
included heating the gelatin to 45 °C as this may have an impact when using 
thermolabile antigens. In addition, aesthetically the gelatin based tablets were not 
appealing due to an off white / yellow discolouration due to the presence of gelatin.  
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6.3.5 Modifications to oral tablets 
Formulations prepared in section 6.3.4 resulted in the tablets with dextran and mannitol 
providing suitable candidates for a vaccine tablet. As a result, different combinations of 
dextran and mannitol were prepared with the inclusion of a strawberry flavouring to one 
of the formulations (Table 6.6). The formulations prepared were once again tested for 
tablet hardness, resuspension to confirm vesicle size and zeta potential and then 
thermogravimetric analysis (TGA) studies to determine moisture content levels within 
the final freeze dried products. Freeze dried products are required to contain less than 5 
% moisture content as the maximum moisture content within the final freeze dried 
product.   
Results within table 6.6 show that prior to addition of excipients the batches of vesicles 
produced are very reproducible showing a consistent vesicle size and zeta potential. 
Upon addition of excipients the vesicle size range decreases which could be due to the 
dextran pulling the VMD lower as the smaller vesicle size range increases. The addition 
of 5 % dextran results in the VMD remaining consistent with the initial VMD (Table 
6.6). Once again this study confirms that the reduction in zeta potential occurs due to 
the presence of mannitol within the formulation as prior to mannitol addition the zeta 
potential is in the -64 mV range. After lyophilisation, rehydration of the samples show 
that the vesicle size (Table 6.6) for all of the formulations was approximately 4.5 µm 
which showed uniformity between the various formulations after freeze drying. The 
zeta potential values upon rehydration showed no significant differences between them 
and are all lower than the initial readings prior to excipient addition as presented in 
Table 6.6.  
Dextran and mannitol, are key excipients in controlling mechanical hardness and 
disintegration time (Chandrasekhar et al., 2009, Seager, 1998). Figure 6.9 demonstrates 
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the tablet hardness procedure for the 10 % dextran, 10 % mannitol and 1 % strawberry 
niosome tablets showing resultant indentation and fracturing of the tablet. Figure 6.10B 
shows that the increase in mannitol concentration to 15 % w/v of the formulations, 
resulted in fracturing of the tablets compared to formulations with only 10 % w/v. The 
addition of 1 % v/v strawberry flavour to the formulation showed significantly (p < 
0.05) higher tablet hardness (16 ± 1.4 N) where the tablets were prone to fracturing, 
resulting in the longest disintegration time. This could be due to the adhesive properties 
of the flavour which has helped the formulation adhere together hence resulting in 
increased disintegration and hardness. 
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Table 6.6: Formulation specifications showing characterisation data for niosomes (5:4:1 MPG:Chol:DCP respectively) for vesicle size and zeta potential at key stages 
including: Formulation of initial vesicles, after addition of excipients prior to FD and upon rehydration after freeze drying (n=5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9: Formulation 8 containing 1 % strawberry, 10 % dextran and 10 % mannitol (very elegant aesthetics) undergoing a hardness test using a 5 mm diameter 
probe showing indentation with fracturing.  
 10% Dextran, 10% 
Mannitol, 1% 
Strawberry 
5% Dextran, 10% 
Mannitol 
10% Dextran, 
15% Mannitol 
10% Dextran, 
10% Mannitol 
5% Dextran, 15% 
Mannitol 
 
Initial Vesicle size (µm) 6.12 ± 0.05 6.31 ± 0.22 6.03 ± 0.18 6.08 ± 0.02 6.18 ± 0.10 
Initial zeta potential (mV) -60.9 ± 4.5 -63.6 ± 2.8 -63.6 ± 8.9 -68.5 ± 2.7 -67.0 ± 10.2 
Vesicle size with excipients (µm) 3.93 ± 0.45 6.19 ± 0.23 4.90 ± 0.65 5.71 ± 0.33 6.14 ± 0.12 
Zeta potential with excipients 
(mV) 
-53.2 ± 10.8 -50.2 ± 6.1 -60.0 ± 8.6 -51.6 ± 7.3 -53.2 ± 6.6 
Vesicle size after FD (µm) 4.25 ± 0.33 4.67 ± 0.56 4.69 ± 0.12 3.98 ± 0.22 4.86 ± 0.11 
Zeta potential after FD (mV) -45.4 ± 3.6 -52.8 ± 6.5 -49.2 ± 7.3 -53.5 ± 7.3 -53.9 ± 7.5 
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Formulation 
 
Figure 6.10: The result of varying mannitol and dextran ratios within the niosome mixture where; A) presents the appearance of the tablets and B) the impact on tablet 
hardness and disintegration time (n=5).  
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Based on the current freeze drying studies, it is possible to prepare a tablet dosage form 
with structural integrity. The pharmacological importance of moisture present within 
the lyophilised tablet is the sensitivity of the antigen/excipients to residual moisture, 
which can impair the medicinal effect of the tablet and can impair long term storage.  
This fact is verified by the specifications in the British Pharmacopeia, which mandates 
that tests for microbial contamination must be performed if moisture is present (> 5 %) 
in solid dosage forms. Moisture harbours the growth and reproduction of microbes 
which provide optimum growth conditions for the bacteria which is unacceptable in oral 
dosage forms. Hence, it is essential to make sure that the final product post 
lyophilisation is free from excess moisture and so does not cause contamination issues.  
Furthermore, traces of moisture in a tablet may lead to longer term stability issues such 
as, friability, dissolution and loss of potency of the drug (which may eventually change 
the permeability of any coatings applied and interfere with the performance of the 
coating layer) (Sugimoto et al., 2006, Nakabayashi et al., 1980).  In addition to 
manufacturing methods it is crucial that the packaging for storage and handling of the 
tablets are not sensitive to moisture and provide an effective barrier for moisture 
(Figure 6.1). To determine moisture content within the formulations, thermogravimetric 
analysis studies (Table 6.7) were carried out (Figure 6.11). 
 
 Table 6.7: Moisture content for all batches of tablets (n=3) (5:4:1 niosomes of MPG:Chol:DCP 
respectively). 
Formulation       Moisture Content (%) 
10% Dextran, 10% Mannitol, 1% Strawberry     4.1 ± 0.1 
5% Dextran, 10% Mannitol     3.8 ± 0.3 
10% Dextran, 15% Mannitol     3.1 ± 0.1 
10% Dextran, 10% Mannitol     2.6 ± 0.2 
5% Dextran, 15% Mannitol     3.1 ± 0.6 
 
Chapter 6: Development of an alternative dosage platform for oral vaccine delivery using freeze drying 
 
242 
 
Figure 6.11: TGA scans overlaid for all formulations showing % moisture content where each 
formulation was carried out (n=3). 
Moisture content analysis was carried out using TGA based on a similar protocol to 
Mohammed et al, (2006) (Figure 6.11). The limits for a freeze dried formulation are 
that no tablet should contain more than 5 % moisture content and the thermogram scans 
(Figure 6.11) and data (Table 6.7) show that all of the tablets prepared pass the moisture 
content test. The moisture content results within this study are in line with Mohammed 
et al, (2006) where they showed that cationic liposome vesicles with the use of 
trehalose as the cryoprotectant after freeze drying showed residual moisture content 
levels to be less than 5 % (Mohammed et al., 2006).  The freeze drying method 
employed a secondary drying phase at +20 °C for 10 hours. However, TGA scans 
(Figure 6.11) show that additional moisture content can be eliminated from the tablets 
by holding the secondary drying temperature at a higher temperature like 50 °C as well 
as the +20 °C, potentially removing another 1.5 % moisture from the tablets. This extra 
moisture thermal treatment if necessary can significantly improve the mechanical 
strength of tablets due to the removal of moisture bridges within the product (Fu et al., 
2004).  As the tablets have passed the requirements, there would be no need to add this 
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extra step as this would cost time, money and expose any thermolabile antigens or 
drugs to the elevated temperature. When correlating the data together, moisture content 
analysis was compared to tablet hardness (Figure 6.12).  The results show that dextran 
content of 5 % w/v results in higher moisture content (~4 %) within the tablets and also 
results in the reduced hardness (4-6 N) of the tablets (Figure 6.12). Studies by 
Nakabayashi et al, (1980) also demonstrated that the increase in moisture content within 
the lactose- cornstarch tablets rapidly decreased the hardness of the tablets 
(Nakabayashi et al., 1980). In addition, the tablets containing the higher residual 
moisture were not prone to fracturing; however, did leave an indentation after the 
hardness test was applied (results not shown). The low moisture containing tablets (< 
3.5 %) resulted in the tablet fracturing into 3-4 pieces upon force suggesting that the 
tablets are drier and hence are more inclined to fracture. Studies by Sugimoto et al, 
(2006) demonstrate that mannitol absorbed little moisture upon increase in relative 
humidity compared to excipients such as glucose or sorbitol which absorb more 
moisture upon increases in relative humidity (Sugimoto et al., 2006). As previously 
shown in section 6.3.4 the presence of mannitol within the formulations resulted in an 
increase in tablet hardness. Furthermore, the increase in moisture content within the 
tablets results in decreased tensile strength upon storage, which reflects our studies 
(Figure 6.12) where (although not significant) the increased moisture content tended to 
result in lower hardness tablets (Sugimoto et al., 2006). The presence of water has 
shown to act as a plasticiser during freeze dying, whereby water can affect the physical 
properties of the freeze dried solid by inducing cake softening, cake collapse, 
crystallisation of amorphous solids, polymorphic conversions between crystalline 
structures and protein aggregation by increasing mobility within the solid (Costantino 
and Pikal, 2004).  
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Figure 6.13 shows the residual moisture content of the formulations and is compared to 
the disintegration times of the tablets. The results show a similar trend for both 
responses although not significant however, the higher the moisture content within the 
tablets the faster the disintegration time (Formulation 9 and 12). This is attributed to the 
tablets containing higher residual moisture content showing parts of the tablet are 
slightly wet and are more cohesive and upon rehydration disintegrate faster, whereas 
the drier tablets require water to be taken up and then disintegration to occur. 
Disintegration occurs faster with the tablets which contain the low dextran content of 5 
% where the moisture content of those tablets was higher and thus, resulted in faster 
disintegration times. In addition, increased mannitol concentrations within tablets has 
been shown in literature to increase the disintegration and dissolution rate of tablets 
(Chandrasekhar et al., 2009, Mizumoto et al., 1996, AlHusban et al., 2010). 
Chandrasekhar et al, (2009) demonstrated that the increase in mannitol within tablet 
formulations resulted in increased dissolution rates which was due to the high water 
solubility of the mannitol (Chandrasekhar et al., 2009). Hence, when increasing the 
mannitol concentration, it is important to increase the dextran content as this will 
increase tablet hardness and in turn increasing the collapse temperature of the 
formulations thus increasing the stability of the product at elevated temperatures.  
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Figure 6.12: The effect of moisture content on the hardness of the freeze dried tablets at different concentrations of dextran and mannitol (n=5). 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
4.5 
0.0 
5.0 
10.0 
15.0 
20.0 
5% dextran, 10% Mannitol 5% dextran, 15% Mannitol 10% dextran, 10% Mannitol 10% dextran, 15% Mannitol 10% dextran, 10% Mannitol, 
1% Strawberry 
M
o
is
tu
re
 C
o
n
te
n
t 
(%
) 
H
ar
d
n
e
ss
 (
N
) 
Hardness Moisture Content 
Chapter 6: Development of an alternative dosage platform for oral vaccine delivery using freeze drying 
 
246 
 
 
Figure 6.13: The effect of moisture content of the tablets after freeze drying on the disintegration time of the tablets at 37 °C (n=5). 
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6.4 Formulation of a vaccine capsule 
As previously shown within this chapter (section 6.3), results show that prior to adding 
mannitol and dextran to the niosome vesicles the average VMD of the vesicles is 
approximately 6 µm and upon addition of excipients decreases to 4-6 µm which is a 
result of the excipients bringing the VMD down and not so much the vesicles reducing 
in size. Upon rehydration after freeze drying the vesicle size averaged out to 4-6 µm 
with the zeta potential remaining unchanged. Moreover, the vaccine tablets produced 
were classed as rapid disintegrating tablets or oral chewable tablets which have several 
benefits. However, the tablets produced (section 6.3) still expose the vesicles and 
vaccine to the external milieu of the stomach which resulted in niosome vesicles losing 
antigen when exposed to gastric conditions as demonstrated in chapter 5. As a result, 
due to the moisture sensitivity of the freeze drying tablets, enteric coating techniques all 
require the use of aqueous phases thus poses deterioration of the tablets during the 
coating. Hence, as an alternative to tabletting, freeze dried vaccine formulations within 
capsules were examined.  
Thus, the aim of this study was to prepare niosome vaccine formulations containing 
H3N2 antigen to load within capsule shells and compare the rehydration characteristics 
to a control tablet to ensure the capsule is not interfering with the vesicles. The intention 
of the capsules was to reduce contact time of the stomach acids and enzymes to the 
vaccine formulation thus offering increased stability within the GIT.  
6.4.1 Niosomes for oral delivery via capsule dosing 
Empty niosomes were produced at a 5:4:1 ratio of MPG:Chol:DCP respectively mixed 
at a 1:1 ratio with  400 mM trehalose and 500 µL aliquots were placed into the bottom 
of the capsule shells and immediately frozen at -70 °C. The capsules were compared to 
a control formulation which was freeze dried in the form of a tablet. The capsule 
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formulations did not require the use of additives such as dextran or mannitol as the 
capsule shell provides structural integrity thus increasing handling and protection of the 
niosome vaccines enclosed. The capsule shells are presented in figure 6.14 with a fill 
volume of 0.5 mL and were added to the capsule holder ensuring the bottom of the 
shells are able to be in full contact with the shelf for efficient lyophilisation conduction. 
 
 
 
 
 
 
 
Figure 6.14: Empty capsule shell and one filled with the niosome wet formulation showing no leakage of 
the enclosed niosomes. 
 
Figure 6.15: Capsule holder designed to hold capsule shell bases allowing the bottom of the shells to be 
in full contact with the lyophiliser base plate to allow efficient drying of the niosomes. 
 
Firstly, vesicle size distribution and surface charge was analysed prior to and after the 
freeze drying cycle has taken place and this data is represented in figure 6.16A. The 
initial vesicle size is comparable to all formulations within section 6.3 with an average 
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vesicle size of 6-6.5 µm and a highly negative zeta potential (> -65 mV). After the 
freeze drying cycle, the capsule shell was taken out of the holder and then initially 
broken up to release the material to confirm if a powdered cake was formed (Figure 
6.16B). Upon confirmation that the material had successfully freeze dried, the capsules 
were rehydrated with 0.5 mL ultrapure water, vortexed and then analysed for vesicle 
size and charge. The vesicles from the capsules reduced in size to an average of 4.5 µm 
which is in line with the control and comparable to previous data (Section 6.3) with the 
zeta potential remaining highly negative (Figure 6.16A) which are still attributed to 
uptake by the Peyer's patches (Tabata and Ikada, 1988, Ebel, 1990, Eldridge et al., 
1990, Tabata et al., 1996). This data is encouraging as it shows that the niosomes are 
the same after freeze drying whether formed as a tablet or encapsulated within capsules.  
After removing the capsules from the capsule holder it was noted that the shells had 
initially shrunk in size which could be due to the vacuum pressure and sublimation of 
water during the primary freeze drying process. This however, proved to be 
advantageous for the niosomal formulations, as the initial shell can be pushed into a 
new capsule shell and a lid placed on top to seal the capsule as shown in figure 6.16B. 
This therefore providing a dual barrier to the capsule protecting the niosomes from 
potential acid attack when in gastric conditions. Another advantage of this capsule 
within a capsule offers the potential to add in other excipient doses into the outer shell 
which will be released prior to the niosome release. This dual dosing technique within a 
single capsule can allow the presence of a small dose of bile acid sequestrants such as 
cholestyramine within the outer capsule shell which when released into the small 
intestine binds the bile acids and interrupts their circulation (Marounek et al., 2010, 
Stedronsky, 1994). 
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Figure 6.16: A) Vesicle size and zeta potential of the niosomes pre and after freeze drying of capsules 
including the tablet control (n=6) and B) appearance of the freeze dried capsule niosome formulation. 
The removal of excess bile acid from the small intestine would prevent the bile acids 
from attacking the vesicles thus offering increased antigen protection with a chance of 
increasing the vesicle and antigen concentration within the Peyer's patches. The 
resultant dual shelled capsules were tested for disintegration time and moisture content 
as presented in figure 6.17.  
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Figure 6.17 represents the moisture content and disintegration time of the capsule and 
the control tablet formulation within gastric media (pH 1.2). Results show that the 
control tablets disintegrate within 5 seconds, compared to the capsules which have a 
disintegration/ release time of 5-6 minutes. Capsules prepared by Jones et al, (2012), 
have shown that tests in humans show that within the fasted state, gelatin based 
capsules disintegrate within 7 ± 3 min compared to a fed state of 12 ± 3 min (Jones et 
al., 2012). The capsules prepared within this study offer this delayed release profile of 6 
minutes and is beneficial as it reduces the contact time of the niosomes and potentially 
any drugs / antigens prone to acid or enzymatic degradation within the stomach. In 
terms of moisture content, the capsules offer similar moisture content levels to the 
tablets previously (Section 6.3) formed and the control formulation within this 
experiment. The moisture content remained below 5 % thus should be sufficient to 
provide stability during storage. Thus, by formulating the niosomes within the capsules, 
they offer a promising platform to oral drug/vaccine delivery. 
 
Figure 6.17: Moisture content and disintegration time (37 °C) of the capsules and control niosome 
formulations after freeze drying (n=5). 
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In summary, empty vesicles have shown to be evident and intact pre and after freeze 
drying and offers an alternative to liquid dosage forms. Niosomes whether in tablet or 
capsule form have both shown low levels of moisture content with the current freeze 
drying cycle used and the desired disintegration time of the formulation whether is it a 
rapid fast melt, oral chewable tablet or a slow release capsule. To determine whether 
this platform had the potential to retain antigen fluorescently labelled H3N2 antigen 
was associated with the vesicles to determine whether the antigen loaded into niosomes 
was present after the freeze drying procedure for the various dosage forms. 
6.5  Determination of antigen content after freeze drying  
Within this study, the aim was to prove that the antigen is present within the 
formulations after the freeze drying process has been carried out. Thus, the test 
formulations for this experiment included a niosome control formulation, a rapid fast 
melting tablet, oral chewable tablet and a capsule (section 6.3 and 6.4).  
When determining the fluorescence of the antigen present within the niosome 
formulations, it was important to run a control of blank niosomes and then subtract this 
from the overall readings to determine actual antigen concentration without any 
background readings. As a result, the formulations were rehydrated and centrifuged 
using a two wash cycle to remove any un-entrapped fluorescent antigen within the 
vesicles. The samples were washed and the pellet hydrated and 100 µL of the pellet was 
placed into the black microplates for fluorescence analysis. The antigen levels were 
calculated upon the dilutions made and showed promising results (Table 6.8) which 
were backed by a previous study using radioactively labelled H3N2 antigen (41.6 ± 
5.27 % - Chapter 5). 
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Table 6.8: Antigen association data showing antigen is present after the freeze drying cycle had taken 
place for niosome formulations (5:4:1 MPG:Chol:DCP respectively) (n=3). 
Formulation Antigen entrapment 
(%) 
Control- Nisv 38.87 ± 2.49 
Capsule- Nisv 30.43 ± 3.37 
Fast Melt- Nisv, 10% dextran 10% Mannitol 36.92 ± 1.80 
Oral Chewable- Nisv, 10% dextran 10% Mannitol 1%v/v 
Strawberry 
46.96 ± 4.51 
 
Table 6.8 presents the results from the antigen incorporation where the data is 
reproducible as the antigen was recovered after rehydration of the tablets and capsules. 
This study confirmed that the antigen retained with the vesicles is backed by a previous 
study using the lower melt method which resulted in an antigen association of 41.6 ± 
5.27 % (Chapter 5). The oral chewable tablet showed higher levels (approx 10 % 
greater) of antigen association compared to the control and other formulations which 
was expected due to the oral chewable tablets being smooth and compact in relation to 
the fast melt tablets. This effect was previously observed in section 6.3 where the 
addition of the strawberry flavour had adhesive glue like properties.  The addition of 
strawberry flavouring exhibited adhesive properties and thus the increased antigen 
association could be related to the presence of the strawberry flavour keeping the 
potential free antigen locked around the vesicles as well as residing within the vesicles. 
Generally, the increased antigen content is beneficial as improved antigen loading 
offers a greater chance for more antigen to be present at the Peyer's patches via the oral 
route as shown in Chapter 5.  
6.6 Conclusion 
Within this chapter, the exploitation of the freeze drying process by the addition of 
excipients to niosome vaccine preparation results in the production of alternative solid 
dosage forms for oral delivery of vaccines. The results demonstrated that prior to 
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adding mannitol and dextran to the niosomes the average VMD of the vesicles was 6 
µm and upon addition of excipients decreased to 4-6 µm which was a result of the 
excipients bringing the VMD down and not so much the vesicles reducing in size. Upon 
rehydration after freeze drying the vesicle VMD averaged out to 4-5 µm with the zeta 
potential remaining unchanged. Tablet hardness studies showed that the increase of 
dextran to 10 % increased tablet hardness, with toughest tablet resulting from the 
addition of 1 % strawberry flavouring due to its adhesive nature hence forming a glaze 
over the tablet and causing the compaction of the product thus resulting in increased 
hardness. The disintegration time varied upon the hardness of the tablets which showed 
a trend that the harder tablets (10 % dextran) took longer to disintegrate than the 5 % 
dextran tablets. Moreover, when carrying out TGA analysis, all tablets and preparations 
prepared passed the moisture content tests where no more than 5 % residual moisture 
was present. Comparing the disintegration time, hardness and moisture content; the 
higher moisture content within the tablets resulted in lower hardness of the tablets and 
showed faster disintegration time. TGA analysis showed that to further reduce residual 
moisture a secondary drying phase at 50 °C could be added to the freeze drying cycle 
potentially removing an extra 1.5 % of residual moisture. However, it is to be noted that 
sealing of tablet vials occurred outside the freeze dryer (at room temperature and 
pressure) and residual moisture could have been introduced within the samples from the 
exposure to atmospheric conditions and humidity.  
In conclusion, the current work in producing an alternative to a liquid dosage form of a 
niosome vaccine delivery system has shown great promise by reformulation into tablets 
and capsules. The tablets and capsules offer a broader spectrum of delivery and can be 
classed due to their disintegration times. The dosage forms produced within this study 
can be classed into four major categories which include: 
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 Oral dispersible pouch ( Control ), 
 Rapid fast melt (less than 10 seconds), 
 Oral chewable tablet (Greater than 30 seconds), 
 Prolonged release capsules (Greater than 5 minutes). 
The use of 10 % mannitol and 10 % dextran produced hard and durable tablets which 
offered strong resistance to mechanical damage and protection of vesicles during 
transit. The antigen association studies using fluorescence proved that the antigen 
remained with the tablets after the lyophilisation. The freeze drying process was 
confirmed with the study from chapter 4 where the trivalent fluzone vaccine based 
niosomes were freeze dried using the same conditions and an immune response was 
detected in Balb/C mice hence the antigen remained stable after freeze drying. The 
antigen association studies confirmed that approximately 30-40 % antigen is able to 
associate itself with the niosome vesicles prepared via the Aston melt method. To 
conclude, this chapter confirms several dosage designs where niosome delivery systems 
are a suitable platform to administer a wide range of drugs/antigens (Potential for 
poorly soluble drugs) via this route where the freeze drying process increases shelf life 
and stability of the formulations. 
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7.0 Final discussion 
The fundamentals of this thesis were to exploit non-ionic surfactant technology for 
delivery and administration of flu vaccine antigens across various routes and to gain 
a better understanding of vaccine trafficking and immunity. This thesis has 
demonstrated that the redevelopment of a niosome preparation method after 
conducting extensive optimisation has overcome current problems associated with 
present niosome production techniques. The proposed Aston melt method within this 
thesis overcomes problems whereby previously, antigen integrity would be 
compromised due to the high process temperatures and the location of antigen in 
respect to the niosome vesicles offered less protection to the antigen. As a result, the 
Aston melt method for production of niosome vesicles is able to allow greater levels 
of antigen to be entrapped within the niosome vesicles based on radioactive and 
trypsin digestion studies thus offering protection to the antigen from the external 
mileu of the GIT or plasma. In turn, providing thermostability to the antigens upon 
storage at elevated temperatures.  
The method development of the Aston melt was successful due to the vast 
optimisation studies carried out which included various techniques that provided an 
insight into surfactant behaviour, thermodynamics of the vesicles, stability studies, 
and characterisation data. To start, the implications of varying surfactant ratios upon 
responses such as suspension pH, vesicle size, vesicle surface charge and peptide 
entrapment within non-ionic surfactant vesicles was determined. Results showed that 
bilosome manufacture can be optimised by controlling specific formulation 
parameters such as homogenisation head type, speed and by keeping assays 
consistent.  DoE was used to plan and conduct experiments in a random order and 
used to extract the utmost information from the data obtained. The aim of designing 
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an experiment through MODDE was to gather data in the fewest number of 
experimental runs, therefore, saving time and resources where the factors in the 
experiment were simultaneously varied. The aim of DOE was to create a database 
whereby analysis using a mathematical model was calculated where the data was 
then interpreted and predictions made which resulted in the optimisation of the 
surfactant ratios for optimum attributes for uptake at the site of action; the Peyer's 
patches. 
In terms of optimising the surfactant ratios, analysis from the DOE studies reflected 
that DCP was the key lipid which influenced the surface charge which was relative 
to the pH of the suspension. The vesicle size was influenced by the addition of bile 
salts within the formulation which was also dependant on the concentration of bile 
salt added. Based on criteria for vesicles to be successfully taken up by the Peyer's 
patches with optimum vesicle size of > 4µm with a highly negative zeta potential 
(Tabata and Ikada, 1988), pH between 7-9 and highest antigen entrapment it was 
predicted that a surfactant ratio of 5:4:1 of MPG:Chol:DCP respectively should be 
used for niosome vesicles with the addition of 70-120 mM bile salt for bilosome 
vesicles. This optimum ratio of surfactants was then further validated by a series of 
experiments to confirm optimum vesicle characteristics for uptake based on literature 
and within this thesis the 5:4:1 ratio of MPG:Chol:DCP respectively was determined 
to be the optimum formulation for future studies. 
Upon determination of surfactant ratios for optimised physical characteristics the 
thermodynamic stability and surfactant interactions based on Langmuir monolayer, 
differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) 
studies were carried out. Thus, studies using DSC, TGA and Langmuir monolayer 
isotherms were conducted to gain a further insight into the behaviour of the 
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surfactants at the ratio of 5:4:1 MPG:Chol:DCP respectively. Initial TGA studies 
showed that the individual components were stable above 200 °C and that when 
combined in the mixture at the operating temperatures ~2 % lipid degradation was 
observed however, lowering the melt temperature was able to overcome this issue 
where no degradation occurred when melting the lipids at 95°C.  In terms of 
monolayer isotherms, the excipients were all in line with literature values and at the 
specified ratio of 5:4:1 of MPG:Chol:DCP respectively the experimental and 
calculated values showed no significant differences thus implying that the mixture 
was homogenous. This was then backed up by DSC studies confirming the presence 
of cholesterol within the bilayer vesicles due to the abolishment of the gel-liquid 
crystalline transition temperature.  
The optimised niosome formulation by the various characterisation techniques and 
analytical techniques demonstrated that the niosome vesicles are stable and are able 
to retain antigen. It has been demonstrated that the advantage of using delivery 
systems is that the antigens can also be protected after administration (Gregoriadis et 
al., 1999, Gregoriadis, 1994). The growing concern over the thermostability of 
vaccines globally, has been one of the key areas of this research to determine 
whether the niosomes produced offer thermostability in addition to allowing a 
reduction within the doses used.  As previously discussed, the development of the 
Aston melt niosomes have shown that the niosome vaccine delivery system was able 
to protect the vaccine with no loss in potency for a period of 3 months at 40 °C, thus 
overcoming the global problems associated with power outages and temperature 
increases worldwide. 
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In terms of oral delivery of vaccines, research has demonstrated that antigen 
administration via the oral route is insufficient to elicit sufficient immune responses 
thus require the use of adjuvants and delivery systems to enhance immunity (Azizi et 
al, 2010). Hence the proposed method of producing vesicles to protect thermolabile 
antigens by lowering the process temperatures (Aston melt) showed that antigen 
associated and entrapped within non ionic surfactant vesicles offer increased 
protection from GI fluids. Digestion studies demonstrated that encapsulated antigen 
is protected and when the oral biodistribution was conducted, the presence of the 
delivery system holding the antigen lead to increased recovery of antigen and carrier 
along the GIT with increased levels at the target sites of the Peyer’s patches and the 
mesentery. Uptake was confirmed in vivo by the use of fluorescent markers and 
Confocal microscopy which expressed that the vesicles remained intact and were 
spherical and present deep within the Peyer’s patches. Studies within this thesis 
demonstrated that on average 1.5 % antigen is taken up by the Peyer’s patches, 
whether this quantity of antigen is enough to elicit strong immune responses need to 
be confirmed by vaccine efficacy studies. Furthermore, in addition to the low 
efficacy associated with administering free antigen alone, the antigen uptake is also 
dependant on the size of the carrier. This thesis demonstrates that the larger vesicles 
(~ 6 µm) are able to reside within the Peyer's patches compared to the corresponding 
smaller vesicles (~ 2 µm)  thus is an indicator of possibly providing increased 
mucosal immunity. However, the studies conducted (Chapter 5) show that it is 
important to control and understand dosing and antigen concentrations administered 
as increased dose concentration may not be commercially viable with the increased 
chance of reduced immunity due to oversaturation and increased systemic tolerance. 
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Hence, it is vital to carry out a dose dependant vaccine efficacy study within the 
future to determine limits for antigen dosing.  
One of the growing concerns globally is the logistics of vaccine delivery to various 
parts of the world which would require trained personnel for vaccine immunisations. 
One of the aims of this thesis was to develop an alternative dosage design from 
needle based vaccines to developing needle free vaccines. Chapter 6 demonstrated 
the vast potential of lyophilising niosome delivery systems whereby, successful 
tablet and capsule based formulations were produced. The tablets produced were 
classed as rapid fast melts which exhibit patient compliance with the advantage of 
aiding global immunisation strategies by allowing the removal of cold chain storage 
and trained personnel. Figure 7.1 demonstrates the current options available for 
niosome based vaccines based on the work within this thesis. 
7.1 Final Conclusions 
To summarise, exploitation of non ionic vesicles as carriers of flu vaccine antigens 
demonstrated that: 
 The 5:4:1 ratio of MPG:Chol:DCP respectively offer the optimum 
characteristics for vesicle size, zeta potential, pH and antigen retention for 
uptake via the oral route. 
 The niosome vesicles prepared, provide thermostability to thermolabile 
antigens for a period of 3 months exposed to elevated temperatures and 
humidity whereby upon administration intramuscularly, showed immune 
responses comparable if not greater than the control commercial vaccine 
stored in the fridge. 
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 Niosome vesicles containing bile salts within their construct has shown to 
induce efficacy in an oral ferret challenge study whereby responses achieved 
were comparable to the commercial vaccine administered intramuscularly.  
 Niosome vesicles are able to be formed as alternative dosage forms other 
than liquids such as fast melt tablets, oral chewable tablets, and capsules 
which maintain vesicle integrity and antigen, not requiring the use of cold 
storage. 
Figure 7.1: Current options for delivery of niosome vesicles via oral or intramuscular delivery 
demonstrating the possible dosage forms available for the delivery of sub-unit influenza antigens. 
7.2 Future work 
This thesis has laid the foundations for a great future in the use of non ionic 
surfactant vesicles as delivery systems of antigens via various administration routes. 
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One of the key studies for the future would be to determine efficacy via the oral 
route and to see if mucosal and systemic immunity can be obtained in parallel by 
optimising the dose administered. Chapter 5 demonstrated that the vesicles prepared 
are able to reach the target site of the Peyer's patches and that the larger vesicles are 
able to reside within them thus potentially boosting mucosal immunity. Hence, a 
vaccine efficacy study would prove whether this can be achieved based on the 
opinions within literature. A vaccine efficacy implementing several design 
considerations which include determining responses of niosome versus bilosome 
vesicles, effect of vesicle size on type of immunity achieved and determination of 
large and small vesicle size doses in trying to boost musical immunity and gain 
systemic immunity via the smaller vesicles. Techniques such as flow cytometry, in 
vitro M cell uptake with dendritic cell studies should be implemented to provide 
further insight into cytokine production, the induced immune responses and T cell 
differentiation. 
Moreover, the lyophilisation of the niosome vesicles has shown to significantly 
provide thermostability to flu vaccine antigens (Chapter 4) and the development 
alternative dosage forms via tablets or capsules (Chapter 6) has also shown that the 
delivery systems are able to remain stable and retain antigen. Thus, this provides an 
avenue to explore the use of a broad spectrum of antigens for various disease states 
and the possibility of using multiple antigens within the vesicles to reduce numbers 
of vaccines required. Long term storage (6 months - 1 year) of the thermostable 
niosome vesicles should be conducted to gain an insight into possible shelf life 
timescales for the vaccine delivery systems.   
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